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Abstract
In the current project innate immune responses to C. pneumoniae infection were 
studied, using a human in vitro model: a combination of lung epithelial cell lines (HEp- 
2 and A549) and primary blood-derived monocyte-derived macrophages (MdMs). The 
experiments were designed with a view to identify the host-pathogen interactions 
early In the infection that may lead to persistence and the development of chronic 
diseases such as atherosclerosis.
Infected epitheiial cells and MdMs released IL-8 and IL-6, while MdMs also released IL- 
ip , TNF-o and IL-10, but not IL-12. The release of cytokines by infected cells was 
modulated by IL-17 treatment.
Infected MdMs, but not infected epitheliai cells displayed an altered surface 
phenotype: CD14, CD40 and CD54 were up-regulated, whereas MHC class I and II, 
and CD45 were down-regulated. Medium derived from infected epitheliai celis 
modulated surface profile of MdMs in a different manner: MHC class I and I I ,  and 
CD91 were up-regulated, while CD14 and CD45 were down-regulated.
IFN-y plays a key role in controliing chiamydial growth through induction of 
indoleamine 2,3 -dioxygenase (IDO). A549 cells were found not to control chlamydial 
growth although they Inducibly expressed IDO mRNA. The expression of Suppressor of 
Cytokine Signailing 3 (S0CS3) was investigated and A549 cells constitutively 
expressed both S0CS3 mRNA and protein, while HEp-2 cells expressed only S0CS3 
mRNA. S0CS3 expression was further up-regulated by infection in both cells. IFN-y 
treatment of A549 cells did not up-regulate S0CS3 mRNA expression, but did so in 
HEp-2 ceils. The intracellular mechanisms of inhibition of IFN-y-mediated chlamydial 
control in these celis remained unciear and require further study.
The findings presented in this thesis are discussed in relation to a hypothesis that
early immune responses of infected lung cells play a crucial role in the outcome of the
infection and that they contribute to the establishment of persistence.
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C h a p t e r  1 
I n t r o d u c t io n
Chlamydiae are common pathogens that cause a number of serious but preventable 
diseases in both humans and animals. Chlamydia trachomatis has been long 
recognised as the most common cause of sexually transmitted disease and trachoma, 
the most common cause of preventable blindness worldwide. More recently, in the last 
decade or so. Chlamydia pneumoniae has emerged as a major cause of human 
respiratory disease. There has been a lot of research into host responses to chlamydial 
infections and the development of immunopathology; but considerable gaps in our 
knowledge remain. The work described in this thesis aimed to analyse the early innate 
immune responses in the iung following C. pneumoniae infections with a view to 
better understanding host-pathogen interactions.
In this chapter I give an overview of the current knowledge about Chlamydiae and 
Chlamydia pneumoniae^ in particular. The rationale underpinning the experimental 
approach and the aims of the project are outlined at the end of the chapter.
1.1 Chlamydia pneumoniae and disease
1.1.1 Global burden of Respiratory Disease
According to the WHO (World Health Organisation), lower respiratory tract infections 
are the leading cause of disability adjusted life years (DALYs) and the third most 
common cause of death worldwide. In 1990, 4.3 million people died as a result of 
lower respiratory tract infections, accounting for 8.5% of the total number of deaths in 
that year. Almost all of these deaths occurred in developing countries (3.9 miliion). 
The projections for the next 20 years are that there will be a decrease in the 
importance of acute infections, but chronic infections are likely to increase both as a 
cause of death and of DALYs (Murray and Lopez, 1997c, Murray and Lopez, 1997d, 
Murray and Lopez, 1997b, Murray and Lopez, 1997a).
1.1.2 Diseases related to Chlamydia pneumoniae
Chlamydia pneumoniae Is a Gram-negative, obligate intracellular pathogen that is 
recognised as a major cause of human respiratory disease. It  is estimated that up to 
50% of the population worldwide is infected by their early twenties. The 
C. pneumoniae seroprevaience is negligible in children under the age of five, except in 
developing and tropical countries. Seroprevaience increases rapidly at ages 5 to 14, 
reaches 50% at the age of 20 and continues to rise slowly to 70% to 80% at ages 60 
to 70. There does not seem to be a significant difference in the seroprevaience 
between the sexes under the age of 15, but it is considerably higher among adult men 
than among adult women. It is not clear why this is so (Biasi et al., 1998, Kuo et al., 
1995).
C. pneumoniae causes both acute and chronic respiratory infections and has been 
associated with a number of diseases; it is associated with 20-30% cases of chronic 
obstructive pulmonary disease (COPD), up to 10% of community acquired pneumonia 
cases and around 5% of pharyngitis, bronchitis and sinusitis (Soler et al., 1998, 
Gerard et al., 2000, Kuo et al., 1995). The expanding spectrum of disease sequelae 
associated with C. pneumoniae infection includes atherosclerosis and ischaemic heart 
disease, multiple sclerosis and reactive arthritis (Smieja et al., 2002, S ri ram et al., 
1999, Stratton and Sriram, 2003, Braun et al., 1994). There are also reported 
associations with cases of otitis media, pulmonary exacerbations of cystic fibrosis, 
development of non-atopic asthma and other clinical syndromes like erythema 
nodosum, sarcoidosis and meningoencephalitis (Block et al., 1997, Emre et al., 1996, 
Blasi et al., 2000, Erntell et al., 1989, Gaede et al., 2002, Anton et al., 2000)
1.2 Classification of Chlamydiae
Chlamydiae are members of the order Chlamydiales. In 1980 the order Chlamydiales 
had one family, the Chlamydlaceae that had just two species; Chlamydia trachomatis 
strains that were identified by their accumulation of glycogen in inclusions and their 
sensitivity to sulfadiazine, and Chlamydia psittaci strains that did not accumuiate 
glycogen and were usually resistant to sulphadiazine (Skerman et al., 1980).
The development of DNA-based classification methods during the 1980s provided new 
techniques for differentiating chlamydiai groups. DNA-DNA reassociation data 
supported eight chlamydial groups on the level of genus or species. This has led to the 
creation of two additional species, Chlamydia pneumoniae (Grayston et al., 1989a) 
and Chlamydia pecorum (Fukushi and Hirai, 1992). Taking this into consideration, a 
new classification was proposed with one family, the Chlamydlaceae containing one 
genus and four species (reviewed in (Herring, 1993). However, in 1993 a new isolate 
was identified forming a ninth chlamydial group of C. trachomatls-Wke-Chlamydla in 
swine (Kaltenboeck et al., 1993). The existence of nine clusters has further been 
supported by analyses of phenotype, antigenicity, associated disease, host range, 
bioiogical data, genomic nuclease restriction and genomic data including phylogenetic 
anaiyses using the ribosomal operon (Everett and Andersen, 1997).
Species within the Chlamydlaceae family have 16S rRNA gene sequences that are 
more than 90% identical. However, four additional groups of Chlamydla-like 
organisms were identified with a more than 80% 16S rRNA sequence identity. These 
bacteria meet the requirement to be included into the Chiamydiales order since they 
are obligate intracellular pathogens and have a Chlamydia-llke developmental cycle.
Taking the variety of Chlamydiae and the new Chlamydia-like organisms into account 
Everett et al proposed a reciassification of the order Chiamydiales. They created a new 
phylogenetic tree based on analysis of 16S rRNA sequence similarity clusters, analysis 
of fuli-length 16S and 23S rRNAs, and on phenotypic and ecological differentiation of 
these organisms (Everett et al., 1999). The proposed reclassification of the order 
Chlamydiales is represented in Table 1.1.
Table 1.1 The proposed reclassification of the order Chlamydiales. Table adapted from Everett 
et al (1999).
Taxon Type/ reference strain
Family I ;  Chlamydiaceae
Genus  Chlamydia
Chlamydia murldarum sp. nov. MoPn
Chlamydia suis sp. nov. S45
Chlamydia trachomatis A /H ar-13
Biovar trachoma C/PK-2
Biovar LGV L2/434 /B U
G enus  Chiamydophiia
Chlamydophlla abortus sp. nov. B577
Chlamydophlla caviae sp. nov. GPIC
Chlamydophlla fells sp. nov. FP Barker
Chlamydophlla pecorum comb. nov. E58
Chiamydophiia pneumoniae comb. nov. TW-183^
Biovar TWAR TW -183
Biovar Koala LPCon
Biovar Equine N16
Chiamydophiia psittaci comb. nov. 6BC
Family llzSimkaniaceae fam. nov.
Simkania negevensis sp. nov. Z
Family I I I :  Parachiamydiaceae fam. nov..
Parachlamydia achantoamoebae sp. nov. Bng
Family IV: WSU 86-1044
The revision includes three new families within the order of Chlamydiales. They were 
included on the basis of their developmental cycle and more than 80% 16S and/or 
23S gene sequence identity. The new families include three new species (Table 1.1). 
The Chlamydiaceae family has been divided into two genera including five new 
species. The genus Chlamydia now consists of three species; Chlamydia trachomatis; 
Chlamydia murldarum and Chlamydia suis. The new genus Chlamydophlla has been 
introduced with six species. Chlamydophlla abortus, Chlamydophlla cavlae and 
Chlamydophlla fells, all previously considered strains of Chlamydia psittaci have been 
established as separate species. The other members of the genus are Chlamydophlla 
pecorum, Chlamydophlla pneumoniae and Chlamydophlla psittaci.
Members of the Chlamydia genus have 16S and 23S gene sequences that are >97%  
identical. The genome size is ~1 Mbp and there are two identical ribosomal opérons.
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Chlamydia spp produce glycogen to varying degrees, some have an extrachromosomal 
piasmid, and they show a variable sensitivity to suplhadiazine. The type species for 
the genus is Chlamydia trachomatis.
The complete 16S rRNA and 23S rRNA genes of Chlamydophlla species are >95%  
identical. The genome is approximately 1.2 Mbp and contains a single ribosomal 
operon. The Chlamydophlla species do not produce detectable quantities of glycogen, 
have varying morphology and varying resistance to suifadiazine. Many Chlamydophlla 
species contain an extrachromosomal plasmid (Everett et ai., 1999). The type species 
for the genus is Chlamydophlla psittaci.
Chlamydophlla pneumoniae is considered to be primarily a human respiratory 
pathogen. The first isolate was obtained from the conjunctiva of a child In Taiwan in 
1965 and was named TW183. Since then many different isolates have been obtained 
from humans worldwide. There have aiso been a number of isolates from animals 
(koala, horse, frog) (Storey et al., 1993, GIrjes et al., 1994, Berger et al., 1999). DNA 
sequence analysis of the ompA gene (see section 1.3.1) indicates that the amino acid 
sequence of MOMP (Major Outer Membrane Protein) varies less than 6% among these 
isolates, and in other species the variation is greater than 30%. Recently the full 
genomes of two chlamydial isolates AR39 and CWL02, were sequenced and compared 
and found to be 99.9% identical. High homology between isolates worldwide seems to 
be characteristic for the species (Read et al., 2000, Shirai et al., 2000).
The proposed reclassification of Chlamydiaies has caused an ongoing debate in the 
Chlamydia research community since its publication. There were calls for rejecting the 
new classification altogether; however the most recent suggestion is to merge the 
Chlamydia and Chlamydophlla genera into one genus but keep 9 separate species of 
Chlamydia. The lack of acceptance of the new nomenclature is particularly true of 
Chlamydia/Chlamydophlla pneumoniae. To demonstrate this, in the period between 
2000 and 2004 there have been 1403 publications on Chlamydia pneumoniae and only 
86 on Chlamydophlla pneumoniae (search conducted on PubMed on 10*^ '^  September 
2004, limiting the search to title and period). In the light of this, the old name 
Chlamydia pneumoniae will be used throughout this thesis.
1.3 Chlamydial Structure
The defining biological characteristic of the genus Chlamydia is its unique intracellular 
developmental cycle, characterised by two distinct forms: the small, infectious 
elementary body (EB) and the larger, dividing reticulate body (RB). The EB has a 
diameter of ~400 nm, with a dense structure and a rigid cell wall, and it is 
metabolically inactive. The RB is variable in diameter (500-1500 nm) and volume (10- 
100 times bigger that that of the EB); it is metaboiicaily active and has an osmoticaily 
and mechanically fragile cell wall (Chi et al., 1987). There are also intermediate forms 
identified as part of the growth phase in the chlamydiai cycle.
1.3.1 Membrane-associated structures
The chlamydial cell wall Is composed of a number of different molecules including 
peptidoglycan, which has a minor function in the osmotic stability of Chlamydiae, and 
a number of different proteins. The protein present in the largest quantity is the 
MOMP. It is expressed in both EBs, where it is highly cross linked by disulphide bonds, 
and in RBs, where the cysteine residues are compietely reduced and there are no 
disulphide bonds. This difference in the cross linking of MOMP causes different cell wall 
rigidity between RBs and EBs. MOMP functions as a porin that allows the passage of 
ATP, and it is functional only in the reduced form, i.e. in RBs (Wyllie et al., 1998). This 
suggests that the tightly packed, highly cross-linked MOMP structure found In EBs 
ensures their protection from the extracellular environment. Also, MOMP is the major 
antigenic protein in all chlamydiae except for C. pneumoniae (Campbell et al., 1990, 
Christiansen et al., 1997), where It may be masked by polymorphic outer membrane 
proteins (POMPs) (Christiansen et al., 1998).
POMPs are a group of surface proteins of high molecular weight and unknown 
function. There are 9 POMP genes in C. trachomatis and as many as 21 POMP genes in 
C. pneumoniae (Stephens et al., 1998). They are expressed by both EBs and RBs of C. 
pneumoniae and C. abortus (Knudsen et al., 1999, Long bottom et al., 1998).
The first proteins to be discovered in the EBs were the cysteine rich proteins OmcA
and OmcB. They are not expressed in RBs (Hatch et al., 1984, Hatch et al., 1986).
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OmcA is expressed on the surface while OmcB is thought to be located mostly in the 
peripiasm, but it may be associated with the inner leaflet of the outer membrane 
(Everett and Hatch, 1995). The ratio of MOMPs to OmcA and OmcB on the surface of 
the EBs is 5 MOMP: 2 OmcA: 1 OmcB (Everett and Hatch, 1991). Other components of 
the chlamydial structure include the outer membrane proteins (OMPs), first discovered 
in C. pneumoniae (Perez et al., 1994) and other potential candidates for this group of 
proteins have been identified in other Chlamydiae (Stephens et al., 1998).
Raulston et al have shown that a portion of heat shock protein 70 (HSP70) is 
expressed on the surface as a part of the outer membrane complexes of chlamydial 
EBs. Also, under reducing conditions, HSP70 is exposed on the surface suggesting that 
it may have a role in chlamydiai entry (Raulston et al., 1993, Raulston et al., 1998) 
Lipopolysaccharide (LPS) is expressed in ali species of Chlamydiae and the 
predominant form of LPS found in cell culture resembles that of Salmonella minnesota 
Re mutant. It has a low endotoxic activity and this seems to be due to its structure 
(Kosma, 1999); however the biological function of LPS still needs to be elucidated. 
Other non-protein molecules present at the surface are a heparan sulphate-llke 
glycosaminoglycan (GAG) and exoglycolipid (GLXA); however their function is not 
clear as yet.
1.3.2 The Nucleoid
The structure of the nucleoid seems to be unique to Chiamydiae; it has a variable 
density, being much denser in EBs than in dividing RBs; however its complete 
structure is not known. The nucleoid contains two histone-like proteins Hcl and Hc2 
encoded by hctA and hctB respectively. Other putative nucieoid proteins have been 
identified from the genome sequence including SET (CT737), SWIB (CT460) and 
Swi/Snf2 (CT555, CT708) (Stephens et ai., 1998). The histone-like proteins are 
associated with DNA; Hcl preferentially binds to supercolled DNA, whereas Hc2 binds 
equally well to linear and supercoiled DNA In vitro. This suggests that Hcl may be 
largely responsible for the DNA compaction seen in EBs, whereas Hc2 may play a
subtle role in nucleoid morphology and perhaps a role in stage-specific gene 
expression (Pedersen et ai., 1996a, Pedersen et al., 1996b).
1.4 Chlamydial developmental cycle
The chlamydial cycle was first described by light microscopy in 1932 by Bedson and 
Biand (Bedson and Bland, 1932) and it was further analysed in great detail by electron 
microscopy later. The cycle can be divided into four stages: attachment, entry, 
development and release. A schematic of the whole chlamydial developmental cycle is 
presented in Figure 1.1.
EB INCLUSION
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g Q
Chlamydial growth cycle
40-72 hrs
18-40 hrs
G
\  «O
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G
Removal of
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Stressful
CONDITION
Figure 1.1 Chlamydial developmental cycle. Key: EB-elementary body; RB-reticulate body; 
AB-aberrant body.
Host celi-pathogen interactions during the attachment stage are not entirely clear and 
will be discussed further in section 1.4.1. After attachment, the EBs are internalised 
into the host cell and are found within a compact, membrane-bound vesicle called the 
inclusion (Figure 1.1). The inciusion does not fuse with the lysosomes, thereby
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evading destruction, a process that is dependent on early protein synthesis by the 
organism. The reorganisation of the EBs into RBs begins within minutes after the 
internalisation, and after 8-12 hours almost pure RB populations are seen. The 
reorganisation is characterised by at least two events: dispersal of the condensed 
nucleoid structure to free the chromatin for increasing transcriptionai activity, and loss 
of infectivity such that infectious particles are not recoverable upon destruction. RBs 
multiply by binary fission and are first observed dividing after about 12 hours.
In order to divide and grow, Chlamydiae need building blocks and these are provided 
by the host cell. The bacteria get their energy partly from the host cell by taking up 
ATP using ADP/ATP translocases NptlCt and Npt2Ct (Kalman et al., 1999). NptlCt 
mediates ATP transport by receiving ATP in exchange for ADP. Npt2Ct cataiyses the 
net uptake of all four ribonucleoside triphosphates. However, Chlamydiae also express 
genes necessary for ATP generation (Hatch et ai., 1982, Stephens et al., 1998). 
Analysis of C. trachomatis gene transcription in active versus persistent infection 
suggests that, in the first phase of active infection, ADP/ATP exchange provides the 
energy required for metabolism with bacteriai glycolysis supplementing host-derived 
ATP, while in persistent infection the primary energy source is host ceii-, and not 
chlamydia-produced ATP (Gerard et ai., 2002).
The inclusion expands as the RBs multiply to accommodate the growing number of 
chlamydial particles. The conversion of RBs to EBs is not a synchronised process, it 
starts about 18 hours after the infection and by 30-40 hours there is a growing 
number of EBs present in the inclusion (Moulder, 1991). The position of the EBs within 
the inclusions varies between chlamydial species. In C. trachomatis, EBs accumulate 
in the lumen of the inclusion, and the dividing RBs are in proximity to the inclusion 
membrane, while in C. pneumoniae they mix together in the lumen (Wolf et al., 
2000). The cell cycle is completed with the release of chlamydial particles from the 
host cell between 36 and 72 hours after the infection, depending on the species or 
strain of Chlamydia. This can happen either by the lysis of the host cell or by
expulsion of whole Inclusions without cell death. The initial number of EBs influences 
the host cell fate. The infection can slow down the host cell DNA replication and 
ultimately lead to cell death. Infected cells can divide and give two infected daughter 
cells or one Infected and one uninfected cell and the latter case may play a role in 
limiting the spread of infection and in establishing persistent infections (Moulder, 
1991).
Persistence can be initiated by interruption of the "normai" developmental cycle by a 
number of different conditions and agents, including antibiotics, nutrient deprivation, 
and immune factors especially IFN-y. In the presence of these factors RBs cease to 
divide and are transformed into large, morphologically aberrant forms called aberrant 
bodies (ABs). Specific markers for the persistent state have not been found, but 
chlamydial gene expression is altered in persistent infections as compared to active 
infections. Genes for DNA synthesis are expressed, but genes for ceii division are not 
(Byrne et ai., 2001, Mathews et al., 2001). If the stressful condition is removed the 
replicative cycle can continue and infectious EBs can be produced.
1.4.1 Attachment and Entry
The processes and molecules involved in the interactions between chlamydial particles 
and the host cell are still not clear, however a number of host cell molecules have 
been suggested as potential receptors for chlamydial particles. N-acetylneuraminic 
acid and N-acetylgiucosamine have been implicated as components of a putative host 
ceii receptor. However, it had been shown that C. trachomatis elementary bodies 
attach as efficiently to insect cells lacking these molecules as they do to the 
Chlamydiae-susceptible McCoy cell line thus leaving this hypothesis open to further 
investigation (Allan and Pearce, 1987).
Other molecules such as heparin and heparan sulphate have also been implied in the
attachment process. When HeLa cells are treated with heparin and heparan sulphate
or heparitinase, the infectivity of C. trachomatis L2 is consistency inhibited (Zhang
and Stephens, 1992, Taraktchoglou et al., 2001). Also, exogenous GAGs were found
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to inhibit the attachment of C. pneumoniae to human epitheliai celis (Wuppermann et 
al./ 2001). Binding of heparin to the organism and the enzymatic removal of heparan 
sulphate moieties from the host ceil surface results in the marked decrease in the 
infectivity of C. pneumoniae in CHO ceils (Wuppermann et ai., 2001). Given that the 
presence or absence of different molecules can affect the attachment processes, it is 
likely that chlamydial attachment and entry is a dynamic process involving multiple 
receptors on the host ceil.
Similar difficulties have been encountered in identifying molecules on the organism 
involved in chlamydial attachment to the host cells - chlamydial adhesin(s). The 
differential effect of trypsinization on the attachment of a serovar B, an LGV biovar 
strain of C. trachomatis, to celis has lead to the suggestion that chlamydial MOMP may 
be involved in the attachment process (Su et al., 1988). Also, MOMP was shown to 
bind to heparan sulphate on the host ceil surface and this observation further supports 
its role as a chlamydial adhesin (Su et ai., 1990, Su et ai., 1996).
The attachment of C. pneumoniae is affected by its morphology. C. pneumoniae TWAR 
strain EBs have two distinct uitrastructurai morphologies: the classic coccoid 
morphology of the Chlamydlaceae family (Popov et ai., 1991) or the prototypical pear- 
shaped EB (Grayston et ai., 1989b). The entry and ingestion of the pear-shaped EBs 
into the cells is different from the EBs of other Chlamydiae. They preferentially first 
attach to the host cell surface by the pointed end and then bind to other parts by 
means of cell wail protrusions. The host ceil membrane invaginates and the C. 
pneumoniae EBs are internalised in vacuolated inclusions (Grayston et ai., 1989b). 
Using scanning and transmission electron microscopy, Coombes & Mahony (2002) 
demonstrated that attachment of C. pneumoniae to host ceils induces the appearance 
of microvilli on host ceil membranes. Invasion occurs between 30 and 120 min after 
ceil contact, with subsequent loss of membrane microvilli (Coombes and Mahony, 
2002).
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The Invasion of HEp-2 cells by C. pneumoniae causes a change in the intracellular 
signalling pathways. There is a rapid increase in MEK-dependent phosphorylation and 
activation of ERKl/2, followed by PI3-kinase-dependent phosphorylation and 
activation of Akt. Tyrosine phosphorylation of focal adhesion kinase (FAK) precedes its 
appearance in a complex with the p85 subunit of PI3-kinase during chlamydial 
invasion. Isoform-specific tyrosine phosphorylation of the docking protein She also 
occurs at the time of attachment and entry. Chlamydial entry (but not attachment) 
can be abrogated with specific inhibitors of MEK, PI3-kinase and of actin 
polymerization. This suggests that activation of cell signalling pathways and an intact 
actin cytoskeieton are essential strategies for C. pneumoniae invasion of epithelial 
cells (Coombes and Mahony, 2002)
Vesicles containing endocytosed elementary bodies are delivered into close proximity 
with the host ceil Golgi apparatus approximately two hours after infection. 
Translocation of the chlamydial entry vacuole requires the active participation of 
Chlamydiae, because if early chlamydial protein synthesis is blocked with the antibiotic 
chloramphenicol, the vacuole-bound elementary bodies remain distributed throughout 
the ceil cytoplasm (Scidmore et ai., 1996). Translocation of early C. trachomatis 
vacuoles to the peri-Golgi region probably involves the host cell cytoskeieton, as 
aggregated elementary bodies are associated with the micro-tubule organising centre 
of the cytoskeieton, while microtubule inhibitors block the aggregation of early 
inclusions (Clausen et al., 1997).
The chlamydial endosome lacks any of the classic host ceil markers of either early 
endosomes (transferrin or transferrin receptor) or late endosomes (cation- 
independent mannose-6-phosphate receptor) and is essentially non fusogenic with 
host ceil lysosomes. This probably relates to some intrinsic property of the elementary 
body cell wall, as normal endosome maturation is prevented if the endosome contains 
purified chlamydial ceil walls or if chlamydial protein synthesis is blocked by antibiotics 
(Hackstadt, 1998). Blockade of normal endosomal maturation occurs as an early event
12
in the first two hours following infection, before the nascent vacuole starts to Intercept 
exocytic host cell membrane transport from the Golgi apparatus. Subsequently, 
chlamydial gene products modify the vacuole so that it becomes fusogenic with a 
subset of sphingomyelin and choiesterol-containing exocytic vesicles from the Golgi 
apparatus (Carabeo et ai., 2003). Giycero-phosphoiipids acquired by the chlamydial 
vacuole from the Golgi apparatus, the mitochondria and endoplasmic reticulum, are 
subsequently modified by the Chlamydiae. The result is that Chlamydiae have a 
phospholipid composition that is much closer to that of the host cell than to that of 
other bacteria, including the unusual presence of cholesterol (Wylie et al., 1997, 
Carabeo et al., 2003).
1.4.2 Development and gene expression
Since the genomes of C. trachomatis and C  pneumoniae have been sequenced, a 
whole new area of chlamydial biology has been opened up for investigation and 
extensive work has been done on analysing their gene expression profiles. Genes have 
been divided according to the time of their expression in the cycle into three groups: 
early transcripts - detected 2 to 6 hours after infection, during the germination of 
EBs to RBs; mid-cycle transcripts - appearing between 6 and 12 hours after 
infection during the growth and multiplication of RBs, and late transcripts, which 
appear between 12 and 20 h after infection, during the differentiation of RBs to EBs. 
Collectively, early gene functions appear weighted toward initiation of macromolecuiar 
synthesis and the establishment of the intracellular niche by modification of the 
inclusion membrane. Late gene functions appear to be predominantly those associated 
with the terminal differentiation of RBs back to EBs (Shaw et ai., 2000). An overview 
of temporal gene expression along with references is presented in Table 1.2 below. 
This Table was adapted from www.chiamvdiae.com with minor changes. Expression 
and regulation of inclusion proteins. Type I I I  Secretory System and heat shock 
proteins will be discussed in more detail in the following sections.
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1.4.3 Regulation of gene expression
Chlamydial development involves the expression of many genes that need to be 
strictly regulated. Gene expression is at least in part regulated by sigma (a) factors 
that modulate the binding of RNA polymerase to specific gene targets. An RNA 
polymerase core enzyme binds to a a factor. The enzyme is then capable of 
recognising the promoter and it can initiate transcription at the transcription start site, 
known as the +1 site. Different a factors allow the relevant RNA polymerase to initiate 
transcription from different promoter sequences. This provides a mechanism of gene 
regulation. If  the a factors themselves are differentially expressed, it follows that the 
genes under their control will be transcribed differentially. The genome sequence of C. 
trachomatis has revealed three a factors (Stephens et al., 1998). They are and
and there are also several predicted enhancer binding proteins, such as NifS. 
Sigma factors are probably capable of recognising different chlamydial gene promoters 
as well as the -10 (TATAAT) and -35 (TTGCCA) boxes that are analogous to E. coii 
promoters recognized by E-a^° (Tan et ai., 1998, Mathews and Sriprakash, 1994). 
Chlamydial a®® promoters are unlike those of E.coii a®® (Mathews and Stephens,
1999). A number of promoters have been identified and a number of genes 
regulated have been proposed; however a  factors and promoter recognition alone are 
unlikely to be sufficient for control of the chlamydial development cycle (Mathews and 
Timms, 2000).
1.4.3.1 Inclusion proteins
In order to ensure their survival within the host ceil, Chlamydiae manipulate the 
intracellular processes. It is thought that they do so through the inclusion membrane. 
In 1994 Rockey and Rosquist identified a 39 kDa protein expressed in the infected 
cells and RBs, but not EBs, of Chlamydia psittaci GPIC (Rockey and Rosquist, 1994). 
The protein was located in the inclusion membrane and was named inclusion protein 
A, IncA (Rockey et al., 1995). Subsequently it was shown that other Chlamydiae also 
express Inc proteins and the inc genes are conserved within the Chlamydlaceae 
family. At least 11 different Inc proteins have been identified in C. trachomatis. Using
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computer modelling, 90 proteins in the C. pneumoniae J138, and 36 proteins in the C. 
trachomatis serovar D sequences were identified that have hydropathy profiles similar 
to the Inc proteins. Only a few Inc-iike open reading frames were found in other 
organisms, suggesting that these proteins are exclusive to the Chlamydiae. 
Comparative genome analysis suggests that the Inc-iike open reading frames have 
multiplied and diverged as orthoiogues (copied genes that retain the same function as 
the original) and paralogues (copied genes that have a different function than the 
original) in the chlamydial genomes, and that some of them lack the N-terminai 
portion or encode a split form (Bannantine et al., 2000, Toh et al., 2003).
The Inc-like proteins constitute a large family and they are likely to play an important 
role in chlamydial infections throughout the life cycle. C. caviae IncA was found to face 
the cytoplasmic side of the inclusion membrane, and is phosphorylated by host ceil 
kinases at its serine and threonine residues (Rockey et ai., 1997). Given the 
importance of kinases in the intracellular signalling machinery of the host ceil, IncA 
might have a role in interfering with these pathways to serve the pathogen. Also 
certain C. trachomatis strains do not express an IncA homologue and produce 
uncharacteristic multiple inclusions in celis instead of one large inclusion indicating 
that IncA mediates the fusion of small homotypic inclusions containing chlamydial RBs 
into one large inclusion (Suchiand et ai., 2000). In addition Inc proteins may be 
involved in preventing fusion between the chlamydial endosome/inclusion with 
lysosomes, and in getting nutrients from the cytosol of the host ceil across the 
inclusion membrane to the Chlamydiae (reviewed in Wyrick, 2000). As seen in Table 
1.3, Inc proteins are expressed early in the development cycle. Even though they are 
membrane-associated proteins, they generally lack the characteristic signal peptides 
that target nascent proteins into bio-membranes. One speculation is that Chlamydiae 
inject the Inc proteins into inclusion membrane using a Type I I I  Secretory System, 
discussed below.
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1.4.3.2 Type I I I  Secretory System
The Type I I I  Secretory System (TTS system) functions as a 'moiecuiar syringe', 
enabling Gram-negative bacteria to inject virulence-related proteins into the 
cytoplasm of host cells (Hueck, 1998). The TTS system differs from ail other bacterial 
secretion mechanisms in that it requires, and is triggered by, the intimate contact of 
the bacterium with a host cell membrane. The TTS system is found in a wide range of 
Gram-negative bacteria including Yersinia, Saimoneiia, Shigelia, Escherichia, 
Pseudomonas, Bordeteiia, Burkhoideria, a number of plant pathogens or symbionts, 
and in Chiamydia (Winstaniey and Hart, 2001).
TTS systems are known to consist of several elements, including the following: 
structural elements within the bacterial membrane, as well as those that are 
assembled upon contact with the host ceil and that extend into the host cytoplasm 
(e.g., ysc genes); effector proteins which are released into the host cell to modulate 
host cell function (e.g. yop genes); a translocator apparatus that provides a pore 
within the host ceil membrane for delivery of effectors (e.g. transiocator genes yopB, 
yopD, and their chaperone icrH)) and specialized chaperones which function to 
stabilize and assure efficient secretion of transiocator proteins, and also to regulate 
expression of some of the TTS genes (e.g., syc genes).
The genetic organisation of the TTS system in Chlamydiae does not form 
"pathogenicity islands"; rather, the genes are scattered over at least four different 
regions of the genome (Stephens et ai., 1998). In order to confirm that C. trachomatis 
possesses a functional TTS system, the expression of genes encoding products with 
similarity to proteins from other TTS systems, has been analysed. These include CopN, 
a putative secreted protein homoiog of the YopN TTS-secreted protein of Yersinia. 
CopN is expressed mid-cycle, and it is found in the inclusion membrane 20 hours after 
the infection. Also, when CopN is transfected into Yersinia enteroiytica, it is expressed 
and secreted by the TTS-system, thereby confirming that Chlamydiae produce 
proteins that can be secreted via a TTS mechanism (Fields and Hackstadt, 2000). As
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mentioned earlier there are indications that Inc proteins may be injected into the 
inclusion by a TTS-system; however Incs are expressed as early as two hours post 
infection, while TTS proteins are expressed mid cycle. Recently the expression of TTS- 
system was demonstrated on purified EB extracts by detecting a core apparatus 
protein CdsJ (Fields et al., 2003). This group also confirmed early activity of the TTS- 
system by secretion of IncC via the Yersinia TTS apparatus (Fields et ai., 2003).
Type I I I  secretory system might also have a role in chlamydial survival. In IFN-y 
induced persistent infections, C. pneumoniae TTS protein ScTN is expressed along 
with MOMP, heat shock protein 60 and others, and this expression profile might help 
Chlamydiae to resist stress from effectors of the Th 1-type immune response 
(Moiestina et ai., 2002).
Proteomic analysis of C. pneumoniae EBs identified 167 genes representing 15% of 
the coding capacity of the genome, including 31 hypothetical proteins (Vandahi et ai., 
2001). Ail of the data are available on the Aahrus database at www.oram.au.dk. A 
number of proteins of the putative C. pneumoniae type I I I  secretion apparatus have 
been shown to be expressed. They are listed in Table 1.3.
Table 1.3 TTS system proteins of C. pneumoniae
Protein Gene Aarhus accession
T III secretion: low calcium response protein icrE or Copn or sctw Q9Z8L4
T III secretion: YOP C/Gen Secretion Protein D yscC or sctC Q9Z7K3
T III secretion: YOP N (Flagellar Type ATPase, ) yscN or sctN Q9Z7J8
T III secretion: YOP L translocation protein yscL or sctL Q9Z780
Another study analysed the temporal expression of TTS genes in C. pneumoniae. 
There are at least 13 genes that are homologous with other known TTS systems. The 
groEL-1 (HSP60), ompA, and omcB genes were used as markers for the early, middle, 
and late stages of the developmental cycle. TTS genes were expressed as follows: 
early stage (1.5 to 8 h), yscC, yscS, yscL, yscJ and icrH-2; middle stage (12 to 18 h), 
icrD, yscN, and yscR) and late stage (24 h), icrE, sycE, icrH-1 and yscT. IFN-y
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treatment affected some of the genes either by down-regulation or by changing the 
time of expression (Siepenkin et al., 2003).
1.4.3.3 Heat Shock Proteins
HSPs are a ubiquitous family of highly conserved proteins that stabilise cellular 
proteins during heat shock, infection and inflammation. Chlamydiae have seven heat 
shock-related chaperone proteins (groELl, groEL2 groEL3, groES, grpE, dnaJ, dnaK). 
These proteins are up-regulated in response to heat or oxidative stress or to IFN-y 
and other products of cell mediated immunity (Byrne et ai., 2001). GroEL/HSP60 and 
GroES are expressed within one hour after infection (Belland et ai., 2003). The a 
factor that regulates heat shock protein expression has not been identified; however 
chlamydial HrcA has been demonstrated to be a regulator of chlamydial heat shock 
gene expression acting in conjunction with a cis-acting DNA element called CIRCE as a 
repressor-operator pair. HrcA repressed the in vitro transcription of a chlamydial heat 
shock promoter in a promoter specific manner (Wilson and Tan, 2002). The role of 
chlamydial heat shock proteins in immune responses will be discussed later in this 
chapter.
1.5 Im m une responses to chlamydial infections
Research to date has shown that the protective immunity to chlamydial infections is 
mediated primarily by a Thl-type response. Early cytokine production by the innate 
arm of the immune system is followed by an adaptive response dominated by CD4+ 
and CD8+ T ceils. An overview of immune responses and the contribution of different 
ceil types and cytokines are discussed in the following section.
1.5.1 Epithelial cells
Epitheiiai/mucosal surfaces are the primary target for Chiamydia spp. infections. 
Chlamydiae can infect the respiratory tract (C. pneumoniae, C. muridarum, C. feiis, C. 
suis), urogenital tract (C. trachomatis LGV biovar), the conjunctiva (C. trachomatis 
trachoma biovar, C. feiis, C. suis, C. pecorum), the gastrointestinal tract (C. psittaci) 
and also the trophoblast layer of the placenta (C. abortus, C. pecorum). Epithelial
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surfaces are a physical barrier to the internal environment, but also have a pivotal role 
in the innate and eariy immune response to pathogen chaiienge.
The airway epithelium performs many homeostatic functions, such as gas transport, 
ceiiular repair and proliferation, barrier protection and ion and fluid transport. It  can 
also regulate local inflammatory and immune responses by producing a range of 
cytokines (IL-6, IL-11) and chemokines (IL-8, MCP), as well as lipid (PGE2) and 
peptide (endothelin, vasopressin) mediators and reactive oxygen species (NO, H2O2) 
(Polito and Proud, 1998). C. pneumoniae infection of airway epithelial cells modulates 
these responses. A number of host transcription factors are activated and this is 
followed by cytokine production. GR, C/EBP-p (CCAAT-enhancer binding protein beta) 
and NFkB (nuclear factor kappa B) are activated between 1 and 6 hours post-infection 
(Gencay et ai., 2003). NFkB activation is followed by release of IL-8 and PGE2 and up- 
regulation of ICAM-1 adhesion molecule. This is followed by subsequent transepithelial 
migration of neutrophils (Jahn et ai., 2000) Another study has shown expression of 
IFN-y, TNF-o and IL-8 mRNA in A549 celis in response to C. pneumoniae infection, but 
only IL-8 protein was found in the supernatants. Expression of IL -lp  and IL-6 mRNA 
or protein was not affected (Yang et ai., 2003). Infected lung epithelial cells in vivo 
are also induced to express histidine decarboxylase (HOC), an enzyme that produces 
histamine, and this is associated with the production of IL-4 in the lung, thereby 
supporting the association of C. pneumoniae infections with allergy and asthma 
(Burian et al., 2003).
1.5.2 Neutrophils
Neutrophils have an important role in the early immune response in chlamydial 
infections. There is evidence of early neutrophil infiltration (by day 2) into the lung, in 
a mouse model of C. pneumoniae pneumonitis (Yang et ai., 1994) and in vitro data 
showed release of IL-8 by infected endothelial ceils followed by increased trans- 
endothelial migration of neutrophils (Moiestina et al., 1999). This implies that 
neutrophils might have a function of eariy IFN-y production and T ceil recruitment. C. 
pneumoniae can infect and multiply in the neutrophils themselves, and render them
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resistant to apoptosis by autocrine production of IL-8, thereby providing another 
reservoir for spreading the infection (van Zandbergen et ai., 2004).
Chiamydia-mediated recruitment of neutrophils might also be aided by IL-17. IL-17 is 
crucial in immune responses to Klebsiella pneumoniae infections, and when it is 
absent there is delayed infiltration of neutrophils, leading to higher bacterial loads and 
higher mortality in infected mice (Ye et al., 2001a, Ye et al., 2001b). IL-17 will be 
discussed in detail in chapter 4. Neutrophil recruitment in C. pneumoniae infections 
might support the association with chronic respiratory diseases such as COPD and 
chronic bronchitis (Sethi, 2000, Beaty et ai., 1991, Blasi et ai., 1993, Von Hertzen et 
ai., 1996). Acute exacerbations of these are associated with an increased number of 
neutrophils in the airways (Selby et ai., 1991). Clearance of C. abortus infection in 
mice is associated with a pronounced infiltration of neutrophils into the liver and eariy 
IFN-y production (Dei Rio et ai., 2000). In a pregnant mouse model of C. abortus 
infection, neutrophils seem to be crucial for the recruitment of CD8+ T ceils into the 
liver. In secondary infections, depletion of neutrophils results in lower levels of early 
IFN-y and TNF-o production and higher bacterial loads (de Oca et ai., 2000, Montes de 
Oca et ai., 2000).
Neutrophils also play a role in host immunity to C. trachomatis infections. As with C. 
abortus, their depletion leads to higher bacterial loads in mice infected with C. 
trachomatis (Barteneva et ai., 1996). Infected epithelial cells release IL-8 and this 
triggers migration of neutrophils to the infection site. The recruitment and activation 
of neutrophils differs between disseminating and non-disseminating serovars (Dessus- 
Babus et ai., 2000, Dessus-Babus et ai., 2002). C. trachomatis-recru\teâ neutrophils 
are activated to release defensins. Neutrophil defensins appear to participate in the 
host defence in ascending pelvic infection and the pathogenesis of pelvic inflammatory 
disease. Defensins are small antimicrobial peptides, part of the innate immune 
responses, that show antimicrobial effects in vitro (Wiesenfeld et al., 2002). Natural 
antimicrobial peptides will be discussed in detail in chapter 7.
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1.5.3 Natural killer (NK) cells
Natural killer ceils are non-ciassical lymphocytes, ceiiular components of the innate 
immune system that do not express antigen-specific receptors at their surface. Their 
effector function consists of target ceil lysis, as well as in Th l cytokine and chemokine 
secretion. NK cytotoxicity appears not to be important for clearance of C. pneumoniae 
infection; however they might contribute by producing IFN-y in the eariy stages of the 
infection, and this could in turn activate macrophages and T cells (Rottenberg et al., 
2000). A similar effect is seen in genital C. trachomatis infection, where the NK 
cytotoxicity seems to be impaired but IFN-y is important (Tseng and Rank, 1998, 
Mavoungou et ai., 1999).
Natural killer cell activity is controlled by a concert of activating and inhibitory signals. 
The interaction of NKR (natural killer ceil receptor) with MHC (Major Histocompatibility 
Complex) molecules inhibits NK cytotoxicity and cytokine production, while failure to 
express MHC renders ceils susceptible to NK-mediated lysis (Moretta et al., 2000). C. 
pneumoniae infected monocytes produce IL-10 that down-regulates MHC class I 
production. This might reduce the presentation of bacterial epitopes by MHC and 
decrease the ability of CD8+ T ceils to eliminate infected ceils (Caspar-Bauguii et ai.,
2000). However, down-reguiation of MHC might allow NK cells to recognise C. 
pneumoniae infected cells and thereby protect the host.
1.5.4 Monocyte-derived Macrophages
1.5.4.1 Eariy contribution of MdMs to anti-chiamydiai immunity
Monocyte derived macrophages (MdMs) have a central role in chlamydial infections.
Alveolar macrophages found in the lung within 2 days of infection in vivo in Swiss
Webster mice (Yang et al., 1994). Ex vivo human alveolar macrophages are activated
to produce IL-8, IL -lp , TNF-o and reactive oxygen species following infection. The
infection also causes up-regulation of MHC class II,  expression while there is no
change in ICAM-1 expression (Redecke et al., 1998). Mouse bone marrow-derived
macrophages infected ex vivo produce IFN-y eariy after the infection, in an IFN-o/p-
dependent, IL-12-independent manner, and this contributes to control of infection
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(Rothfuchs et al., 2001). MdMs support C. pneumoniae infection in vitro. Infection can 
induce differentiation of monocytes into macrophages, ceiis are activated to produce 
TNF-o, IL -lp , IFN-y and IL-6, and there is increased CD14 and ICAM-1 expression on 
the ceii surface (Quinn and Gaydos, 1999, Kaukoranta-Toivanen et ai., 1996, 
Heinemann et ai., 1996, Yamaguchi et al., 2002). In some cases in vitro growth of C. 
pneumoniae in monocyte/macrophages is restricted. The amount of infectious progeny 
released from infected MdMs in vitro varies and seems to depend on the length of time 
in culture and also on the level of differentiation of MdMs, but the number is always 
lower compared to epithelial cells (Quinn and Gaydos, 1999, Kaukoranta-Toivanen et 
al., 1996). Even when the growth is restricted, residual chlamydial epitopes are 
enough to induce proliferation of T ceiis up to a week after chlamydial mRNA is 
detected (Airenne et al., 1999). IFN-y treatment of infected MdMs does not affect the 
rate of chlamydial growth, but high doses of the cytokine diminish the number of 
infectious progeny released by the MdMs, suggesting that immunological pressure can 
cause persistence (Airenne et ai., 2000).
1.5.4.2 Macrophages in atheroscierosis development: the role of HSP and LPS 
Infected monocytes are responsible for the dissemination of C. pneumoniae in vivo 
both by hematogenous and lymphatic routes (Moazed et ai., 1998, Yang et al., 1995). 
Infection with C. pneumoniae, but not with C. trachomatis increases adhesion of 
infected MdMs to non-atherosclerotic vessel walls of healthy mice (May et al., 2003, 
Kalayoglu et al., 2001). C. pneumoniae infection increases trans-endotheiiai migration 
of infected MdMs across the blood-brain barrier and they might contribute to the 
development of sporadic Alzheimer's disease (MacIntyre et al., 2003). In addition, 
infected monocytes increase the susceptibility of endothelial ceiis to C. pneumoniae 
infection, but not to infection by C. trachomatis or C. psittaci (Lin et ai., 2000). This 
could be the mechanism for establishment of vascular wall infection of endothelial and 
smooth muscle cells, and might subsequently lead to the development of 
atheroscierosis.
The increased adhesion of infected macrophages to endothelial ceiis might be due to
chlamydial LPS (Kalayoglu et al., 2001). Indeed, chlamydial LPS induces macrophage
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foam cell formation, a hallmark in early atheroma development (Kalayoglu and Byrne, 
1998). High levels of lipids in blood, iow-density-iipoprotein (LDL) in particular, 
contribute to development of plaques. Chlamydial infection of macrophages activates 
native LDL to become atherogenic by cellular oxidation and a process that is mediated 
by chlamydial heat shock protein 60 (cHSP60) (Kalayoglu et al., 1999). cHSP60 is 
produced in large amounts during persistent infections and co-localises with human 
HSP60 within macrophages in atherosclerotic lesions. It regulates expression of TNF-o 
and matrix metaiioproteinase (MMP) expression by the macrophages (Koi et al.,
1998). Both human and chlamydial heat shock proteins can activate vascular 
endothelial cells, smooth muscle cells and macrophages through the Toll-like receptor 
4 (TLR4) pathways (Koi et ai., 2000, Buiut et ai., 2002, Sasu et ai., 2001). Heat shock 
proteins induce expression of E-seiectin, ICAM-1, VCAM-1 on endothelial ceiis and 
secretion of IL-6 by ail three ceii types. The activation of the ceils is abolished with 
heat treatment, which implies that HSP60 rather than LPS is the major chlamydial 
component that elicits inflammatory responses, since HSPs are heat labile (Koi et al.,
1999). However, very recently there have been reports claiming that HSP-induced 
inflammatory responses are due to the LPS contamination of recombinant HSP 
preparations, and that on their own HSPs do not induce any inflammation (Gao and 
Tsan, 2003a, Gao and Tsan, 2003b). This stiii needs to be fully investigated and 
remains an area of controversy.
The role of infected macrophages in C. pneumoniae infections supports the importance 
of C. pneumoniae as a cofactor in the development of atheroscierosis.
1.5.5 Dendritic ceils
Dendritic ceiis (DC) are key antigen processing ceiis and play a central role in linking
innate immunity (involving TLRs) and antigen-specific, cytokine stimulated cell-
mediated immune responses. C. pneumoniae are taken up by dendritic ceiis but do
not multiply within them to produce inclusions. Nevertheless dendritic celis are
potently stimulated by C. pneumoniae uptake as shown by NFkB activation. There is
secretion of IL-12p40 and TNF-o, the expression of MHC class I I,  CD40, CD80, and
24
CD86 is up-reguiated. The activation of dendritic ceiis by C. pneumoniae is dependent 
on the presence of TLR2 and independent of TLR4 with the exception of IL-12p40 
secretion (Prebeck et al., 2001, Costa et al., 2002). Similar responses are seen with C. 
trachomatis, where infected dendritic ceiis are activated and produce IL-12 and TNF-o 
but not IL-10. Following invasion, C. trachomatis does not develop into characteristic 
inclusion bodies. Despite no obvious co-iocalization between C. trachomatis vacuoles 
and MHC loading compartments, infected DC efficiently present antigens to CD4+T 
ceiis and also expand antigen-specific CD8+T cells (Ojcius et al., 1998, Matyszak et 
al., 2002).
1.5.5.1 Toll-like receptors
Members of the TLR family recognize conserved microbial structures, such as bacterial 
LPS and viral double-stranded RNA, and activate signaling pathways that result in 
immune responses against microbial infections. Ail TLRs activate MyD88-dependent 
pathways to induce a core set of stereotyped responses, such as inflammation. 
However, individual TLRs can also induce immune responses that are tailored to a 
given microbial infection. Thus, these receptors are involved in both innate and 
adaptive immune responses. The mechanisms and components of these varied 
responses are only partly understood. Microbial induction of the TLR pathway in 
dendritic ceiis blocks the suppressive effect of CD4+CD25+ T regulatory ceiis, allowing 
activation of pathogen-specific adaptive immune responses. This block of suppressor 
activity is, in part, dependent on IL-6 released by dendritic ceiis (Pasare and 
Medzhitov, 2003). TLR4 is the best-characterised member of the TLR family and is 
recognised as the key receptor for the LPS of Gram-negative bacteria. Recently 
however, there have been reports that different LPS molecules signal through different 
TLRs. E. coii LPS signals through TLR4, but Porphyromonas gingivaiis LPS signals 
through TLR2 (Pulendran et ai., 2001, Netea et ai., 2002). This seems to be a 
consequence of different conformations of the Lipid A moiety of the LPS.
The activation of immune responses in chlamydial infections seems to depend largely
on TLR2; however TLR4 does have a limited role. TLR2 seems to play a role in both
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early production of inflammatory cytokines and development of chronic inflammatory 
pathology in C. trachomatis genital infection (Darviiie et ai., 2003). Both C. 
pneumoniae and C. trachomatis activate dendritic celis through TLR 2 (Prebeck et al., 
2001, Prebeck et al., 2003). On the other hand, purified chlamydial LPS and cHSP60 
require TLR4 to activate a variety of ceiis (Prebeck et ai., 2003, Costa et ai., 2002, 
Buiut et al., 2002, Sasu et al., 2001). It is likely that other members of the Toll-like 
receptor family contribute to the activation of immune responses to chlamydial 
infections, but this stiii needs to be elucidated.
1.5.6 T cells
Protective immunity against intracellular bacteria is mostly dependent on the 
activation of T-cell-mediated immune responses. A number of mouse models were 
developed to investigate the role of different celis in chlamydial immunity. T cells play 
a crucial role in all chlamydial infections through Thl-type responses and the 
production of IFN-y. In BALB/c mice there is large infiltration of mononuclear ceiis into 
the lung during the primary infection, and ~70%  of these cells are T cells. During 
reinfection this is further enhanced and there is a strong Thl-type response with IFN-y 
production (Penttiia et al., 1998). Similar results were found by Rottenberg et ai 
(1999). By using a range of mouse knockouts they showed that CD4+T ceiis initiaiiy 
facilitated the bacterial growth in the absence of CD8+T cells. CD8+T cells hindered 
the eariy detrimental effect of CD4+T ceiis and in later stages of infection both types 
of cells worked against the infection. The early detrimental effect of CD4+T ceiis 
seemed to be through a Th2 cytokine pattern with high IL-10 and IL-4 mRNA levels 
and the delayed accumulation of IFN-y. CD8+T cell-mediated protection was perforin 
independent and associated with the release of IFN-y that pushes the CD4+T cell- 
mediated response to Th l (Rottenberg et al., 1999, Svanholm et al., 2000). Anti- 
chlamydial CD8+T cell responses are antigen specific (Wizei et ai., 2002). During 
reinfection the bacterial load is lower, the clearance of the infection is quicker and 
protection is CD8+T cell-dependent. This was shown by depletion of CD4+ or CD8+T 
celis. Whereas CD4+T cell depletion did not have an effect on infection kinetics.
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depletion of CD8+T cells abolished the protection, reverting the kinetics and bacterial 
load to the same levels found during primary infection (Penttiia et ai., 1999).
1.5.7 B cells
Recently, the concept that cell-mediated immune responses alone impart the 
immunity to intracellular pathogens has been challenged. A number of studies have 
demonstrated a protective role of specific antibody/B ceii responses (Teitelbaum et al., 
1998, Edelson et al., 1999, Mittrucker et al., 2000, Elkins et al., 1999, Winslow et al.,
2000). This was also demonstrated in C. trachomatis mouse pneumonitis lung 
infections where B-ceii-deficient mice showed a higher mortality rate and also a 
disruption in T cell responses (Yang and Brunham, 1998). B ceils also contribute to the 
outcome of genital C. trachomatis infections. CD4+T ceiis and B ceiis work in synergy 
and provide protection from reinfection. B ceils also seem to have a crucial role in 
secondary infections as shown by depletion of both CD4+T and CD8+T ceiis (Morrison 
et ai., 2000, Morrison and Morrison, 2001). A more recent report implied that B cells 
participate in anti-chiamydiai immunity in genital infections, via FcR-mediated effector 
functions of antibodies (Moore et al., 2002). The role of B cells has also been studied 
in C. abortus and the results proved similar (Buendia et al., 2002). In the case of C. 
pneumoniae there are very few reports. There is infiltration of B cells into the lung 
during both primary and secondary infection. On the other hand resistance to C. 
pneumoniae infection does not seem to be associated with increased titres of specific 
antibodies, since higher levels of anti-0MP2 IgG can be found in IFNyR knockout mice 
with high infection susceptibility compared to the controls (Rottenberg et al., 1999). 
However, taking into account ail the results available for other chlamydial species 
there is a high probability that B celis significantly contribute to immunity against C. 
pneumoniae.
1.5.8 Cytokine production and immunity to chlamydial infections
Cytokines play a key role at ail levels of chlamydial infections. Chlamydiae are potent 
inducers of both pro-infiammatory and anti-infiammatory cytokine expression in a 
number of different ceii types. IFN-y is the key cytokine for control of chlamydial
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growth. It has a role both in the eariy innate responses and in the formation of 
protective immunity. The initial IFN-y burst produced by innate ceiis controls the 
bacterial load and is necessary for the accumulation of nitric oxide, superoxide 
production and catalysis of tryptophan, probably related to bacterial stasis/killing 
(Rottenberg et al., 2000). The protective immunity is mediated by CD8+T celis and is 
IFN-y dependent (Penttiia et al., 1998, Penttiia et al., 1999, Vuola et al., 2000, Wizel 
et al., 2002).
Production of IFN-y by bone-marrow derived macrophages seems to be IFN-o/p 
dependent and IL-12 independent; however, other studies show that lack of early IL- 
12 production leads to diminished levels of IFN-y. In turn, IFN-y is necessary for IL- 
12p40 accumulation in the lung, suggesting a positive feedback regulation between 
these cytokines (Rothfuchs et ai., 2001, Geng et ai., 2000a). In order for IFN-y to 
control chlamydial growth in vitro, ceiis need to be pre-treated with the cytokine at 
inhibitory concentrations (Summersgiii et al., 1995). When used in sub-inhibitory 
doses in vitro IFN-y can contribute to the establishment of persistence (Pantoja et ai.,
2001). By inducing a persistent state it also changes the gene expression pattern, and 
there is a marked increase in the expression of MOMP and cHSP60, which can in turn 
cause a stronger inflammatory response, thus causing immunopathoiogy (Byrne et ai., 
2001, Moiestina et ai., 2002). Other cytokines contribute to inhibition of chlamydial 
growth. TNF-o can synergise with IFN-y; however, it cannot control the growth 
independently of IFN-y in epithelial cells in wfro (Summersgiii et al., 1995). Other 
reports claim that TNF-o controls chlamydial growth in monocytes in vitro in an IFN-y 
independent manner. TNF-p also inhibits chlamydial growth in epitheliai celis, but it 
does so by inducing nitric oxide synthase expression and production of nitric oxide 
(NO), a powerful bacteriostatic. Another interesting finding is that TNF-(3 can be added 
to ceii cultures at the time of the infection or even up to 16 hours post-infection, and 
it still inhibits the growth (Matsushima et ai., 1999).
Other cytokines contribute to anti-chlamydial immunity by indirect activation of 
specific cell-mediated responses. IL-6 is released by infected epitheliai ceiis and
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macrophages. Early IL-6 production may contribute to Thl-type immune responses by 
inhibiting CD4+CD25+ regulatory T ceil responses (Pasare and Medzhitov, 2003). On 
the other hand, IL-10, a cytokine that down-reguiates inflammatory responses, is 
released by infected MdMs. It down-regulates MHC class I expression, and renders the 
infected ceiis resistant to apoptosis, and both of these events can modify immune 
responses and favour the establishment of persistence (Caspar-Bauguii et al., 2000, 
Geng et al., 2000a). IL-10 knockout mice experience a shorter duration of infection, 
less microbial burden and limited ascending infection compared to wiid-type mice in C. 
trachomatis genital infections (Igietseme et al., 2000). Another regulatory mediator 
produced in responses to C. pneumon/ae infection is PGEz. PGEz can inhibit the 
production of IL-12, IL-6 and TNF-o from macrophages activated with LPS, paired with 
an increased IL-10 production (van der Pouw Kraan TC et ai., 1995, Strassmann et 
ai., 1994). PGEz can also suppress IFN-y production by inhibiting gene transcription 
and inducing a Th2-type dominant immune response (Katamura et al., 1998).
In summary, cytokines released in response to chlamydial infections contribute to the 
control of growth, and also to the immunopathoiogy caused by Chlamydiae thereby 
determining the outcome of the infection.
1.5.9 Factors contributing to chlamydial persistence
From the research to date it is clear that there is a highly complex relationship
between Chlamydiae and their hosts, and it is therefore likely that the establishment
of persistence in chlamydial infections is a combination of pathogen driven
mechanisms and the host immune response. As discussed previously Chlamydiae
actively inhibit "digestion" by the host ceil and modify the environment in order to set
up a successful infection. Apoptosis is an active process of cellular suicide triggered by
a variety of physiological and stress stimuli. It  is considered a primary defence against
intracellular infections and can limit the spread of intracellular pathogens by provoking
inflammatory responses and phagocyte activation. Chlamydia-infected ceiis are highly
resistant to apoptosis induced by a variety of stimuli including TNF-o, Fas antibody,
granzyme B/perforin, and staurosporine. These factors interfere with many apoptotic
pathways through blockade of mitochondrial cytochrome c release or caspase-3, both
29
crucial points in apoptosis (Fan et al., 1998, Airenne et ai., 2002, Greene et ai., 2004, 
Perfettini et al., 2003, van Zandbergen et al., 2004). Apoptosis resistance seems to 
correlate with IL-10 production from infected PBMC, while in neutrophils it is IL-8 
dependent (Geng et ai., 2000b, van Zandbergen et ai., 2004). Concentrations of IFN-y 
that induce the formation of aberrant, persistent Chlamydiae, inhibit apoptosis 
following C. muridarum infection. These results suggest that IFN-y may contribute to 
pathogenesis of persistent Chiamydia infections in vivo by preventing apoptosis of 
infected ceiis (Perfettini et ai., 2002).
Another pathogen-driven mechanism of persistence might be inhibition of major 
histocompatibility complex (MCH) activation. MHC-peptide complex expression is 
crucial for mounting an antigen-specific immune response. MHC class I and class I I  
are recognised by CD8+ and CD4+ celis respectively, and to avoid recognition many 
intracellular pathogens have evolved strategies for inhibiting MHC expression on the 
infected cells (Reiner et ai., 1987, Schuller et al., 1998). Chlamydiae inhibit MHC 
expression through a chlamydial protease- or proteasome-iike activity factor (CPAF) 
(Zhong et ai., 2001). This factor mediates the degradation of upstream stimulatory 
factor (USF-1) specific for MHC class I I  expression and RFX5 downstream transcription 
factor specific for the IFN-y-dependent induction of MHC class I expression (Zhong et 
ai., 1999, Zhong et ai., 2000). Down-reguiation of MHC class I expression is also 
associated with IL-10 production by the infected celis (Caspar-Bauguii et al., 2000). 
MHC molecules can be expressed by non-professional APCs, such as epithelial cells 
and levels of MHC expression on epitheliai ceils can be significantly up-regulated by 
IFN-y. IFN-y dependent induction of MHC expression may greatly enhance the ability 
of the infected ceiis to present the pathogen-derived peptide on the cell surface for T 
cell recognition and activation of Thl-type immunity. It seems that the inhibition of 
the IFN-y signalling pathways would be a useful way to evade T ceil activation. 
Suppressors of Cytokine Signalling (SOCS) are a group of negative regulators of 
cytokine signalling that are up-reguiated by certain pathogens, and interfere with 
cytokines and IFN-y in particular (Stoiber et al., 2001, Imai et al., 2003). The role of
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s o c s  in relation to IFN-y and control of chlamydial growth will be discussed in chapter 
6.
1.6 Anti-chlamydial therapy
1.6.1 Antibiotic treatment
Given the serious implications of a prolonged chlamydial infection there is a growing 
interest in finding a suitable therapy and developing an effective vaccine to protect 
against chlamydial infection and prevent tissue pathology. A large number of 
antibiotics have been tested in vitro and C. pneumoniae is susceptible to three families 
of antibiotics: tetracyclins, macrolides and fluoroquinones (Fenelon et al., 1990, Lipsky 
et al., 1990, Robiin and Hammerschiag, 1998, StrigI et ai., 2000, Roblin and 
Hammerschiag, 2000, Miyashita et ai., 2001, Roblin and Hammerschiag, 2003, 
Hammerschiag et al., 2003, Miyashita et al., 2003). However, in vitro results must be 
assessed by clinical and pharmacokinetic studies by measuring the outcome of the 
infection in relation to serum, tissue and intracellular levels of different antibiotics. 
Azithromycin, levoflaxin and clarithomycin are now commonly used to treat C  
pneumoniae respiratory infections. Ail three compounds are associated with lower 
levels of inflammatory cytokines produced by epithelial celis; however they do not 
eradicate the infection even after prolonged treatment up to 30 days (Kutlin et al., 
1999, Kutlin et ai., 2002). Azithromycin therapy is associated with decreased cytokine 
levels and overall reduction of inflammation but the effects are not long-term 
(Anderson and Muhlestein, 2000, Muhlestein et al., 2000, Semaan et al., 2000). Also, 
antibiotic treatment does not affect chlamydial growth in infected monocytes, 
something that can further aid their role in atherogenesis (Gieffers et ai., 2001). 
Therefore, immediate therapy of acute infection may be necessary to prevent the 
proatherogenic effects of C. pneumoniae infection. In the light of these findings early 
detection is crucial but it is difficult in major part due to the lack of readily available, 
standardized diagnostic methods. In addition recent studies of serologic and PCR 
assays for diagnosis of C. pneumoniae infection have suggested that there may be 
substantial inter-iaboratory variation in the performance of these tests (reviewed by
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(Boman and Hammerschiag, 2002). Until such time as there is a sensitive and reliable 
test, effective antibiotic therapies of C. pneumoniae infections will remain difficult.
1.6.2 Vaccine development
Understanding chlamydial immunobiology gives us important information for vaccine 
design. The research to date shows that Thl-type T cell-dependent responses convey 
protective immunity, whereas Th2-type responses are associated with 
immunopathoiogicai responses connected with the worsening of bacterial load and 
disease severity in mice (Rottenberg et ai., 1999). On the basis of this knowledge 
there are many ongoing attempts to develop an effective and safe anti-chiamydiai 
vaccine. Currently many of these are targeted toward the development of a DNA 
vaccine based on a protective chlamydial antigen. DNA vaccination is defined as the 
use of selected genes from pathogenic microorganisms within a eukaryotic expression 
plasmid. The plasmids contain methylated CpG motifs, which elicit innate cytokine 
responses that promote Thl-type immune responses. Intracellular synthesis of the 
microbial protein, especially within transfected professional antigen-presenting ceils, 
facilitates the presentation of antigen on MHC class I and class I I  molecules and the 
induction of cell-mediated immunity.
It  is crucial to identify the chlamydial antigens that are suitable for use in vaccination. 
Sequencing the chlamydial genome was a major step in this process. MOMP is the 
most promising candidate for a vaccine against C. trachomatis genital infections. It  
induces protective immunity when administered in a variety of delivery vehicles and 
adjuvants (naked DNA; CpG motifs; Freund's adjuvant; lipophilic immune response- 
stimulating complexes (ISCOMs); MOMP DNA-transfected Saimoneiia typhimurium) 
recombinant Vibrio cholerae ghosts (rVCG)), and delivery routes (oral; intranasal; 
intramuscular; subcutaneous) (Knight et ai., 1995, Pal et al., 1997, Zhang et al., 
1997, Igietseme et ai., 1998, Brunham and Zhang, 1999, Igietseme and Murdin, 
2000, Pal et al., 2002, Eko et al., 2003). Dendritic celis pulsed with recombinant 
MOMP in vitro secrete IL -12 and stimulate T cell proliferation and IFN-y production.
However, when dendritic ceiis are pulsed ex vivo with MOMP and adoptively
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transferred to naïve mice, there is a Th2 type, rather than a Th l type immune 
response and the mice are not protected from infection (Shaw et ai., 2002).
MOMP-based vaccination has aiso been shown to have protective properties against C. 
pneumoniae infections, but much weaker than the same vaccine for C. trachomatis. 
This could be for a number of reasons, like reduced expression or lower 
immunogenicity (Murdin et al., 2000). Chlamydial HSP60 is a major activator of ceii 
mediated immunity and is produced in abundance during persistence. Intranasai 
immunisation of C57B1/6 mice with an hsp60 DNA vaccine induced protection against 
C. pneumoniae that was correlated with higher IFN-y levels, was CD4+ and CD8+T 
ceii-dependent, and in which no specific antibodies were raised. Intradermal 
immunisation in the same study caused a strong specific antibody response, but no 
protection (Svanholm et al., 2000). A cocktail of plasmids containing MOMP, Omp2 
and hsp60 was used for intramuscular immunisation of BALB/c mice. Both MOMP and 
hsp60 vaccination induced a reduction in bacterial load and a strong cell-mediated 
immunity, but a weak antibody response. Omp2 caused a strong specific antibody 
reaction, but failed to protect (Penttiia et al., 2000).
In addition to DNA vaccines, efforts are also being made to develop vaccines using 
whole organisms, such as live attenuated vaccines and vaccines using nonviable 
chlamydial organisms. The advantage of this approach might be that the immunity is 
developed against ail the potential epitopes and could therefore give better protection. 
Temperature-sensitive mutants of C. abortus have been previously shown to be 
effective in preventing chlamydial abortion in sheep (Rodolakis and Bernard, 1984); 
however there are no attenuated strains of C. trachomatis or C. pneumoniae. Su et ai 
developed a surrogate live attenuated vaccine model for C trachomatis genital 
infections by treating the mice with sub-chlamydiacidal concentrations of an antibiotic 
following an infection. Antibiotic-treated mice generated levels of Chiamydia-spec\f\c 
antibody and cell-mediated immunity equivalent to those of control mice, and they 
showed the same level of protection of control infected mice (Su et al., 2000). The
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same group used dendritic celis (DCs) that were puised ex vivo with heat killed C. 
trachomatis that were then adoptively transferred into mice. DCs produced IL-12p40 
and IL-6, and induced Chiamydia-spec\f\cCD4+ Thl-type immune responses that elicit 
levels of protective immunity against chlamydial genital tract challenge equal to that 
obtained after infection with live chlamydial organisms (Su et ai., 1998).
Major efforts have been put into development of a chlamydial vaccine, but none of 
them have proven ideal. Recent advances in chlamydial genomics and proteomics 
should enhance the chance of identifying putative vaccine candidates and effective 
delivery systems.
1.7 Summary
In this chapter the current knowledge about chlamydial diseases is presented. 
Chlamydial infections and related diseases present a growing problem for national 
health systems worldwide. With the incidence of serious chronic conditions such as 
atheroscierosis and COPD projected to rise in the near future, it is vitally important to 
understand the underlying mechanisms of disease development. C. pneumoniae has 
been implicated as a contributory factor to these diseases as well as being recognised 
as a major cause of respiratory disease. C. pneumoniae induces a Thl-type immune 
response that may contribute to the immunopathoiogy associated with chlamydial 
infections. However, the mechanism by which C. pneumoniae maintains persistent 
infections and how it manipulates host cell responses are not fully understood. Further 
investigation is needed to identify these mechanisms and to better understand host- 
pathogen interactions in order to design novel therapies, and safe and effective 
prevention strategies. The experiments presented in this thesis focused on 
investigating the early immune responses following C. pneumoniae infections with a 
view to better understand how C. pneumoniae respiratory infections may contribute to 
the development of chronic diseases.
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1.8 Hypothesis and Aim o f project
As discussed above, C. pneumoniae research has shown that infection causes 
inflammatory responses, and that prolonged infections may contribute to the 
establishment and exacerbation of chronic diseases. Based on the research at the time 
of starting this project, my hypothesis was that the early immune responses of 
infected lung ceils (epithelial cells and MdMs) are responsible for the outcome of the 
acute infection and contribute to the establishment of persistence. To address this 
hypothesis, the following studies were pursued:
♦ The establishment and validation of an in vitro model of C. pneumoniae infection 
using a combination of lung epithelial ceii lines and primary biood-derived MdMs 
(Chapter 3)
♦ Investigation of the cytokine profile induced by infection in lung epitheliai ceils and 
MdMs and how these responses are modulated by the treatment of cells with IL-17 
(Chapter 4)
♦ Description of how C. pneumoniae infections change the expression of surface 
molecules on infected ceiis, and the implications of these findings for the 
development of immune responses (Chapter 5)
♦ Investigation of the control of chlamydial growth by inflammatory cytokines and 
their potential role in the establishment of persistence by the induction of 
Suppressors of Cytokine Signalling (SOCS) (Chapter 6)
♦ Preliminary studies into the role of the natural antimicrobial molecules Elafin and 
SLPI in the control of chlamydial growth. (Chapter 7)
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C h a p t e r  2
M a t e r ia l s  a n d  M e t h o d s
2.1 Cell culture and Chlamydia pneumoniae stocks
2.1.1 General culture conditions
All aspects of cell culture and the handling of Chlamydia pneumoniae were performed 
under biosafety level two conditions. All cell lines and primary cuitures were 
propagated and maintained in antibiotic-free media (unless stated otherwise) In a 
humidified 5% CO2 environment at 35°C (Thermo Life Sciences Ltd, Basingstoke, UK). 
This temperature was chosen to mimic the iung environment. Ceil viability was 
determined by nigrosine exclusion (BDH Chemicals, Poole, UK).
The following human recombinant cytokines were used: IL-17, IFN-y (R&D Systems 
Europe Ltd, Abingdon, UK). After purchase they were diluted in IMDM+5%FCS, 
aliquoted and stored at -70°C until use.
2.1.2 Cryopreservation
Cells were cryopreserved at a density of 1-4x10® viabie cells/ml in freezing medium 
which constituted of: 50% of the appropriate culture medium, 40% heat inactivated 
foetai calf serum (FCS; PAA Laboratories Ltd, Yeovil, UK) and 10% dimethylsulfoxide 
(DMSO; SIgma-Aldrich Company Ltd, Poole, UK). Cell suspensions were aliquoted into 
1ml Nunc Cryotubes (GIBCO BRL, Paisley, UK), cooled to -70°C at a rate of 
approximately l°C/minute, using a Nalgene Cryo freezing vessel containing 
isopropanol (GIBCO BRL), then transferred to liquid nitrogen for long-term storage.
2.1.3 Cell lines and growth conditions
Cells were maintained and propagated in Iscove's modified Dulbecco's medium (IMDM, 
GIBCO BRL) supplemented with 5% FCS (IMDM + 5% FCS). This medium was used in 
all cultures unless otherwise stated. The cultures were routinely maintained in 225 cm  ^
vented tissue culture flasks (Corning Costar, High Wycombe, UK). Cells were passaged 
using trypsin/versene (Appendix 9.1.2). All the cell lines used are listed in Table 2.1.
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Table 2.1 Details of cell lines used and passage rates.
C ell
LINES
T y p e  o f  cell Pa s s a g e  r a t e /
WEEKD e r iv e d  fr o m  , M o r p h o l o g y GROWTH PROPERTIES
HEP-2 Larynx Carcinoma epithelial Adherent 1:5 2x
A549 Lung carcinoma EPITHELIAL Adherent 1:5 2x
NCI-H441 Lung papillary adenocarcinoma EPTHELIAL Adherent 1:5 Ix
THP-1 Acute monocyhc leukaemia; monocyte MONOCYTE Suspension 1:10 Ix
U937 histiocytic lymphoma; macrophage MONOCYTE Suspension 1:10 Ix
2.1.4 Primary Blood-Derived Monocytes
2.1.4.1 Isolation of blood-derived monocytes
Primary blood-derived monocytes were isoiated from anonymous single donor Buffy 
coats obtained from the Scottish National Blood Transfusion Service after pathogen 
screening. The Buffy coats were transferred into a 75 cm  ^ vented tissue culture flask 
and diluted 1 in 2 with Calcium-Magnesium-free (CMF) PBS (Appendix 9.1.1). 15 ml of 
Hlstopaque-1077 (Lymphoprep™; Axis-Shield, Norway) was aliquoted into 50mi 
centrifuge tubes (Corning Costar) and using a pipette, 25ml of Buffy coat/PBS solution 
was gently layered onto the histopaque, making sure that a clear interface formed 
between the layers. This mixture was then centrifuged at 1190 g (CR422; Jouan LTD, 
Ilkeston, UK) at 20°C for 20 minutes without a brake. After the spin, a creamy layer 
was visible at the interface between the plasma and histopaque. Using a 1.5 mi 
pasteur pipette, the top section of creamy layer was gently removed and transferred 
into a new 50 ml centrifuge tube. At the bottom of the interface is where the dead and 
dying neutrophils are found. CMF-PBS was added to make up 50 ml and the cells were 
washed twice by spinning at 290g at 20°C for lOmin without a brake. After the second 
wash the cells were pooled into one tube and topped up with CMF-PBS to 50 ml, and 
then live cells were counted by nigrosine exclusion (1:20 dilution) in a 
haemocytometer. For every 10® cells, 1ml of PBS and 4ml of Red Cell Lysis Buffer 
(RCLB; Appendix 9.1.4) was added, and the solution was placed on ice for 10 minutes. 
CMF-PBS was then added to make up 50 ml and cells were washed as before at 290g 
at 4°C for lOmln. The supernatant was discarded; cells were resuspended In 50 ml of 
CMF-PBS and passed through a 40pm nylon mesh filter (Falcon; Becton Dickinson,
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Oxford, UK), to eliminate any clumps. Following the filtration the cells were recounted 
as above. Yield were typically 0.5-1x10^ cells per Buffy coat.
2.1.4.2 Purification of Monocyte-derived Macrophages (MDMs)
After the last count cells were washed and resuspended In serum-free IMDM to allow 
adherence for 2 hrs at 35°C. Cells were used at approximately 2 x 10® cells per Icm^ 
of culture surface. After two hours the cells were washed vigorously with PBS two to 
three times by pipetting the PBS over the cells. After the last wash fresh culture 
medium (IMDM+5%FCS) was added. Cells were again washed at 24 and 48 hours. 
The percentage of MdM at 48 hours varied between samples, but it was approximately 
70% of total cells as assessed by elastase and GIEMSA staining. After the last wash 
cells were used for further experiments.
2.1.5 Chlamydia pneumoniae AR39
C. pneumoniae AR39 was obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Tissue culture-derived stocks were obtained by propagation of C. 
pneumoniae in HEp-2 ceils. Sub-confluent Hep-2 cells grown in 225 cm  ^vented tissue 
culture flasks were washed with 5 ml of Hanks Buffered Saline Solution (HBSS; GIBCO 
BRL) supplemented with 0.2 mg/ml NazCOg. Following the wash the cells were treated 
with 30 pg/ml of DEAE dextran/HBSS for 20 minutes at RT. After that cells were 
incubated with 4 ml of IMDM+ 5% FCS containing C. pneumoniae at a multiplicity of 
infection (MOI) of 0.1, for 4 hours at 35°C. The inocuium was pipetted off after 4 
hours and cells were supplemented with fresh IMDM +5%  FCS containing Ipg/ml 
cycioheximide (Sigma-Aldrich Company Ltd) and 25pg/ml gentamycin (Sigma-Aldrich 
Company Ltd). Chlamydiae were harvested on day 3 by disrupting the HEp-2 cells by 
shaking the culture flask with 3mm diameter sterile glass beads. The resultant 
suspension was centrifuged at 290g for 10 minutes to remove debris. Supernatants 
were collected and centrifuged at maximum speed of 16,000g (Biofuge pico; Heraeus, 
Austria) at 4°C for 20 minutes to pellet the Chlamydiae, which were then resuspended 
in Chlamydial Transport Medium (Appendix 9.1.4) and stored at -70°C until further 
use.
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2.2 Polymerase Chain Reaction (PCR)
2.2.1 RNA extraction
Total RNA was extracted using the Qiagen RNeasy Mini kit (Qiagen Ltd, Surrey, UK) 
according to the rnanufacturer's instructions. RNeasy technology combines the 
selective binding properties of silica-gel-based membrane with the speed of microspin 
technology. A high-salt buffer system allows up to 100 pg of RNA longer than 200 
bases to bind to the RNeasy sllica-gel membrane. Samples are first lysed and 
homogenised in the presence of a highly denaturing guanidine isothiocyanate (GITC)- 
containing buffer (lysis buffer R L T ), which immediately inactivates RNases to ensure 
isoiation of intact RNA. Ethanol Is added to provide appropriate binding conditions, and 
the sample is then applied to an RNeasy mini column where the total RNA binds to the 
membrane and contaminants are efficiently washed away (wash buffers R W l  and 
R P E ). RNA is then eluted in 30 pi of RNase/DNase free water. Average RNA content 
for HeLa ceils is approximately 15 pg per 10® cells. RNA was stored at -20°C.
Following extraction the quality of RNA was checked by gel electrophoresis. This was 
done on 1% agarose gels (Appendix 9.1.5) at lOOV for 30-45 minutes. The RNA bands 
correspond to 28S and 18S RNA and were compared to an RNA marker (Ambion 
Europe Ltd, Huntingdon, UK).
The concentration and purity of RNA was determined using a spectrophotometer 
(CECIL 2041; Cecil Instruments Ltd, Cambridge, UK) by measurement of UV 
absorbance. RNA absorbs UV light at 260nm (Azeo) and protein absorbs at 280nm 
(Azso)- Samples were diluted 1:20 in RNase/DNase-free water prior to measurement. 
RNA concentration was calculated using the following equation:
|jg  R N A /m l=  A 260X 20 (d ilu tio n  fa c to r )  x  40 (convers ion  fa c to r )
Purity was determined by AzeoMzso ratio. For pure RNA samples this value is 
approximately 1.8-2 and the values obtained were within this range.
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2.2.2 cDNA synthesis
Complementary DNA (cDNA) was synthesised from total RNA using the TaqMan® 
Reverse Transcription Reagents (Applied Biosystems, Warrington UK). The kit 
includes: MultlScribe™ reverse transcriptase, RNase inhibitor, dNTP mixture, oligo 
d(T)i6, random hexamers, lOX RT buffer, MgClz solution. The mix was prepared in 25 
pi as follows: 2 pi lOX RT buffer; 4.4 pi MgClz solution; 4 pi dNTP mixture, 1 pi 
random hexamers; 0.4 pi RNase inhibitor; 0.5 pi MultiScribe™ reverse transcriptase. 
RNase/DNase-free water and 400 ng of total RNA were added to make up 25 pi. The 
whole procedure was carried out on ice. Reverse transcription was done in Hybaid PCR 
Thermal Cycler (MBS; Hybaid Ltd, Ashford, UK) using the following programme: 20 
minutes at 25°C; Ih r at 48°C; 5 minutes at 95°C; cool down at 4°C. Newly 
synthesised cDNA was diluted 1.5x with RNase/DNase-free water to obtain the 
working solution, and stored at -20°C.
2.2.3 Standard PCR
Pqiymerase Chain Reaction is a standard technique used for amplification of specific 
DNA sequences by the thermostable Taq DNA polymerase (Chlen et al., 1976). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping 
gene. The PCR reaction mixture contained the following components in order: 2.5 pi 
lOX reaction buffer; 2.5 pi of each lOx primer (100 pM); 2.5 pi of dNTP mix (2mM of 
each); 0.2 pi (1 U) of Taq DNA polymerase (Roche Diagnostics Ltd, Lewes, UK); 1.5 pi 
to 2.5 pi of cDNA and RNase/DNase-free water to give a final reaction volume of 25 pi. 
PCR conditions and genes analysed are listed in Table 2.2.
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2.2.4 Real-time RT-PCR
Real-time RT-PCR is a powerful technique used for detection and quantification of 
mRNA. It is the most sensitive method for detection and quantification of gene 
expression levels, particularly for low abundance mRNA, and to elucidate small 
changes in mRNA expression levels. The technique combines two features: the 5'-3' 
exonuclease activity of Taq polymerase and dual-labelled oligonucleotide probes, 
which only emit a fluorescent signal upon cleavage of the probe, based on the FRET 
principle (Fluorescence Resonance Energy Transfer). The target-specific probe is 
labelled with a fluorescent dye (reporter) on the terminal 5' base and a quenching dye 
(puencher) at the terminal 3' base. During the PCR the probe hybridises to an internal 
region of a PCR product and the 5' exonuclease activity of the polymerase cleaves the 
probe. This separates the fluorescent and quenching dyes and fluorescence increases 
in each cycle, proportional to the rate of probe cleavage. Fluorescence values are 
recorded during every cycle and represent the amount of product amplified to that 
point in the amplification reaction. The more templates present at the beginning of the 
reaction, the fewer number of cycles it takes to reach a point in which the fluorescent 
signal is first recorded as statistically significant above background. This value is 
defined as the CT -threshold cycle.
Generally two quantification methods can be performed: absolute and relative 
quantification. In absolute quantification the absolute number of mRNA copies is 
determined by comparison to an appropriate external calibration curve. The relative 
method is based on the expression ratio of the target gene to a reference gene. The 
following equation is most commonly used for calculation of the relative expression: 
The amount of target (gene of interest), normalized to an endogenous reference 
(18S rRNA, GAPDH) and relative to a calibrator (internal control-untreated cells), is 
given by:
2 “ Aa c t
A C T ta rg e t— (  C T ta rget“ C T re f)
—AACT= A C T ta rg e t“AC Tcaiibrator
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This is described in detail in ABI PRISM 7700 Sequence Detection System User Bulletin 
#2 (2001) (http://docs.appliedbiosystems.eom/peb1odocs/04303859.pdf).
Real time PCR was performed using ABI PRISM 7700 Sequence Detection System 
(Applied Biosystems). All the reagents and plasticware were purchased from Applied 
Biosystems: Taqman 2x PCR Mastermix, 96 well PCR plates and 8 caps strip and 
target specific primers and probes. 18S rRNA was used as the reference gene and was 
labeled with VIC (Vinyl chloride) as the reporter and the target gene probes were 
labeled with FAM (6-carboxyfluorescein). TAMRA (Tetramethylrhodamine) was used on 
both as the quencher. All the samples were run in duplicates including negative 
controls. The PCR mix was prepared in the following order: 25 pi of Taqman 2x Master 
mix; 14 pi of primer/probe mix (25pmol); 2.5 pi 18S (25pmol); 5.5 pi of 
DNAse/RNase free water. 23.5 pi was pipetted into each well and 1.5 pi of cDNA was 
added to make up a total volume of 25 pi. In negative controls 1.5 pi of water was 
added instead of cDNA. PCR conditions were: 2 minutes at 50°C and 10 minutes at 
95°C, followed by 40 cycles of 2-step PCR consisting of 15 seconds at 95°C, 1 minute 
at 60°C.
The results were analysed using the relative quantification method described above. 
Primers and probe were designed by Dr Lynn Forsyth (Centre for Inflammation 
Research, University of Edinburgh) using Primer Express software (ABI Prism, Perkin- 
Elmer, Beaconsfield, UK). Primer and probe sequences used for analysis of S0CS3 
expression are listed in Table 2.3.
Table 2.3 Primers and probes for genes analysed by Real time RT-PCR.
G e n e P r im e r / P r o b e  S e q u e n c e s
S0CS3 Forward 5'-AGAAGATCCCCCTGGTGTrGA-3'
Reverse 5'-TTCCGACAGGAGAGATGCTGAAGAGT-3' 
Probe 6fam-5'-CCGGCCCCTCTCCTCCAACG-TAMRA-3'
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2.3 Flow Cytometry
Flow cytometry is an analytical tool that allows the discrimination of different particles 
on the basis of size and colour. The profile of surface molecule expression on lung 
epithelial cells and MDMs was analysed by flow cytometry on BD FACSCalibur^*  ^ (BD 
Biosciences) using the CellQuest software (BD Biosciences). From each sample 10,000 
cells were acquired in a viable cell gate based on forward and side scatter. Molecules 
analysed are listed in Table 2.4. All antibodies were used at Ipg/m l.
Table 2.4 List of antibodies used in flow cytometry of surface molecules.
MOLECULE ORIGIN CLONE CONJUGATE CELLS ANALYSED S o u r c e
CD14 MOUSE MCA1568 RPE/FITC Md M Serotec Ltd
CD40 MOUSE MCA1590 FITC Md M Serotec Ltd
CD45 MOUSE 5BI FITC Md M Miltenyi Biotec Ltd
CD54 MOUSE MCA1615 FITC EPITHELIAL, Md M Serotec Ltd
CD91 MOUSE MCA1965 FITC Md M Serotec Ltd
CD119 MOUSE MCA1450 NONE EPITHELIAL Serotec Ltd
HLADR MOUSE G46-2.6 FITC EPITHELIAL, Md M BD Pharmingen
H LA ABC MOUSE G46-6 RPE EPITHEUAL, Md M BD Pharmingen
TLR4 MOUSE MCA2061 RPE MdM Serotec Ltd
IGGI 
ISOTYPE CONTROL
MOUSE NOT PROVIDED FITC EPITHELIAL, MdM Serotec Ltd
I gG2a 
isotype control
MOUSE NOT PROVIDED RPE EPITHELIAL, MdM Serotec Ltd
2.3.1 Flow cytometry analysis of MDMs
Monocyte-derived Macrophages (MDMs) were isolated and cultured as described in 
section 2.1.4. After the initial culture in serum-free IMDM, cells were washed and 
replenished with IMDM+15% FCS. After the last wash at 48hrs, cells were treated and 
collected at four different time points. Prior to collection, detachment buffer (Appendix
9.1.6) was added to the culture medium at 1ml of buffer per lOcm^ of culture surface 
and cells were incubated for 30 minutes at 35°C. The ceils were collected with a 
rubber cell scraper (Corning Costar) into 50ml centrifuge tubes and topped up with 
PBS. Cells were washed once by centrifugation at 290 g for 5 minutes at 4°C, 
resuspended in cold FACS wash buffer (PBS/2%FCS/0.2%NaN3) and aliquoted into 96- 
well round-bottomed plates (Fisher Scientific UK Ltd; Loughborough, UK) at
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approximately 2x10® cells per well and washed again as above. A mixture of mouse 
IgG l and IgG2a (1:100 dilution of high density culture supernatant of clones VPM20 
and 21 respectively; in-house MRI (Dutia et al., 1990)) was added for 15 minutes at 
4°C to block non-specific binding. Test antibodies were then added to the wells for 30 
minutes at 4°C. Cells were washed twice and resuspended in cold PBS and were 
analysed immediately after by flow cytometry.
2.3.1.1 Viability of MDMs
Viability of MDMs was determined using 7AAD nuclear dye (7-Aminoactinomycin D; 
Molecular Probes Europe BV, Leiden, The Netherlands) by measuring fluorescence on 
the FL-3 channel. A separate sample was stained with 5pg/ml of 7AAD for 30 minutes 
to set the channel voltage and compensation. To measure viability of all other samples 
5pl of 7AAD was added immediately prior to acquisition.
2.3.2 Flow cytometry analysis of epithelial cells
Cells were treated and collected at 4 time points. They were detached using Acutase 
(Sigma-Aldrich). Celis were washed twice with PBS, Acutase was added (enough to 
cover the surface) and left for 5 minutes at RT. Cells were collected, washed twice in 
PBS by centrifugation and aliquoted as above. Biocking of non-specific binding was 
done either with mouse IgGl/IgG2a mixture as above or with normal rabbit serum 
(1:200, MRI) depending on the test antibody. Cells were then stained with a primary 
antibody for 30 minutes at 4°C. All antibodies except anti-IFN-yR were directly 
conjugated. IFN-yR was detected using two different protocols: 2-step FITC detection 
or 3-step biotin/streptavidin-APC detection. After the primary antibody FITC- or biotin- 
conjugated rabbit anti mouse secondary antibody (DakoCytomation UK) was added, 
and left for 30 minutes. Following that, streptavidin/APC (allophycocyanin; Molecular 
Probes Europe BV) was added to the biotinylated sample for another 30 minutes. After 
the final staining, the cells were washed twice as before, resuspended in 1% 
paraformaldehyde/PBS solution, and left at 4°C until acquisition. Routine viability 
checks of epithelial cells treated with Acutase showed 90-100% viability.
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2.4 Cytokine analysis
2.4.1 ELISA
The presence of IL-6 in cell culture supernatants was analysed by Sandwich ELISA 
(Flexia, BioSource, Nivelles, Belgium) according to the manufacturer's protocol. 
Polystyrene 96 well microplates were coated with 100 pI/well of coating antibody 
diluted in PBS and left overnight in the fridge. The following day excess antibody was 
washed off and the plates were blocked with blocking solution (5%  
BSA/PBS/0.1%Tween20 (Polyoxyethylenesorbiton monolaurate; Sigma-Aldrich Ltd)) 
for 2 hrs at RT. After 2 hrs, 100 pI/well of standard and samples was added along with 
50 pi of horse radish peroxidase (HRP)-labelled detection antibody and left for 2 hours 
at RT with continual shaking. Plates were washed and 100 pi of chromogen 
tetramethylbenzidine (chromogen TMB) was added per well and incubated for 30 
minutes with continual shaking. The reaction was stopped and optical density was 
measured at 450 nm (MRX Microplate Reader; Dynex Technologies, Ashford, UK). IL-6 
concentration was calculated using Revelation computer software (Dynex 
Technologies).
2.4.2 Cytokine Bead Array
The presence of IL2p70, IL -lp , IL-8, IL-6, ILIO and TNF-o in cell culture supernatants 
was analysed by BD™ Cytometric Bead Array (CBA) (BD Biosciences, Oxford, UK) 
according to manufacturer's protocol. CBA is a particle-based immunoassay combined 
with sensitivity of amplified fluorescence detection by flow cytometry. Six bead 
populations with distinct fluorescence intensities were coated with capture antibodies 
specific for IL-8, IL -lp , IL-6, IL-10, TNF, and IL-12p70. The six bead populations were 
mixed together to form the CBA which is resolved in the FL3 channel of a BD 
FACSCalibur™ flow cytometer. The capture beads, PE-conjugated detection antibodies, 
and recombinant standards or test samples are incubated together to form sandwich 
complexes. Following acquisition of sample data using the flow cytometer, the sample 
results are generated in graphical and tabular format using the BD CBA Analysis
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Software. Statistical model is described in chapter 4 and an example is shown in 
Appendix 9.4.1.
2.5 Western Blotting
Protein expression of SOCS was studied by Western Blot. Cells were collected with 
trypsin/versene and then washed with PBS twice to get rid of any FCS, and the pellets 
were then frozen at -20°C. Whole cell lysates were prepared in the following way. 
Samples were defrosted; 1ml per 10  ^cells of freshly prepared lysis buffer (Appendix
9.1.7) was added; cells were homogenised by pipetting with a 200 pi tip 50 times and 
left on ice for 10 minutes. Using dry ice the lysates were passed through several (3-5) 
cycles of freeze/thawing with 10 minute intervals on ice. After the last cycle they were 
homogenised again as above. The lysate was then transferred into a 1.5ml eppendorf 
tube and spun down at 16000g for 3 minutes. The supernatants were aspirated and 
the concentration of protein was determined using the BCA protein assay (Pierce, 
Perbio Science UK, Tattenhall, Cheshire, UK) according to manufacturer's protocol. 
Pellets were kept frozen at -20°C. Proteins were separated by electrophoresis using 
precast 10% Bis-Tris gels in MOPS buffer (Appendix 9.1.8) (NuPAGE, Novex, 
Invitrogen Ltd., Paisley, UK) at 200V for 90 minutes. Proteins were transferred onto a 
nitrocellulose membrane (Invitrogen Ltd.) for 3 hours at 70mA per gel using a semidry 
blot. The membrane was washed 3 times (PBS/0.1% Tween 20) for 10 minutes. It  
was then blocked for 30 minutes in 5% milk/PBS/0.l%Tween 20 (dried milk powder. 
Marvel, UK). SOCSl or S0CS3 antibody (sc-9021 (SOCSl) sc-9023 (S0CS3); Santa 
Cruz Biotechnology; Insight Biotechnology Ltd., Wembley, UK; (S0CS3) Fusion 
Antibodies, Belfast, UK) was then added at 0.5 pg/ml and incubated for 1 hour at 
room temperature followed by 3 washes as above. HRP (horseradish peroxidase) 
conjugated secondary antibody was added at 0.5 pg/ml was added and incubated for 
another hour. After the incubation the proteins were detected by ECL (Amersham 
Biosciences Ltd, Little Chalfont, UK). The membrane was washed, dried and ECL was 
added for 1 minute. ECL Hyperfilm (Amersham Biosciences Ltd) was exposed to the 
membrane for different periods of time depending on the intensity of the desired 
bands. The membranes were stripped of the SOCS antibody to be re-stained for p-
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actin using the same protocol as above. Stripping buffer constituents and the protocol 
for stripping are listed in Appendix 9.1.8.
2.6 Immunohistochemistry
For analysis by immunohistochemistry cells were grown on 8-well chamber slides 
(Labtech, Nalgene Nunc). Cells were rinsed with PBS and then fixed in one of two 
ways:
(1) With 100% cold acetone for 10 minutes. Slides were then air dried at RT and 
stored at -20°C until staining. These slides were used to detect chlamydial 
infection by staining for chiamydial LPS using immunofluorescence.
(2) With 90% acetone/10% methanol for 10 minutes. Slides were air dried at RT and 
overiaid with 100 pi of 5% polyethylene glycol (PEG)/50% methanol/50%  
deionised HzO, to preserve the celluiar structure. Slides were left at RT for the 
PEG to dry out, and were then stored at RT for up to a week. These slides were 
used for analysis of SOCS expression by DAB detection and co-localisation of 
chlamydial LPS and SOCS by double immunofluorescence.
2.6.1 DAB Immunohistochemistry
S0CS3 expression was analysed by light microscopy using a DAB colour reagent 
(Diaminobenzidine; DakoCytomation UK) detection system. Slides overlaid with PEG 
were first washed in methanol for 5 minutes to dissolve the PEG. This was followed by 
a peroxidase block with 0.15%H2O2/methanol for 10 minutes. Siides were then 
washed three times with PBS for 5 minutes. After that 2-3 drops per well of avidin 
block (Vector Laboratories Ltd, Peterborough, UK) were added and left for 10 minutes, 
followed by three washes as above, and 2-3 drops of biotin block per well added for 
another 10 minutes. After another round of washing, a final Dako protein block 
(DakoCytomation) was added for 10 minutes. After that rabbit anti human S0CS3 
polyclonai antibody (sc-9023; SantaCruz; Insight Biotechnology Ltd., Wembley, UK) 
diluted in Dako Diluent (DakoCytomation) to 1:50 to 1:200 (4-1 pg/ml) was added at 
lOOpI per well and left for 30 minutes. Slides were washed five times with PBS, and 
lOOpI per well of secondary HRP conjugated goat anti rabbit antibody at 1 pg/ml
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(DakoCytomation) was added and left for another 30 minutes. Slides were washed 
again as above and 100 pi per well of Avidin/Biotin Complex (Vector ABC RTU; Vector 
Laboratories Ltd) was added, left for 30 minutes and washed three times. DAB colour 
reagent (1 drop into 1 ml of buffer; DakoCytomation) was added at 150 pi per well for 
5 minutes and washed well another 3-4 times. Slides were transferred into a staining 
rack. Nuclei were counterstained with haematoxylin for 20 seconds, washed 
thoroughly under tap water, passed through ethanol of ascending concentration (76%, 
95%, 100%) to dehydrate the cells, passed through xylene to clear, and mounted with 
a diethyl pyrocarbonate (DEPC) permanent mounting medium (Thermo Shandon UK, 
Runcorn, UK ). They were left to dry out overnight and analysed the next day.
2.6.2 Immunofluorescence
2.6.2.1 Single Immunofluorescence
Chlamydial infection was detected by mouse anti-LPS monoclonal antibody (clone 
13/4; in-house (Graham et al., 1995)). Slides were defrosted and washed in PBS for 
2-4 minutes at RT prior to staining. Anti-LPS antibody diluted 1:200 was added at 100 
pi per well and left for 30 minutes at RT in the dark. Slides were then washed 3 times 
in PBS for 5 minutes, lOpg/ml of FITC-conjugated rabbit anti-mouse immunoglobulin 
(DakoCytomation Ltd, Cambridge, UK) secondary antibody was added and left for 
another 30 minutes at RT. Slides were washed as above and nuclei were 
counterstained with 2pg/ml of PI (Propidium Iodide, Molecular Probes Europe BV) for 1 
minute and washed 3 times. Slides were mounted with 50-100 pi of Mowioi 4.88 
(Sigma-Aldrich) mounting medium. They were ieft in the fridge overnight for the 
Mowioi to harden and were then analysed on an Olympus BX50 fluorescent microscope 
using a long pass filter so to detect both PI and FITC at the same time. Photographs 
were taken on the same microscope using an Olympus PM-20 camera on high 
sensitivity film (Ektachrome 320T; Kodak).
2.6.2.2 Double Immunofluorescence
For co-localisation of chlamydial LPS and S0CS3, slides were stained by double 
immunofluorescence and analysed by confocal microscopy (Leica TCSNT confocal
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system; Leica Microsystems Heidelberg GmbH, Germany). Slides were immersed in 
methanol for 5 minutes to remove PEG, washed twice in PBS for 5 minutes and 
blocked with Dako protein block for 10 minutes. After that 100 pi of mouse anti-LPS 
(1:200; MRI) was added and left for 30 minutes. Slides were washed 5 times for 3 
minutes, and then 1.5 pg/ml of secondary Alexa Fluor® 568 conjugated goat anti­
mouse immunoglobulin (red; Molecular Probes Europe BV) was added at 100 pi per 
well. Slides were washed as above and the same procedure was repeated for S0CS3. 
Rabbit anti-S0CS3 antibody was added at Ipg/m l, and Alexa Fluor® 488 conjugated 
goat anti-rabbit immunoglobulin (green; Molecular Probes Europe BV) was added at 1 
pg/ml. After the last antibody, slides were washed 5 times as above and nuclei were 
counterstained with 100 pi of 2 pM To-Pro (blue; To-Pro®3-iodide; Molecular Probes 
Europe BV) for 5 minutes. Slides were then washed twice with PBS and once with ultra 
pure water. They were mounted with Mowioi, left in the fridge overnight and anaiysed 
the next day by confocal microscopy.
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C h a p t e r  3
IN  VITRO  MODEL OF CHLAMYDIA PNEUMONIAE  INFECTION IN  
THE LUNG
3.1 Introduction
The aim of the project was to analyse the earliest immune responses to primary C. 
pneumoniae infection of the lung in humans with a view to understanding how these 
early responses contribute to long term persistent infections. It would have been 
desirable to study the host cell-pathogen interactions in primary human lung epithelial 
cells; however it is becoming increasingly difficult to obtain primary human material 
for research purposes and gain ethical approval. Taking this into consideration a 
combination of established human iung epitheiial cell lines and primary biood derived 
monocytes was used to establish a model of early C. pneumoniae infection in vitro. In 
this chapter the establishment of the model will be discussed in detail.
3.2 Experimental Approach
Cell culture conditions, propagation of C. pneumoniae and purification of primary 
blood-derived monocytes are described in detail in section 2.1. Flow cytometry 
analysis of A549 and HEp-2 cells is described in section 2.3.2 and immunofluorescent 
staining of infected cells in section 2.6.2.1.
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3.3 Results and Discussion
3.3.1 Growth of C. pneumoniae in transformed lung epithelial 
cell lines
Host cell phenotype has a bearing on the size and appearance of the inclusions and 
the rate of C. pneumoniae growth. In order to establish a suitable model for the study 
of early immune responses in lung epithelial cells, three different lung epithelial cell 
lines were initially considered for this model:HEp-2 cells, derived from a larynx 
carcinoma, used commonly for C. pneumoniae studies; A549 cells derived from a lung 
carcinoma, a cell line widely used for in vitro human lung work, commonly described 
as a type I I  pneumocyte (Lieber et al., 1976); and H441 cells, derived from a papillary 
adenocarcinoma of the lung.
All three cell lines supported C. pneumoniae growth; however, H441 cells were later 
abandoned due to their slow growth (division time around 50 hours) and also a 
heterogeneous appearance of cells in culture (Figure 3.1). A549 and HEp-2 cells were 
used in all other experiments and their ability to support C. pneumoniae growth is 
discussed in this section.
infected cells uninfected cells
Figure 3.1 Infection of H441 lung epithelial cells. Cells were seeded In 8 well chamber 
slides at a density of 10^ cells/ml and cultured overnight. They were infected with C. 
pneumoniae (M0I=1) and samples were collected 72 hours after infection. Cells were stained 
for chlamydial LPS (green) and nuclei were counter stained with propidium iodide (red). 
Original magnification 200x. Experiment repeated 4x.
HEp-2 cells were used for propagation of C. pneumoniae stocks. During propagation of 
C. pneumoniae in HEp-2 cells it was observed that it takes around 72 hours for the 
inclusions to become visible in culture. Prior to, and after 72 hours (around 96 hours)
the inclusions are not visible. At 72 hours there are also some inclusions visible in the
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culture medium that were probably released whole from the infected cells. Their 
number is dependent on the initial multiplicity of infection (MOI) added to the cells. 
The appearance of inclusions in cell culture is shown in Figure 3.2.
Uninfected ceils
n fected  ceils 72  hours
Figure 3.2 Propagation of C. pneumoniae in HEp-2 cells over 72 hours. Cells were infected with 
C. pneumoniae (MOI=0.2). Pictures were taken from cells in culture on a phase contrast light 
microscope. Key: red arrows - inclusions; yellow arrows - nuclei; green circles - floating 
inclusions. Original magnification 400x. Experiment repeated more than 5x.
During propagation of C. pneumoniae stocks HEp-2 cells were maintained in medium 
containing cycioheximide (Ipg /m l) to arrest cell growth and allow more abundant 
growth of C. pneumoniae. Cycioheximide treatment may affect the kinetics of 
chlamydial growth compared to untreated cells. To ascertain whether there is a
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difference, HEp-2 cells were infected for 6 days and kept in cycloheximide-free 
medium. Samples were collected every 24 hours and stained for chlamydial LPS. The 
results of this experiment are presented in Figure 3.3. There is no 48 hour sample due 
to technical error; however the appearance of the cells at that time point was similar 
to that shown for A549 cells (Figure 3.4 B).
MOI=10 M0I=1 uninfected
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Figure 3.3 Kinetics of infection of HEp-2 cells over 144 hours. HEp-2 cells were seeded in 8 
well chamber slides at 10^ cells/ml and were left overnight. They were infected with C. 
pneumoniae MOI of 1 or 10 and cells were fixed and examined at 24 hour intervals for up to 6 
days. Cells were stained for chlamydial LPS (green) and nuclei were counter stained with 
propidium iodide (red). Key: Left column MOI=10; Centre column M0I=1; Right column 
uninfected cells. (A) to (E) cells analysed 24 to 144 hours after infection. Original magnification 
200x. Experiment repeated 3x.
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This experiment confirmed that the growth cycle of C. pneumoniae is approximately 
72 hours in HEp-2 cells. The inclusiohs develop over 72 hours (Figure 3.3 A and B) 
such that by 96 hours chlamydial particles are released giving the inclusions a "halo" 
appearance (Figure 3.3 C). Over the foliowing 48 hours the release of particles 
continues, and this results in the staining being spread out throughout the HEp-2 
monoiayer (Figure 3.3 D and E). There is a consistent difference in the number of 
inclusions and the amount of LPS between the two muitiplicities of infection. Also 
when infected with M 0I=1, there are more cells in the monolayer in the later stages of 
the infection compared to MOI=10, indicating that higher concentrations of C. 
pneumoniae induce more ceii death (Figure 3.3 D and E).
The same experiment was repeated with A549 cells and the results are shown in 
Figure 3.4. A549 cells support chlamydial growth over the entire period of study (144 
hours). The appearance of the inclusions and the kinetics of their growth are similar to 
HEp-2 cells. However there is one obvious difference between the two cell lines and 
that is the amount of LPS in the later stages of infection. The staining on A549 celis is 
iess "messy" compared to HEp-2 cells throughout the infection. These results show 
that infected A549 cells release less LPS than infected HEp-2 cells. It  has previously 
been shown that the amount of LPS released by Chiamydia-'mfected cells correlates 
with the number of inclusions in the cells (Brown et al., 2001). To ascertain whether 
there is a difference in the amount of LPS released by A549 and HEP-2 cells, the levels 
of LPS from one experiment (corresponding to the images presented) were anaiysed 
by ELISA and those results are shown in Figure 3.5. There was a clear difference in 
the amount of LPS released from HEp-2 and A549 cells. HEp-2 cells released LPS in 
the later stages of infection, while A549 cells did not release detectable levels of LPS. 
The sensitivity range of this ELISA is between 0.78 -100 pg/mi.
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Figure 3.4 Kinetics of infection of A549 cells over 144 hours. A549 cells were seeded in 8 well 
chamber slides at 10^ cells/ml and were left overnight. They were infected with C. pneumoniae 
MOI of 1 or 10 and cells were fixed and examined at 24 hour intervals for up to 6 days. Cells 
were stained for chlamydial LPS (green) and nuclei were counter stained with propidium iodide 
(red). Key: Left column MOI=10; Centre column M0I=1; Right column uninfected cells. 
(A) to (F) cells analysed 24 to 144 hours after infection. Original magnification 200x. 
Experiment repeated 3x.
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Figure 3.5 Release of LPS by infected lung epithelial cells. (A) HEp-2 cells (B ) A549 cells. Cells 
were infected with C. pneumoniae (M0I=1 or 10) and samples were collected at 24 hour 
intervals for up to 6 days. This experiment was not repeated; the supernatants analysed 
correspond to the images shown in images 3.3 and 3.4
Having selected A549 and HEp-2 cells as models of infection, the next step was to 
perform a similar analysis on monocytes.
3.3.2 Growth of C. pneumoniae in monocytes
Initially, two human pro-monocytic cell lines were chosen for analysis of C. 
pneumoniae infections in monocytes. These were THP-1, a commonly used cell line 
derived from peripheral blood acute monocytic leukaemia, and U937, a pro-monocytIc 
cell line derived from histiocytic lymphoma. Both of these cells grow in suspension and 
are not adherent. Both cell lines supported C. pneumoniae growth as can be seen in 
Figure 3.6. However these cells were difficult to mature and this presented a technical 
barrier for the type of experiments I wanted to do with monocytes, so these cells were 
abandoned in later experiments in favour of primary blood-derived monocytes.
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Figure 3.6 Infection of U937 and THP-1 human pro-monocytic cell lines. (A) THP-1 cells (B) 
U937 cells. Cells were cultured in suspension at 10^ cells/ml. They were infected with C 
pneumoniae (M0I=1) for 72 hours. Cytocentrifuge preparations were stained for chlamydial LPS 
(green) and nuclei were counter stained with propidium iodide (red).
As can be seen in Figure 3.7, primary MdMs can support the growth of C. pneumoniae 
for at least 6 days. The fully developed inclusions are seen between 72 and 96 hours 
(Figures 3.7 C and D) implying a difference in the kinetics of infection compared to 
lung epithelial cell lines. In later stages, the cells are larger and there is more staining 
present in the cytoplasm (Figure 3.7. F). However LPS staining in the cytoplasm of 
infected MdMs is not as marked as in infected HEp-2 cells (Figures 3.3 D and E, and 
3.7 F). To confirm this, the amount of LPS released from infected MdMs was measured 
by LPS ELISA as described above. As can be seen in Figure 3.8, MdMs do not release 
detectable levels of LPS.
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Figure 3.7 Infection of primary blood derived MdMs over 144 hours. Cells were seeded in 8 well 
chamber slides at 10® cells/ml and were cultured for48 hours. After 48 hours cells were Infected 
with C. pneumoniae (M0I=1 or 10). Cells were fixed and examined at 24 hour intervals for up 
to 6 days. Cells were stained for chlamydial LPS (green) and nuclei were counter stained with 
propidium iodide (red). Key: Left column MOI=10; Centre column M0I=1; Right column 
uninfected cells. (A) to (F) cells analysed 24 to 144 hours after infection. Original magnification 
200x. Experiment repeated 3x.
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Figure 3 .8  Release o f LPS by infected prim ary MdMs over 144 hours. Cells were seeded 
in 8 well chamber slides at 10® cells/ml and were cultured for 48 hours. After 48 hours cells 
were infected with C. pneumoniae (M0I=1 or 10) and samples were collected at 24 hour 
intervals for up to 6 days. This experiment was not repeated and the supernatants used 
correspond to the images shown in the Figure 3.7
In summary, primary MdMs can support the growth of C. pneumoniae for at least 6 
days; however infected MdMs do not release measurable quantities of LPS. This may 
also mean that unlike highly susceptible HEP-2 cells, infected MdMs do not release 
infectious progeny. Other studies have shown that in vitro growth of C. pneumoniae in 
monocyte/macrophages is restricted and the amount of infectious progeny released is 
different. The number of infectious progeny seems to be dependent on both the length 
of time primary MdMs spend in culture prior to infection, and also on the stage of MdM 
differentiation. However the number of infectious progeny released by infected MdMs 
is always lower compared to epithelial cells (Quinn and Gaydos, 1999, Airenne et al., 
1999, Kaukoranta-Tolvanen et al., 1996, Kaukoranta-Tolvanen et al., 1996).
3.4 Model
In order to establish a model for this project the following findings were considered:
♦ All cell types analysed support the growth of C. pneumoniae
♦ C. pneumoniae growth cycle in HEp-2 and A549 human lung epithelial cells lasts 
approximately 72 hours
♦ C. pneumoniae growth cycle in primary MdMs is between 72 and 96 hours long
♦ There are differences in the amounts of LPS released following infection of different 
cell types
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Taking these facts together the following in vitro model was established:
♦ Human lung epithelial cell lines A549 and HEp-2 and primary blood-derived MdMs
♦ All responses following infection of human lung epithelial cell lines A549 and HEp-2 
were studied within the time of one cycle of C. pneumoniae growth, i.e between 72 
and 96 hours
♦ All responses in primary MdMs were studied within one cycle of C. pneumoniae 
growth and this is between 72 and 96 hours
O
Figure 3.9 In vitro model of C. pneumoniae infection. This schematic represents possible cell to 
cell interactions of infected cells. Key: Blue cells -  lung epithelial cells; red dots -  chlamydial 
particles; pink cell -  MdM; rectangles - cell surface receptors.
The model is presented in Figure 3.9 and it was used throughout the project. A variety 
of immune responses were analysed and these are presented in the following chapters 
as outlined in the aims of project section of chapter 1 (page 35).
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C h a p te r  4  
P r o f i le  o f  c y to k in e s  a n d  chem okines in d u c e d  by  
Chlamydia pneumoniae  in fe c t io n  a n d  M o d u la t io n  o f
RESPONSES BY I L - 1 7
4.1 Introduction
C. pneumoniae infection in the lung induces a pro-inflammatory response that is 
characterised by the release of pro-inflammatory cytokines and chemokines, and by 
the infiltration of neutrophils and monocytes soon after infection. The underlying 
mechanisms of cytokine production, cell recruitment and activation of inflammatory 
cells are not fully understood. (Molestina et al., 1999)) have shown that infection of 
endothelial cells with C. pneumoniae Is followed by IL-8 release and migration of 
neutrophils into the site of the infection. Lung epithelial cells also produce IL-8 and 
therefore can contribute to the inflammation. However, it is likely that other 
inflammatory mediators contribute to the process of the immune response activation. 
One such mediator with an emerging importance in lung immune responses and lung 
infections is XL-17.
Recently it has become clear that IL-17 plays a crucial role in lung pathology through 
its involvement in neutrophil recruitment and activation. Enhanced levels of IL-17 are 
found in chronic conditions such as asthma and chronic bronchitis, and also in severe 
acute inflammation (Molet et al., 2001, Barczyk et al., 2003). High concentrations of 
IL-17 are associated with high neutrophil counts (Laan et al., 2002) and it has been 
shown that IL-17-mediated neutrophil recruitment and activation is dependent on IL-8 
and MIP-2 produced by bronchial epithelial cells and on autocrine production of these 
chemokines by neutrophils themselves (Laan et al., 1999, Hoshino et al., 2000, Linden 
et al., 2000, Ferretti et al., 2003). Neutralisation of IL-17 inhibits the neutrophil 
recruitment associated with LPS challenge (Ferretti et al., 2003, Miyamoto et al.,
2003). LPS induces rapid release of IL-17, and in addition IL-17 has been shown to be
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crucial for clearance of Klebsiella pneumoniae infections in the lung (Ye et al., 2001a). 
K. pneumoniae Infection triggers a rapid release of IL-17 as early as 12 hours after 
infection and the levels are maintained over 48 hours. Mice deficient in IL-17 receptor 
exhibit higher bacterial load, lower levels of G-CSF and MIP-2 in the lung, and 100%  
mortality 48 hours after K. pneumoniae infection (Ye et al., 2001b). On the other 
hand, over-expression of IL-17 in the lung by adenoviral transfection is associated 
with increased neutrophil recruitment and the release of MIP-2, TNF-a, IL -Ip  and G- 
CSF as well as enhanced bacterial clearance and survival (Ye et al., 2001a). IL-17 
production is also associated with other infections; however its effects have not been 
extensively studied (Infante-Duarte et al., 2000, Patera et al., 2002).
The principal sources of IL-17 are activated T cells, both CD4+ and CD8+, of both 
type 1 (IFN-y) and type 2 (IL-4). However other cells, such as eosinophils, neutrophils 
and macrophages, can also release IL-17 (Molet et al., 2001, Ferretti et al., 2003, 
Miyamoto et al., 2003). K. pneumoniae-inàuceâ release of IL-17 from activated CD4+ 
and CD8+ T cells has been shown to be TLR-4 dependent and mediated at least in 
part by IL-23 production from DC (Happel et al., 2003). Whether IL-17 release is TLR- 
4-dependent in all cells remains to be investigated. IL-17 is a potent inducer of 
cytokines from different cell types. In vitro it can increase the synthesis of IL-11 and 
IL-6 by bronchial fibroblasts (Molet et al., 2001), the production of IL-6 and IL-8 by 
bronchial epithelial cells (Kawaguchi et al., 2001) and can activate primary 
macrophages to release IL -lp , TNF-a, IL-6, IL-10, IL-12 and PGEz (Jovanovic et al., 
1998).
The role of IL-17 in C. pneumoniae infections has not been reported to date; however, 
it is possible that it plays a crucial role in Chlamydia-'mbuceô immunopathology. There 
are a number of parallels to be drawn between IL-17-dependent and Chlamydia- 
induced immune responses: chlamydial lung infections are associated with early 
neutrophil recruitment and activation (Yang et al., 1994, van Zandbergen et al.,
2004); there is a strong infiltration of T cells (Penttila et al., 1998); and the cytokine
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profile Induced by C. pneumoniae Is similar to that of IL-17 treatment.
Taking all of these facts into consideration this study was designed to investigate the 
following:
♦ Release of cytokines by infected epithelial cells (A549 and HEp-2) and infected 
MdMs
♦ Release of cytokines following IL-17 treatment by epithelial cells and MdMs
♦ Modulation of immune responses to C. pneumoniae infection by IL-17
♦ Activation of MdMs by infected epithelial cells measured by cytokine production
4.2 Experimental approach
Cytokine production by epithelial cells and MdMs was analysed using the Human 
Inflammation CBA kit (IL -ip , TNF-a, IL-8, IL-6, IL-10 and IL-12; BD Biosciences) The 
method is described in detail in section 2.4.2 of Chapter 2. A sample standard curve is 
presented in Appendix B. IL-6 production by MdMs treated with conditioned medium 
was measured by ELISA as described in section 2.4.1 of Chapter 2. Isolation and 
culture of MdMs is described in section 2.1.4.
Briefly, A549 and HEp-2 lung epithelial cells were seeded at 2x10^ cells/ml per well in 
24 well plates in IMDM+5%FCS and left to adhere overnight. MdMs were isolated and 
seeded at 2x10® cells/ml per well in 24 well plates and left in culture for 48 hours in 
IMDM+5%FCS. Cells were treated as follows:
♦ Infected with C. pneumoniae at M 0I=1 or 10, with or without 50 ng/ml IL-17; 
samples were collected at different time points up to 96 hours after infection. The 
experiment was repeated with epithelial cell lines three times, while MdMs isolated 
from six donors were analysed.
♦ In a separate experiment the MdMs were treated with 10% conditioned medium 
(CM) that was prepared from A549 cells infected with C. pneumoniae (M 0 I= 1 ). 
A549 cells were infected for 24, 48 or 96 hours. The supernatants were collected, 
filtered through a 0.2pm filter to remove chlamydial particles, and stored at -20°C  
until use. After thawing, the supernatants were diluted to 10% by adding fresh 
IMDM+5% FCS. MdMs were treated with CMs harvested at different times and
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supernatants were collected 24, 48 and 96 hours after CM-treatment. This was 
repeated on MdMs isolated from three donors.
Statistical model and analysis
Because of the unbalanced nature of the data the REML directive was used in Genstat 
edition to fit a model to the data (GenStat Committee (ed.R.W.Payne), 2000). A 
repeated rheasures model was used with a uniform correlation structure (subjects 
were taken as the donor/treatment combinations or experiment/treatment 
combinations). This is equivalent to fitting a split-plot model with donors designated 
as blocks, treatments as main plots and time as split plots. The data for each cytokine
were positively skewed and so all analyses have been carried out using log
transformed data, logio(x+l).
For the CM experiments, a Student's t  test was performed and the significance was 
determined as follows:
P value greater than 0.1 not significant
P value less than 0.05 significant
4.3 Results
4.3.1 Cytokine release by lung epithelial ceils following C. 
pneumoniae infection and IL-17 treatment
Epithelial cells (A549 and HEp-2) were treated as follows: untreated cells; C. 
pneumoniae M 0I=1; C. pneumoniae MOI=10; IL-17 50 ng/ml; C. pneumoniae M 0I=1  
+ IL-17 50 ng/ml; C. pneumoniae MOI=10 + IL-17 50 ng/ml. Production of IL-8, IL-6, 
IL-10, IL-12p40, IL -lp  and TNF-a following the treatments was analysed by CBA. 
Neither A549 nor HEp-2 cells produced detectable levels of IL -lp , TNF-a, IL-10 or IL- 
12p40. IL-6 and IL-8 were produced by both cell lines.
The data are presented as both tables and charts of the logio of the means from three 
independent experiments, with standard error bars for each data set (Figures 4.1 to 
4.4). The raw data are presented in Appendix 3 (Section 9.3 of Chapter 9).
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Figure 4.1 IL-6 production (pg/ml) by HEp-2 cells. The values presented are logio of means 
from three independent experiments. Error bars in the chart express the SE value. SE=0.05443 
Note: values in blue are over the limit of the assay (5000 pg/ml) and were taken as the 
maximum value. This may bias the data slightly.
T im e T r e a t m e n ts
CONTROL IL-17 MOI=l M0I=1 +IL-17 MOI=10 MOI=10 +IL-17
24 HR 1.904 2.62 2.027 2.906 2.246 2.835
48 HR 2.013 2.695 2.065 2.878 2.59 3.147
96 HR 2.581 3.144 2.787 3.455 3.699 3.699
4
3.5
L:
1* 2
1.5 
1
24
HEp-2 IL-6
48
t im e
96
□  control
□  IL-17
□  M0I=1
□  M0I=1 +IL-17
□  MOI=10
■  MOI=10+IL-17
Figure 4.2 IL-8 production (pg/ml) by HEp-2 cells. The values presented are logio of means 
from three independent experiments. Error bars in the chart express the SE value. SE=0.09128 
A) table; B) chart. Note: values in blue are over the limit of the assay (5000 pg/ml) and were 
taken as the maximum value. This may bias the data slightly.
T im e
T r e a t m e n ts
CONTROL IL-17 MOI=l MOI=l +IL-17 MOI=10 MOI=10 +IL-17
24 HR 0.89 1.185 0.905 1.535 1.179 1.27
48 HR 1.041 1.377 1.035 1.612 1.366 2.025
96 HR 1.332 1.907 1.532 2.375 3.699 3.699
HEp-2 IL-8
E 2.8
□  control
■  IL-17
□  M0I=1
□  M0I=1 +IL-17
□  MOI=10
■  MOI=10+IL-17
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Figure 4.3 IL-6 production (pg/ml) by A549 cells. The values presented are logio of means from
three independent experiments. Error bars in the chart express the SE value. SE=0.1065 A)
table; B) chart
T im e T r e a t m e n ts
CONTROL IL -17 M O I= l M O I= l + IL -17 M OI=10 M O I=10 + IL -17
2 4  HR 0.95 1.08 0.949 1.054 1.595 1.344
4 8  HR 0.655 0.799 0.896 0.994 1.531 1.538
9 6  HR 0.828 1.058 1.076 1.054 1.771 1.649
A549 IL-6
5» 1.1
□ control
□ IL-17
□ M0I=1
□ M0I=1 + IL-17
□ MOI=10
■ MOI=10 + IL-17
Figure 4 .4  IL-8 production (pg/ml) by A549 cells. The values presented are logio of means from 
three independent experiments. Error bars in the chart express the SE value. SE=0.1391 A ) 
table; B) chart
T im e
T r e a t m e n ts
CONTROL IL -17 M O I= l M O I= l + IL -17 M O I=10 M O I=10 + IL -17
24  HR 1.171 1.472 1.204 1.481 1.952 1.683
4 8  HR 1.306 1.662 1.581 1.772 1.581 2.589
9 6  HR 2.787 3.155 3.103 3.162 3.103 3.568
4 n
3.5 J
1 '1
I  2.5 
g 2 -j
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24
A549 IL-8
à a
A #
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96
□ control
□ IL-17
□ M0I=1 
oMOI=1 + IL-17
□ MOI=10
■ MOI=10 + IL-17
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In sum m ary, C. pneum oniae  induces an in flam m atory response in lung epithe lia l cells 
by induction of IL-8  and IL-6. D ifferent cells lines preferentia lly  produce d iffe ren t 
cytokines (HEp-2 produce more IL-6  and A549 produce more IL -8 ). The production o f 
both cytokines is dose and tim e dependent in both cell lines. IL-17 trea tm en t o f both 
uninfected and infected cells increases levels o f IL-8 both cell lines. IL-6  levels are 
increased by IL-17 trea tm en t in HEp-2 cells, while in A549 cells there is a downward 
trend in infected cells.
The same set o f experim ents was repeated w ith MdMs and the results are presented in 
the follow ing section.
4.3.2 Cytokine release by MdMs following C. pneumoniae 
Infection and modulation by IL-17 treatment
The production of in flam m atory cytokines by MdMs was analysed by CBA. The results 
are presented as logio o f means from  6 donors, grouped by cytokines and they are 
presented as both tables and charts (Figures 4.5 to 4 .10). A sum m ary o f the statistica l 
analysis is presented at the end o f th is  section. The raw data are presented in 
Appendix 3 (section 9.3 o f chapter 9).
Figure 4.5 IL-6 production (pg/ml) by MdMs. The values presented are logio of means from six 
donors. Error bars in the chart express the SE value. SE=0.3266 A) table; B) chart
T im e T r e a t m e n ts
CONTROL IL -17 M O I= l M O I= l + IL -17 M OI=10 M O I=10 + IL -17
24 HR 0.716 0.561 3.284 3.189 3.661 3.676
48 HR 0.843 1.343 3.78 3.884 4.438 4.319
96 HR 0.788 0.757 3.848 3.808 4.487 4.501
IL-6
tim e
a
96
□  control
■  IL-17
□  M0I=1
□  M0I=1 +IL-17
□  MOI=10
■  MOI=10 +IL-17
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Figure 4.6 IL-8 production (pg/ml) by MdMs. The values presented are logio of means from six 
donors. Error bars in the chart express the SE value. SE=0.1286 A) table; B) chart. Note: 
values in blue are over the limit of the assay (5000 pg/ml) and were taken as the maximum 
value. This may bias the data slightly
T im e T r e a t m e n ts
CONTROL IL -17 M O I= l M O I= l+ IL -1 7 M OI=10 M O I=10 + IL -17
24 HR 2.845 3.03 4.417 4.458 4.764 4.812
48 HR 2.984 3.546 4.971 4.917 5.422 5.194
96 HR 3.359 3.411 5.054 4.968 5.057 5.046
IL-8
E 4.5
□  control 
O IL-17
□  M0I=1
□  M0I=1 +IL-17
□  MOI=10
■  MOI=10 +IL-17I
tim e
Figure 4.7 IL-10 production (pg/ml) by MdMs. The values presented are logic of means from 
six donors. Error bars in the chart express the SE value. SE=0.2010 A) table; B) chart
T im e T r e a t m e n ts
CONTROL IL -17 M O I= l M O I= l + IL -17 MOI=10 M O I=10 + IL -17
24 HR 0.672 0.646 1.581 1.545 2.104 2.137
48 HR 0.678 0.822 1.722 1.619 2.308 2.336
96 HR 0.839 0.631 1.675 1.59 2.214 2.146
3 1 
2.5 ,
1 1 .5 '
o 1 4 
0.5 1
0 4-
24
IL-10
f t
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48
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96
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■  IL-17
□  MO 1=1
□  M0I=1 +IL-17
■  MO 1=10
■  MOI=10 +IL-17
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Figure 4.8 IL -lp  production (pg/ml) by MdMs. The values presented are logio of means from
six donors. Error bars in the chart express the SE value. SE=0.3669 A) table; B) chart
T im e T r e a t m e n ts
CONTROL IL -17 M O I= l M O I= l + IL -17 M O I=10 M O I=10 + IL-17
2 4  HR 1.026 0.894 1.411 1.299 2.642 2.522
4 8  HR 1.243 1.104 1.452 0.939 3.023 2.741
9 6  HR 0.857 0.916 1.117 0.948 2.891 2.639
IL-1 p
E 2.5 4
□  control
□  IL-17
□  MO 1=1
□  M0I=1 +IL-17
□  MOI=10
■  MOMO+IL-171
Figure 4.9 TNF-c production (pg/ml) by MdMs. The values presented are logic of means from 
six donors. Error bars in the chart express the SE value. SE=0.2353 A) table; B) chart
T r e a t m e n ts
T im e
CONTROL IL -17 M O I= l M O I= l + IL -17 M O I=10 M O I=10 + IL -17
2 4  HR 0.503 0.442 2.077 1.99 2.514 2.406
4 8  HR 0.524 0.545 1.618 1.358 2.556 2.477
9 6  HR 0.584 0.562 1.097 0.98 2.172 1.98
TNF-a □  control
□  IL-17
□  M0I=1
□  M0I=1 +IL-17
□  MOI=10
■  MOI=10 +IL-17
tim e
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Figure 4.10 IL-12 production (pg/ml) by MdMs. The values presented are logio of means from
six donors. Error bars in the chart express the SE value. SE=0.1203 A) table; B) chart
T im e T r e a t m e n ts
CONTROL IL -17 M O I= l M 0 I= 1  + IL -17 M O I=10 M O I=10 + IL -17
2 4  HR 0.6361 0.6627 0.7448 0.8296 0.7865 0.6582
4 8  HR 0.705 0.6696 0.727 0.7139 0.6639 0.7392
9 6  HR 0.7109 0.567 0.5906 0.6509 0.5966 0.5719
IL-12p40
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In conclusion, C. pneum oniae  infection induces an in flam m atory response in the 
infected MdMs by induction o f IL-8 , IL-6 , IL - lp  and TNF-o, but also the regulatory 
cytokine IL-10. The effect o f C. pneum oniae  is dose dependent fo r all cytokines except 
IL-8. Release of IL-8 and IL-6  is increased w ith tim e, while TNF-o levels drop a fte r 24 
hours. The production of IL-10 and IL - lp  is not tim e dependent. The effect o f IL-17 
trea tm en t is very lim ited. In uninfected cells it induces only IL-8  48 hours a fte r 
infection. Treatm ent o f infected cells shows a down-ward trend in release o f IL -8 , IL- 
ip  and TNF-o, but th is is not significant.
4.3.3 Release of IL-6 by MdMs following treatment with 
conditioned medium
CM was prepared from  A549 cells infected w ith  C. pneum oniae  (M 0 I= 1 ) fo r 24 
(CM24), 48 (CM48) and 96 (CM96) hours, and used to activate MdMs in order to 
investigate how infected epithelia l cells may activate alveolar macrophages. IL -6  was 
chosen as a m arker o f activation since it is a known product o f activated MdMs. The P 
values o f the one tailed paired t-te s t are presented in Table 4.1 and the mean values 
o f IL-6 released by infected A549 cells and CM-treated MdMs are presented in Table
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4.2.
Table 4.1 P values of the one tailed paired t  test for CM treatment of MdMs. Key: ( ) - not 
significant; (□ )  -  significant; bold -  very small values, so probably not meaningful; CM24 -  
CM derived from A549 cells infected for 24 hours; CM48 - CM derived from A549 cells infected 
for 48 hours; CM96 - CM derived from A549 cells infected for 96 hours.
T reatm ent Tim e JI" CM24 CM48 CM96
24 0.2834 0.3575 0.1096
U ntreated  V s
48 0.1195 0.0724 0.0892
10%  CM
96 0.2705 0.1269 0.1447
Table 4.2 Means of IL-6 levels In infected A549 cells and CM-treated MdMs. Means for MdMs 
from three independent experiments; means for A549 from 2 independent experiments. A549 
IL-6 levels are from undiluted supernatants. Key: CM24 -  CM derived from A549 cells infected 
for 24 hours; CM48 - CM derived from A549 cells infected for 48 hours; CM96 - CM derived 
from A549 cells infected for 96 hours.
T im e
A549 CM24 CM48 CM96
INFECTED UNTREATEDMdMs
TREATED
MdMs
UNTREATED
MdMs
TREATED
MdMs
UNTREATED
Md Ms
TREATED
Md Ms
24 162.64 4005.9 4515.9 6406 5756.6 4654.2 5357.9
48 135.45 3562 4149.6 3932 4510.8 3761.6 5014
96 183.11 3900 4477.1 4137.2 5042.7 3189.2 5814.9
Amounts of IL-6 in A549 cells infected by M 0I=1 C. pneumoniae measured by ELISA 
are very similar at all three time points (shown in red). Background levels of IL-6 were 
high in untreated MdMs. Treatment of MdMs with any of the CMs did not induce a 
significant Increase in IL-6.
4.4 Discussion
Production of cytokines following C. pneumoniae infection has been shown in a variety 
of cell types. Epithelial cells, neutrophils, macrophages, DC and T cells all contribute to 
the cytokine profile and through that to the overall immune response. C. pneumoniae 
induces a largely pro-inflammatory response characterised by induction of mediators 
such as IL-6, IL-8, TNF-o, IL -lp , IL-12p40 and IFN-y (Kaukoranta-Tolvanen et al., 
1996, Heinemann et al., 1996, Kol et al., 1999, Prebeck et al., 2001, Rothfuchs et al., 
2001, Costa et al., 2002, Yamaguchi et al., 2002, Burian et al., 2003, Gencay et al., 
2003, Yang et al., 2003, van Zandbergen et al., 2004); however the production of
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anti-inflammatory mediators IL-10 and PGE2 has also been reported (Redecke et al., 
1998, Caspar-Bauguil et al., 2000, Jahn et al., 2000). These findings suggest a highly 
complex network of pro- and anti-inflammatory mediators involved in cross-activation 
of different cells recruited to the site of infection, and the modulation of their 
responses. How this network of cytokines contributes to the overall immunity to C. 
pneumoniae infections remains to be clarified.
In the current investigation it was shown that C. pneumoniae infection activates lung 
epithelial cells to release IL-8 and IL-6 but not any of the other cytokines analysed 
(IL -lp , TNF-o, IL-12p40 or IL-10; Figures 4.1 to 4.4). Primary MdMs are activated to 
release IL-8, IL-6, IL -lp , TNF-o and IL-10 but not IL-12p40 (Figures 4.5 to 4.10). C. 
pneumoniae was found to exert dose dependent effects. It was also shown that CM 
derived from infected epithelial cells does not activate MdMs to produce significant 
amounts of IL-6 (Tables 4.1 and 4.2).
Cytokine production by host cells following infection is one of the first steps in 
mounting an immune response. However it is difficult to dissect how and in which 
sequence different host cells activate each other, or how each of the cytokines 
contributes to the early immune responses. The release of IL-8 may contribute to 
neutrophil recruitment to the site of the infection and their subsequent activation, 
while IL-6 may further contribute by activating a Th l type response by inhibiting 
CD4+CD25+ regulatory T cells (Pasare and Medzhitov, 2003). TNF-o production by 
MdMs can contribute to control of chlamydial growth by synergising with IFN-y as 
reported by (Summersgill et al., 1995). TNF-o may also contribute to the inflammation 
along with IL -ip  by activation of Th l type responses.
The most interesting and surprising finding was the release of IL-10 coupled with the 
lack of IL-12p40 production by infected MdMs. As discussed in Chapter 1, the release 
of IL-10 by infected cells is associated with down-regulation of MHC class I molecules 
and an increased resistance to apoptosis by Infected cells (Caspar-Bauguil et al.,
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2000, Geng et al., 2000). This could contribute to persistent infections. Also, the lack 
of IL-12p40 production by infected MdMs may decrease IFN-y production, the key 
cytokine in the control of chlamydial growth. These findings suggest that C. 
pneumoniae induces such an immune response as to ensure a long-term infection, 
and this may explain the lack of symptoms seen in chlamydial infections: a balanced 
cytokine profile and inhibition of controlling mechanisms. Other responses may include 
modulation of cel I-surface molecules and activation of inhibitory mechanisms. These 
responses were also analysed and are discussed in the following chapters.
To further understand how C. pneumoniae activates immune responses, MdMs were 
treated with CM derived from infected epithelial cells. The initial idea was to use a co­
culture system similar to that used in a study on activation of macrophages by 
epithelial cells infected with Mycobacterium avium (Sato et al., 2002). However, I was 
unable to find a suitable culture system where I could ensure that no chlamydial 
particles (EBs) could cross the barrier and infect the cells, and this was crucial since 
the aim was to analyse activation by mediators released from infected cells and not by 
infection. For that reason, it was decided to use a conditioned medium. Epithelial cells 
were infected; supernatants were filtered to remove chlamydial particles (EBs) and 
then used at 10% of original concentration. 10% CM was used for a number of 
reasons, principally the amount of medium needed in total and the need to have a 
sufficient amount of fresh medium to maintain the cells. The production of IL-6 was 
chosen as a marker of activation since it is a known product of activated MdMs. CMs 
derived from three time points (24, 48 and 96 hours of infection) were used, and none 
of them induced significant levels of IL-6. However, this finding does not mean that 
the cells were not activated, and other markers of activation might give a different 
result. Future studies could include a more comprehensive analysis, including other 
cytokines such as IL-8, IFN-y, GM-CSF, IL -ip , TNF-o, IL-10 and possibly others; a 
higher MOI could be used in the initial infection of epithelial cells; and also different 
CM concentrations may give a different effect. In addition to measuring IL-6 
production following CM-treatment, modulation of cell-surface molecules was also
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analysed and this is discussed in the next chapter.
As discussed above IL-17 is a cytokine with a growing importance in lung pathology 
and lung infections, as shown by Ye et al (2001) who demonstrated its importance in 
the down-regulation of inflammatory responses and clearance of Klebsiella 
pneumoniae. It was also shown that IL-17 is important in neutrophil recruitment 
following LPS exposure of the lungs (Linden et al., 2000). In the present study it was 
shown that IL-17 up-regulates the release of IL-8 and IL-6 by C. pneumoniae-'mfected 
epithelial cells (Figures 4.1 to 4.4), while it causes a down-ward trend in the release of 
IL-8, IL -lp  and TNF-o by infected MdMs, but this is not significant ( Figures 4.6, 4.8 
and 4.9). IL-17 treatment alone also induced IL-8 and IL-6 production in both 
epithelial cell lines and IL-8 production in MdMs soon after treatment. These findings 
suggest that IL-17 present in the lung may play a role in neutrophil recruitment 
activation of the early responses, but may also prevent excessive inflammation 
following infection. Future studies could be transferred into a mouse model with over­
expression of soluble IL-17 receptor or by introducing a blocking antibody, or the 
other extreme, over-expression of IL-17. In both cases the study could investigate 
whether the animals demonstrate any change in duration of infection, bacterial burden 
or cytokine production. That approach would offer a more complete picture into the 
role of IL-17 in C. pneumoniae infection.
As stated in Chapter 2, the purity of the primary blood derived MdMs, was around 
70%. The major contaminant cell population were neutrophils and this is likely to 
affect the cellular responses including cytokine production. One known product of 
neutrophils that was analysed in this study is IL-8. How the presence of neutrophils 
affects the production of cytokines is difficult to dissect; however they may increase 
the total amount of IL-8 released and affect the production of other cytokines in other 
ways. Also, given the role of IL-17 in neutrophil-mediated responses in lung 
pathology, effects of IL-17 may also be skewed by the presence of neutrophils. 
However, this does not render the results obtained with primary cells less valuable;
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this just needs to be kept in mind when analysing and presenting the results.
In summary, this investigation has shown that C. pneumoniae induces a pro- 
inflammatory response in infected cells characterised by the production of 
inflammatory cytokines and chemokines. However, this is balanced by the release of 
IL-10 from infected MdMs. Also, the production of inflammatory cytokines is down- 
regulated by IL-17 treatment, indicating that this cytokine may play a crucial role in 
chlamydial immunopathology by dampening the inflammation induced in infected cells.
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Ch a p t e r  5
M o d u la t io n  o f  S u rfa c e  M a r k e r  E x p re ss io n  on  lu n g  
e p i th e l ia l  c e l ls  a n d  M dM s f o l lo w in g  C. pneumoniae
INFECTION
5.1 Introduction
Cells can communicate by releasing mediators or altering the expression of cell- 
surface molecules to indicate they are infected and thereby promote an effective host 
immune response. In the previous chapter, profiles of chemokines and cytokines 
released by lung epithelial cells and MdMs following C. pneumoniae infection were 
presented. To investigate whether C. pneumoniae infection alters the expression of 
cell-surface molecules, a total of 8 cell-surface markers were chosen for analysis on 
MdMs and lung epithelial cells. These markers include molecules found on MdM surface 
(CD45, CD14); receptors involved in pathogen recognition (TLR4, CD14); receptors 
involved in the activation of adaptive immune responses (MHC class I and I I  
molecules, CD40, CD45, CD91) and an adhesion molecule (CD54/ICAM 1). All may 
contribute to the immunopathology following C. pneumoniae infection and their 
potential importance is discussed below.
It has been shown that Chlamydiae activate a variety of cell types through the Toll­
like receptors, TLR2 and TLR4 in particular (Darville et al., 2003, Prebeck et al., 2001, 
Bulut et al., 2002, Netea et al., 2002, Prebeck et al., 2003). The activation of TLR4 is 
mediated through ligation of CD14 on the surface of APCs, and C. pneumoniae has 
been shown to up-regulate CD14 expression on infected MonoMac 6 human 
macrophage cells (Heinemann et al., 1996). Both chlamydial LPS and cHSP have been 
shown to activate cells in a CD14/TLR4-dependent manner (Kol et al., 2000, Sasu et 
al., 2001, Costa et al., 2002, Prebeck et al., 2003). In the last few years cHSP, rather 
than chlamydial LPS, has been identified as the major chlamydial component 
responsible for eliciting inflammatory host immune responses (Kol et al., 2000). More
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recently new research suggests that this may be a result of LPS contamination of the 
samples used to activate the cells, and not a true HSP-dependent effect; however this 
is still a controversial area of research (Gao and Tsan, 2003).
CD91 has recently been recognized as a common HSP receptor on APCs. HSP- 
chaperoned exogenous antigens are delivered to APC that in turn present these 
through MHC class I thereby activating adaptive immune responses (Binder et al., 
2000, Basu et al., 2001). Additionally, HSPs released from cells as a result of stress or 
necrotic death activate APCs and, as these are highly conserved from bacteria to 
mammals, the ability of HSP to activate APC provides a unified mechanism for 
response to internal and external stimuli (Basu et al., 2000, Li et al., 2002). 
Considering the importance of cHSPs in the activation of an immune response and the 
role of CD91 as a common receptor, it is possible that CD91-dependent signals play an 
important role in the establishment of anti-chlamydial immunity. Another potential 
role of cHSPs released during infection is the up-regulation of adhesion molecules 
including E-selectin, VCAM-1 and CD54/ICAM-1 as demonstrated by Kol et al., (1999), 
a process that may contribute to atheroma development.
Activation of the innate immune system via pathogen-recognition receptors/pathogen- 
associated molecular patterns (PRR/PAMPs) is one of the first steps in mounting an 
immune response. This is followed by activation of the acquired immune system for 
generation of specific immunity and immunological memory. An important component 
of this is antigen presentation and activation of T cells. The ability of MdMs to activate 
T cell responses may be affected by chlamydial infection. C. trachomatis can down- 
regulate both MHC class I and I I  molecule expression in a variety of human cells 
(Zhong et al., 2000, Zhong et al., 1999). C. pneumoniae can also down-regulate MHC 
class I expression on human monocytes, while it up-regulates the expression of MHC 
class II,  CD40, CD80 and CD86 in infected dendritic cells in mice (Redecke et al., 
1998, Caspar-Bauguil et al., 2000, Prebeck et al., 2001).
Collectively these observations suggest that Chlamydiae modulate expression of 
surface receptors. As discussed in Chapter 4, C. pneumoniae infection activates host
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cells to release inflammatory mediators. Chlamydia-derived proteins such as cHSP, Inc 
or LPS could also be released. These mediators might in turn alter the expression of 
surface molecules on infected cells, thereby influencing cell to cell communication and 
activating the host immune response. To investigate the effect of C. pneumoniae on 
the expression of cell-surface molecules, the following questions were addressed:
♦ Does C. pneumoniae infection of lung epithelial cells change the expression of 
CD54, HLA ABC, HLA DR or CD119 (IFN-y R)?
♦ Does C. pneumoniae infection of MdMs alter the expression of CD14, CD40, CD45, 
CD54, CD91, HLA ABC, HLA DR or TLR4?
♦ Does conditioned medium from infected epithelial cells alter the expression of cell- 
surface molecules on MdMs?
5.2 Experimental approach
The expression of CD14, CD40, CD45, CD54, CD91, HLA ABC, HLA DR and TLR4 was 
analysed by flow cytometry on primary blood derived monocytes, and the expression 
of IFN-yR, HLA ABC, HLA DR and CD54 was analysed on human lung epithelial cell 
lines A549 and HEp-2. Epithelial cell lines were cultured as described in section 2.1. 
The isolation and culture of MdMs is described in section 2.1.4. Flow cytometry 
protocols and antibodies used are described in section 2.3.
Epithelial cells were seeded in IMDM+5%FCS in culture flasks and left overnight to 
adhere. The following day they were infected with C. pneumoniae (M 0 I= 1 ) and cells 
were collected 6, 24, 48 and 72 hours after infection.
For analysis by flow cytometry MdMs were handled as follows. After 48 hours of 
culture in IMDM+15% FCS with no other stimuli, the following treatments were added:
• C. pneumoniae (M 0I=1) for 6, 24, 48 and 72 hours. This was repeated on 
MdMs derived from 4 donors.
• 10% CM from A549 epithelial cells infected with C. pneumoniae (M 0 I= 1 ) for 24
hours. The supernatant was collected, filtered through a 0.2pm filter to remove
infectious EBs, and frozen at -20°C until use. After thawing, the supernatant
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was diluted to 10% in fresh IMDM+15% FCS. MdMs were collected 6, 24, 48 
and 72 hours after culture in CM. This was repeated on MdMs derived from 3 
donors.
All the samples were stained for CD14 and one other surface molecule, together with 
the viable cell stain 7AAD. The results were analysed by gating the CD14 +ve live cell 
population to present CD14 positive cells expressing the target molecule.
An example of how CD14 +ve cells were gated for analysis is shown in Figure 5.1. 
First, dead cells were excluded by 7AAD staining in a 7AAD/FSC plot (R l); gated, 
viable cells were then presented on a FSC/SSC plot and a new gate (R2) was drawn 
around the monocyte population. The final gate (R3) was set up on a CD14 histogram 
to represent CD14 positive cells. Finally, all three gates were combined (R1+R2+R3) 
to present the target surface molecule in a histogram. Cells from 7 donors were 
analysed and the results for all individual donors are presented.
R3
FSC CD14
Figure 5.1 An example of gating on CD14 expressing MdMs for analysis of other surface 
molecules. Key: FSC - forward scatter, SSC -  side scatter. R3=R1+R2
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5.3 Results
5.3.1 C. pneumoniae infection of lung epithelial cells does not 
alter the expression of cell-surface molecules
The expression of HLA ABC, HLA DR, CD54 and IFN-y receptor o-chain (CD119) on 
HEp-2 and A549 lung epithelial cell lines was analysed by flow cytometry. The results 
are presented below in Figures 5.2 to 5.5. Tables with mean fluorescence intensity 
values (MFI) for HLA ABC and CD54 following infection are presented with the 
histograms in Figures 5.4 and 5.5.
Both A549 and HEP-2 cells express IFN-y receptor o-chain (CD119; Figure 5.2) in the 
resting state. Modulation of IFN-y receptor expression following C. pneumoniae 
infection is discussed in detail in chapter 6 in the context of chlamydial control.
Neither cells line expresses HLA DR (MHC class II;  Figure 5.3) but they both express 
HLA ABC (MHC class I; Figure 5.4) HLA ABC expression is not affected by chlamydial 
infection in either A549 nor HEp-2 cells (Figure 5.4), while the levels of CD54 are very 
low and change is not detectable (Figure 5.5).
BA
Figure 5.2 The expression of IFN-yR (CD119) on uninfected lung epithelial cells. (A ) HEp-2 
cells (B) A549 cells. Key: purple filed - IFN-y R; blue line - cells only; green line - step 
control; red line - 2"*^  step control; - 3’’^  step control.
B
L
Figure 5.3 The expression of MHC class I I  (HLA DR) on uninfected lung epithelial cells. (A) 
HEp-2 cells (B) A549 cells. Key: purple filed - HLA DR; red line - isotype control.
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In summary, C. pneumoniae infection does not affect the expression of MHC ciass I 
moiecuies on iung epitheiiai ceiis (A549 and HEp-2), and its effects of CD54 
expression are unciear, but as far as this study is concerned C. pneumoniae does not 
affect CD54 expression either. The next step was to analyse what effect chlamydial 
infection has on MdMs.
5.3.2 C. pneumoniae infection of MdMs modulates expression of 
surface molecules
Expression of CD14, CD40, CD45, CD54, CD91, HLA ABC, HLADR and TLR4 was 
analysed by flow cytometry on MdMs from 4 donors and the results are presented in 
full as histograms grouped by target moiecuies, and in Tables of corresponding MFI 
values and percentage of expression change (Figure 5.7 to 5.14). Forward scatter vs 
side scatter profiles of MdMs from the donors are presented in Figure 5.6. From these 
it is clear that the ceiis have similar profiles and that the gating is similar.
Ail the moiecuies were expressed on the MdMs analysed. C. pneumoniae infection 
modulated the expression in different ways. CD14 was up-regulated in two donors 
with small changes in the other two (Figure 5.7). CD40 was up-regulated in two, 
down-reguiated, with no changes in the one donor (Figure 5.8) CD45 was also up- 
reguiated in two donors and down-reguiated in the other two; however the changes 
were smaller (Figure 5.9). The expression of CD54 was up-regulated in 2 and down- 
reguiated in the other two donors (Figure 5.10). The effect of infection bn CD91 was 
variable with up-reguiation early in the infection and down-regulation later in two 
donors, and a mixed effect on the other two donors (Figure 5.11). MHC ciass I and I I  
were both down-reguiated in ail four donors (Figures 5.12 and 5.13).
The expression of TLR4 was very low in all donors and the infection had a variable 
effect on TLR4 expression.
84
%n
6hr 24hr 48hr
FSC
72hr
Donor 1
Donor 2
Donor 3
»
Donor 4
B
%o
6hr 24hr 48hr 72hr
Donor 1
Donor 2
Donor 3
Donor 4
FSC
Figure 5.6 Forward scatter Vs side scatter (FSC/SSC) profiles of MdMs from 4 donors. (A) 
uninfected cells (B) infected cells. Key: X axis -FSC; Y axis - SSC.
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In summary, C. pneumoniae infection of MdMs moduiates the expression of surface 
moiecuies on MdMs; however there are differences between donors in the baseiine 
ieveis of expression of different moiecuies and also in how C. pneumoniae infection 
affects their expression.
To obtain a more complete picture as to how MdMs are activated as part of the 
immune response to C. pneumoniae infections, and how they interact with infected 
ling epithelial ceils, expression of the same surface moiecuies was further analysed 
following activation of MdMs by medium derived from infected epithelial ceils.
5.3.3 Conditioned medium modulates the expression of ceil- 
surface molecules on MdMs
MdMs were treated with conditioned medium (CM) and the change in expression of 
surface molecules was analysed in the same way as described above. The forward 
scatter vs side scatter profiles of each of the donors are presented in Figure 5.15. The 
results are presented as in the previous section with histograms for each individual 
donor and a table of corresponding MPI values in Figures 5.16 to 5.23.
Overall, the effect of CM-treatment on MdMs was less pronounced than C. pneumoniae 
infection, and variability between donors is greater. There was a mixed effect on the 
expression of CD40, CD45 and TLR4 (Figures 5.17, 5.18 and 5.23). CD14 and CD54 
were down-reguiated in two donors and up-regulated in one (Figures 5.16 and 5.19) 
and the effect on CD91, MHC class I and I I  was the opposite, with up-reguiation in two 
donors and down-reguiation in one (Figures 5.20, 5.21 and 5.22).
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BFSC ----------------------- ►
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Donor 6
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Figure 5.15 Forward scatter Vs side scatter (FSC/SSC) profiles of MdMs from 3 donors. (A) 
uninfected cells (B) infected cells. Key: X axis -FSC; Y axis SSC.
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To summarise, the expression of celi-surface moiecuies is modulated by C. 
pneumoniae either by infection or by the inflammatory response that is induced in 
infected epitheiiai ceiis.
5.4 Discussion
Ceii to ceii communication is a central component of buiiding an immune response. 
This communication is iargely dependent on the activation of ceil-surface molecules 
(receptors) that transfer signals into the ceil thereby activating it to respond. Certain 
pathogens, and intraceiiular pathogens in particuiar, such as cytomegaiovirus or 
adenovirus, have devised mechanisms to moduiate the expression of surface 
moiecuies (MHC class I down-regulation) as part of evading the host immune response 
(Benz et al., 2001, Slater and Campbell, 1997, Hou et ai., 2002, Sparer and Gooding, 
1998, Korner and Burgert, 1994, Bosse and Ades, 1991). The experiments described 
in this chapter were designed to investigate if C. pneumoniae moduiates expression of 
surface molecules on both lung epitheiiai cells and MdMs.
Lung epitheiiai cells are the primary target of C. pneumoniae infection and they are 
activated to release pro-infiammatory modulators IL-6 and IL-8 (discussed in chapter 
4). A selection of 4 celi-surface moiecuies with different functions in the immune 
response was chosen for analysis: classical MHC class I (HLA ABC), MHC class I I  (HLA 
DR); IFN-y receptor o-chain (CD119) and CD54. Both A549 and HEp-2 cells express 
IFN-y receptor in the resting state (Figure 5.2) and the expression ieveis are not 
changed by C. pneumoniae infection; however this is discussed in detail in chapter 6 
in the context of chlamydial control by IFN-y.
Neither A549 nor HEp-2 cell line express MHC class I I  (HLA DR; Figure 5.3), a finding 
that confirms a previous report by Gao et al., (1999) that A549 cells do not express 
MHC class I I  molecules in the resting state. MHC class I I  expression can be induced by 
inflammatory cytokines and some pathogens (Cunningham et ai., 1994, Gao et ai., 
1999); however C. pneumoniae infection did not induce any expression.
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Both cell lines express MHC class I (HLA ABC; Figure 5.4) and this was not modulated 
by chlamydial infection. The lack of effect on MHC class I expression does not 
necessarily mean that C. pneumoniae does not influence the MHC class I antigen 
processing and presentation pathway. It may change the rate of MHC class I recycling 
or in other ways affect antigen presentation by lung epithelial cells, and this can be 
addressed in future studies that could include functional analysis.
There was no clear demonstration of CD54 expression on A549 and HEp-2 cells and 
expression was not modulated by C. pneumoniae infection. The staining for CD54 can 
be repeated in future analysis with a multiple step analysis that may give a clearer 
result.
In retrospect it would have been interesting to look at other moiecuies including CD40 
and TLR4. CD40 is expressed on a variety of cells including epitheiiai ceiis, and plays 
an important role in the inflammatory processes (Schonbeck and Libby, 2001a, 
Cagnoni et al., 2004). TLR4 plays an important role in bacterial immune responses, 
and it would have been interesting to analyse whether C. pneumoniae affects TLR4 
expression on epitheiiai ceiis. A larger number of molecules analysed would have given 
a more complete picture of the role of epithelial cells in anti-chlamydial immune 
responses.
In the previous chapter it was shown that MdMs infected with C. pneumoniae release 
IL-8, IL-6, IL -ip , TNF-o and IL-10, and in this chapter it was demonstrated that C. 
pneumoniae also modulates the expression of celi-surface markers (Figures 5.7 to 
5.14). It was further shown here that CM derived from infected A549 epitheiiai cells 
modulates the expression of celi-surface moiecuies differently from infection (Figures 
5.16 to 5.23).
Eight surface molecules (CD14, CD40, CD45, CD54, CD91, HLA ABC, HLADR, TLR4) 
were chosen to give an indication of how C. pneumoniae affects surface molecule
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expression and to obtain a more complete picture of how anti-chiamydiai immunity 
developed. Infected MdMs expressed increased levels of CD14, CD40, CD45 and CD54 
in two donors with no effect on the other two (Figures 5.7, 5.8, 5.9 and 5.10) The 
levels of MHC class I and I I  (Figures 5.12 and 5.13) were decreased in ail donors. The 
effect on CD91 was different between donors with no consistency (Figure 5.11) and 
this is also the case for TLR4 (Figure 5.14). CM-treatment of MdMs down-reguiated 
CD14 and CD54 expression in 2 donors and up-regulated it in one (Figures 5.16 and 
5.19); up-regulated CD91, MHC class I and I I  expression in two donors and down- 
reguiated it in one (Figures 5.20, 5.21 and 5.22), and there was a mixed effect on the 
expression of CD40, CD45 and TLR4 (Figures 5.17, 5.18 and 5.23).
On the whole, CM-treatment of MdMs had a weaker effect on the expression of surface 
moiecuies than C. pneumoniae infection. It  is likely that CM is a cocktail of pro- 
inflammatory cytokines such as IL-8 and IL-6, anti-infiammatory mediators such as 
PGE2, and chlamydial components such as LPS, cHSP60 and Inc proteins released by 
the infected epithelial ceils. Such a balanced mix could activate MdMs so that they 
promote a weak inflammatory response.
As discussed in the previous chapter, the purity of the MdMs was about 70% and the 
presence of other cell population may affect the results. This was true in cytokine 
analysis however in the analysis of ceii surface markers, I only gated on CD14 positive 
cells and subsequently analysed the expression of the other markers. So, the cells 
presented are all CD14 positive.
The most pronounced change observed was in the expression of CD14. The up- 
regulation of CD14 following infection (Figure 5.7) confirms previous results obtained 
from a MonoMac6 human macrophage ceii line (Heinemann et al., 1996). Enhanced 
expression of CD 14 could increase the responsiveness of MdMs to C. pneumoniae. On 
the other hand CM-treatment of MdMs down-regulates CD14 expression. These 
findings suggest that the level of CD14 expression on the surface of MdMs may have a
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bearing on the severity of Chiamydia-induced immune responses. In this respect it is 
interesting to note that a polymorphism in the CD14 promoter gene (C (-260)—>T) is 
associated with a higher density of CD14 expression on the macrophage surface and 
also with a higher risk of myocardial infarction and atherosclerosis in individuals 
expressing both aiieies (CD14 TT) (Hubacek et ai., 1999). Additionally, Eng et al have 
recently shown that CD14 TT homozygotes suffer a significantly higher risk of C. 
pneumoniae infection (Eng et ai., 2003). Taking that into consideration one could 
suggest that donor 1 may be more susceptible to C. pneumoniae compared to donor 2 
(Figure 5.7) since they express different ieveis of CD14, however this requires a 
different experimental approach and plan.
The expression of MHC class I and class I I  molecules changes in the opposite way to 
CD14 (Figures 5.12 and 5.13). They are down-regulated by infection and up-regulated 
by CM-treatment. Down-reguiation of MHC class I and I I  combined with enhanced 
levels of CD14 may be a contributing factor to long term persistent infections by 
increasing the cells' susceptibility to infection and by interfering with the effective 
activation of adaptive immune response and the creation of protective immunity. 
Other pathogens have been shown to manipulate the expression of MHC moiecuies as 
part of immune evasion, so it is possible that Chlamydiae do the same (Tomescu et 
al., 2003).
Even though the expression of CD14 was modulated by both infection and CM- 
treatment, there was no clear demonstration of a change in TLR4 expression ieveis by 
either treatment (Figures 5.14 and 5.23). This is interesting considering that CD14 is a 
key component of the TLR4 signalling pathway, and it has also been shown that both 
chlamydial LPS- and cHSP60- mediated activation of host cells is CD14/TLR4 
dependent (Koi et ai., 2000, Sasu et al., 2001, Costa et al., 2002, Prebeck et al., 
2003). The lack of correlation in the modulation of CD14 and TLR4 expression by C. 
pneumoniae suggests that the expression of TLR4 and CD14 may not be coordinated.
Another way that cHSP60 may potentially activate immune responses is through
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CD91, a common heat shock protein receptor. cHSP60 has an important roie in both 
immediate inflammatory responses following C. pneumoniae infection and long-term in 
the development of atherosclerosis. There is an abundance of both cHSP and human 
HSP present during C. pneumoniae infections (discussed in detail in section 1.5.4.2 of 
chapter 1). Given the potential importance of cHSPs in inflammatory responses 
following C. pneumoniae infections the working hypothesis was that CD91 contributes 
to the immune responses following infection and that its expression on MdMs is 
modulated by C. pneumoniae. The level of CD91 expression was not greatly affected 
by infection, but CM-treatment enhanced CD91 ieveis. This may be due to the 
presence of cHSP in the CM and may contribute to immune responses. To further 
establish whether CD91 is involved in anti-chiamydial immunity a number of 
experiments can be conducted. For example: blocking of CD91 function with an 
antibody, using confocai analysis to see whether the receptor is being internalised 
following infection; analysis of CD91 expression by Real Time RT-PCR for 
quantification and also kinetic studies. Although CD91 is recognised as a common heat 
shock protein receptor, there are few reports on its role in the immune response 
following infections. Stebbing et ai., (2003) have shown that high CD91 expression on 
macrophages is associated with the maintenance of long-term nonprogression of AIDS 
in HIV +ve patients, possibly by maintaining CD8+ T ceil responses.
The remaining molecules analysed (CD40, CD45 and CD54) were all modulated 
similarly. CD45 was chosen for analysis solely as a leukocyte common antigen; 
however the results show that both infection and CM-treatment moduiate its 
expression (Figures 5.9 and 5.18). Infection enhanced the expression while CM- 
treatment had a mixed effect. CD45 is involved in a number of T cell processes and it 
can act both as a positive and a negative regulator of T ceii activation. It  has recently 
been shown that CD45 acts as a phosphatase for Janus kinases (JAK), thereby acting 
as a negative regulator of cytokine receptor signalling. It has also been shown that 
targeted disruption of the cd45 gene leads to enhanced cytokine and interferon- 
receptor-mediated activation of Jaks and Stats (Irie-Sasaki et al., 2001, Penninger et
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al., 2001, Irie-Sasaki et al., 2003). As I mentioned before, IFN-y is the key cytokine in 
controlling chlamydial growth and C. pneumo/i/ae-mediated up-reguiation of CD45 
may interfere with IFN-y dependent control of chlamydial growth. Findings presented 
here indicated that CD45 may play a crucial role in the outcome of C. pneumoniae 
infection, however this remains to be analysed.
CD40 is expressed on a number of different types of both lymphoid and non-lymphoid 
ceiis, including macrophages, endothelial and epitheiiai cells (Schonbeck and Libby, 
2001a, Cagnoni et ai., 2004). It  was originally thought that CD40 is involved only in 
T/B lymphocyte interactions, mediating T ceii-dependent B-ceii activation and 
differentiation required for humoral immune responses. However more recently it has 
become clear that CD40/CD40L is a key part of Inflammation and it has been 
associated with pathogenic processes of chronic inflammatory diseases, such as 
autoimmune diseases, neurodegenerative disorders, graft-versus-host disease, 
cancer, and atherosclerosis (reviewed by Schonbeck and Libby, (2001b). CD40 
expression was up-regulated following C. pneumoniae infection, although there was 
variation between donors when ceiis were CM-treated (Figures 5.8 and 5.19). Up- 
regulation of CD40 may contribute to C. pneumoniae-meô'iated immunopathology. 
Higher expression of CD40 can contribute to Th l type responses, and it can also up- 
regulate the expression of CD54 (ICAM-1) which can in turn enhance adhesion of cells 
and promote atheroma development (Kiener et al., 1995). Both treatments had a 
similar effect on CD54 expression, which was up-regulated in some donors and down- 
reguiated in others (Figures 5.10 and 5.19). The up-regulation of CD54 may partly be 
a result of CD40 ligation; however this conclusion cannot be made from this study. 
Future studies could include functional analysis similar to the experiments suggested 
for CD91. Increased expression of CD40 and CD54 by the infected macrophage could 
increase the cell's pro-inflammatory responses and Its pro-atherosclerotic properties.
Overall, there is donor variability in the expression of the moiecuies analysed and in 
the way that C. pneumoniae affects their expression. This may be due to a number of 
reasons. Since the blood is obtained from anonymous donors, there is no way of
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knowing their medicai history including previous chlamydial infections. Even though 
the blood bank performs a health check to ensure the donor is healthy at the time of 
giving blood, this is limited to colds, allergies and chronic conditions. Once the blood is 
collected there is an initial pathogen screen, however this does not include testing for 
chlamydial infection. Another important factor is the donor's genetic profile, which 
may contribute to the differences in the ieveis of surface molecule expression, to the 
donor's susceptibility to C. pneumoniae infections, and what symptoms they are likely 
to suffer. One way of overcoming this issue is to analyse a much larger donor base in 
order to obtain a more unified picture of how C. pneumoniae modulates immune 
responses of MdMs.
The quality of the Buffy coats and the isolation procedure on particular days may also 
have influenced the results. There are processes in the blood collection that are 
outwith experimental control, such as the length of time ceils are sitting ex vivo before 
they are dispatched for research use, and this may affect the quality of each individual 
sample. Lastly, the fact that directly conjugated primary antibodies were used, may 
have affected the sensitivity of the analysis. For instance, TLR4 and CD91 consistently 
showed low-level expression. Multiple step analyses may reveal different results. The 
same is true of CD54 analysis in epithelial cells.
In summary, this study has shown that C. pneumoniae moduiates the expression of a 
number of surface molecules involved in different aspects of buiiding a specific, 
protective immune response. However C. pneumoniae-ôepenôent modulation of 
surface moiecuies was only seen in MdMs, while infection did not have an effect on 
epitheiiai cells. In addition to the chosen moiecuies analysed (CD14, CD40, CD45, 
CD54, CD91, HLA ABC, HLA DR, TLR4) it is highly probable that C. pneumoniae affects 
the expression of many more moiecuies with different immune functions. These 
findings suggest that C. pneumoniae actively induces the immune response by 
modulation of both cytokine responses and the expression of surface molecules. 
However the final outcome of C. pneumoniae infection in each individual may also 
depend on a number of genetic and environmental factors.
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C h a p t e r  6
Co n t r o l  o f  c h l a m y d ia l  g r o w t h  by  I n f l a m m a t o r y  
Cy t o k in e s  a n d  Ex p r e s s io n  o f  S u p p r e s s o r s  o f  Cy t o k in e  
S ig n a l l in g
6.1 Introduction
T helper 1 (Th l) cell-mediated Immunity is important for host protection from C. 
pneumoniae infections, with T cell-derived IFN-y playing a key role (Rottenberg et al., 
1999, Penttila et al., 1998, Penttila et al., 1999). IFN-y induces expression of 
indoleamine-2,3-dioxygenase (IDO), an enzyme that degrades intracellular pools of 
tryptophan (trp), an essential nutrient for. chlamydial growth. Since the C. 
pneumoniae genome does not contain the trp operon (Kalman et al., 1999), 
degradation of tryptophan arrests chlamydial growth (Mehta et al., 1998, MacKenzie 
et al., 1999). Other cytokines such as TNF-o can synergise with IFN-y to induce IDO 
expression (Summersgill et al., 1995).
The anti-chlamydial effects of IFN-y are highly dose-dependent and do not necessarily
result in eradication of the organism from host cells, but instead can result in
persistence (Entrican et al., 2002). This finding points to a highly complex host-
pathogen relationship where immune pressure can ultimately lead to long-term
survival of the organism in a latent phase within host cells. Chlamydial persistence is
often associated with severe immunopathology, and our current knowledge indicates
that the responsiveness of host cells to inflammatory cytokines including IFN-y is one
of the key elements that define the outcome of infection (Rottenberg et al., 2002).
Inflammatory cytokines require tight host regulation to minimise the development of
immunopathology. This can occur either by production of anti-inflammatory cytokines
or by the induction of intracellular molecules that negatively control cytokine
signalling in response to ligation of cell-surface receptors. Suppressors of cytokine
signalling (SOCS) are a family of eight cytoplasmic molecules [SOCSl to S0CS7 and
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CIS (cytokine-inducible SH2-containing protein)] that are essential mediators for 
negatively regulating cytokine signalling. They share structural similarities and are 
characterised by a central SH2 domain and a unique motif, the SOCS box, in their C- 
terminal region (Hilton, 1999, Krebs and Hilton, 2001, Chen et al., 2000). SOCS have 
been detected in various tissues and are produced in response to different stimuli 
including cytokines, LPS and some bacterial infections (Stoiber et al., 2001, Stoiber et 
al., 1999, Lejeune et al., 2001, Losman et al., 1999, Ding et al., 2003, Dey et al., 
2000, Dey et al., 1998, Hortner et al., 2002). SOCS regulate the magnitude and 
duration of responses triggered by various cytokines by inhibiting their signal 
transduction pathway in a classic negative feedback loop (Lang et al., 2003, Croker et 
al., 2003). SOCS interfere with Janus kinase/Signal Transducers and Activators of 
Transcription (Jak/Stat)-dependent signalling pathways. They bind directly to cytokine 
receptors or to the catalytic domain of Jak proteins and prevent the recruitment and 
phosphorylation of Stats. IFN-y signalling is largely Jak/STAT dependent. Pathways 
activated by IFN-y are described in Figure 6.1.
Figure 6 .1  Sianal-transduction 
pathways activated bv IFN-v. 
Ligand-induced oligomerization 
of the IFN-y receptor subunits 
IFNGRl and IFNGR2 leads to the 
phosphorylation and activation of 
Jakl, Jak2, IFNGRl and S ta tl. 
S ta tl homodimers translocate to 
the nucleus, bind to y-activated 
sequence (GAS) elements and, 
in collaboration with other 
transcription factors (e.g.BRCAl 
and MCM5), regulate gene 
expression. Several other signal- 
transduction pathways are 
activated also in parallel with the 
Jak-S tatl pathway in response 
to IFN-y (shown in the box). 
Pyk2 is a mitogen-activated 
protein tyrosine kinase; Vav, Cbl 
and Crk are adaptor proteins; 
C3G and Ras GTPase-activating 
protein 1 (Rap-1) are G-protein- 
linked signaling molecules; and 
Fyn is a Src-family tyrosine 
kinase. Abbreviations: BRCAl,
breast cancer susceptibility gene 
1; ERK, extracellular-signal- 
regulated kinase; Jak, Janus 
kinase; MCM5, mini-chromosome 
maintenance protein 5; PI 3-K, 
phosphatidylinositol 3-kinase; R l, IFNGRl; R2, IFNGR2; SHP, Src-homology-2-domain- 
containing protein tyrosine phosphatase; S ta tl, signal transducer and activator of transcription 
1. This Figure copied from Ramana et al., (2002) with permission from Elsevier Science.
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SOCSl and S0CS3 have both been associated with IFN-y signailing (Song and Shuai,
1998, Stoiber et al., 1999). SOCSl binds to Jakl and Jak2, which are associated with 
IFN-y R subunits 1 and 2 respectively. This then prevents STATl phosphorylation and 
subsequent activation of IFN-y responsive genes. S0CS3 also inhibits IFN-signaliing 
through inhibition of STATl activation, but the effects are weaker (Stoiber et a!.,
1999, Cacalano et a!., 2001, Woldman et al., 2001, Ko va ri k et ai., 1998). The 
mechanisms of SOCS activity have been extensively studied but there have been a 
limited number of reports on their expression and role in pathological conditions and 
infections (Dogusan et al., 2000, Federici et al., 2002, Hong et al., 2002, Hong et ai., 
2001, Seki et al., 2003, Raccurt et al., 2003).
Previous work in the laboratory has shown that certain lung epithelial ceils differ
substantially in their ability to control chlamydial growth in response to IFN-y 
treatment. Unresponsiveness of lung epithelial ceils to IFN-y could have serious 
implications for the outcome of chlamydial infection and the induction of protective 
immunity. In this chapter experiments designed to clarify the mechanisms of this 
phenomenon are presented. They were designed to:
♦ Investigate the ability of epithelial cells to control chlamydial growth in response to 
IFN-y and investigate the induction of IDO, a control mechanism for C. pneumoniae
♦ Investigate the expression of SOCSl and S0CS3 in lung epithelial ceils in response 
to IFN-y and chlamydial infection, with a view to better understand the
mechanisms of chlamydial persistence as a result of immunological pressure.
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6.2 Experimental approach
Methods used in this chapter are described in detail in Chapter 2.
For analysis of mRNA expression in all experiments the ceils were seeded in 24 well 
plates at 2x10^ ceiis/weil in 1 ml of IMDM supplemented with 5% FCS. Cells were left 
overnight to adhere and were treated the following day. Stimuli added were always 
diluted in IMDM supplemented with 2% FCS. Samples were collected at different 
times after treatment and RNA extracted (section 2.3.1). Gene expression was 
analysed either by standard RT-PCR (section 2.2.3) or Real Time RT-PCR (section 
2.2.4).
Surface expression of IFN-y receptor was analysed by flow cytometry (section 2.3.2).
For western blotting analysis of S0CS3 protein, ceils were seeded in 75cm^ flasks at 
O.SxloVm! in 10 ml of medium. The preparation of the lysates and western blot 
analysis is described in section 2.5.
All in situ immunohistochemistry and immunofluorescence experiments were done on 
8 well chamber slides. Cells were seeded at Ix lO f cells/ml at 600pl per well. Ceils 
were left to adhere overnight and were treated the following day. Methods are 
described in detail in the following sections: DAB immunohistochemistry, section 
2.6.1; Single immunofluorescence, section 2.6.2.1; Double immunofluorescence, 
section 2.6.2.2.
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6.3 Results
6.3.1 Control of chlamydial growth in lung epithelial cells in 
response to IFN-y
The ability of IFN-y to induce anti-chiamydial responses in lung epithelial cells was 
investigated. HEp-2 and A549 ceils were treated with 500 U/mi of IFN-y at various 
times in relation to infection with M 0I=1 of C. pneumoniae: 24 hours prior to 
infection, at the time of infection, and 24 hours after infection, in order to investigate 
the ability of the ceils to control the growth in response to IFN-y. HEp-2 ceils 
controlled the growth of C. pneumoniae when they were treated with IFN-y prior to 
infection and not in any other case (Figure 6.2 b). The effect of IFN-y treatment on 
chlamydial growth will be discussed further in Section 6.3.7.3. A549 ceils did not 
control chlamydial growth in response to IFN-y at ail (Figure 6.2 e). The inclusions in 
A549 cells treated with IFN-y were similar in size and appearance to untreated ceils at 
ail time points (compare Figure 6.2 d and e).
C. pneumoniae 
d
C. pneumoniae +  IFN-y 
e
Uninfected cells 
f
C. pneumoniae C. pneumoniae + IFN-y Uninfected cells
Figure 6.2 Control of chlamydial growth by epithelial cells in response to inflammatory 
cytokines. Cells were treated with 500 U/ml of IFN-y for 24 hours prior to infection with C. 
pneumoniae (M0I=1). Cells are stained for chlamydial LPS (green) and the nuclei are 
counterstained in (red). Upper panel HEp-2 cells, lower panel A549 cells. Original magnification 
200x.
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The inability of A549 ceiis to control chlamydial growth in response to IFN-y was a 
surprising finding. This may be due to a number of reasons, one of them being the 
lack of IFN-y receptor on the cell surface, or an inhibition of IFN-y-dependent 
signalling pathways. In order to address this phenomenon I decided to start by 
analysing the expression of IFN-y receptor on both ceil types.
6.3.2 Expression of IFN-y receptor on A549 and HEp-2 cells
Both A549 and HEp-2 ceiis were found to express comparable levels of IFN-y receptor
on their surface, and C. pneumoniae infection does not alter the expression (Table 6.1
and Figure 6.3). The expression was analysed by flow cytometry and MFIs are
presented in Table 6.1. From MFI data it seems that the expression is down-
reguiated; however the histograms show that the distribution of ceiis is very spread
out rather than a normal distribution (Figure 6.3) and any apparent shift in MFI may
have a limited value in explaining the change of IFN-y receptor expression.
Table 6.1 Mean fluorescence intensities of IFN-y receptor expression on A549 and HEp-2 lung 
epithelial cells following C. pneumoniae infection.
M o l e c u l e CELLS
6 hr
IFN-y RECEPTOR 
2 4 hr 4 8 hr 7 2 hr
A549
UNINFECTED 1 7 0 .8 3 5 0 4 .8 1 2 2 9 .2 7 9 9 .7 0
INFECTED 1 2 7 .7 0 4 1 6 .6 6 7 8 .2 1 9 9 .7 6
HEp-2
UNINFECTED 1 5 1 .8 9 2 5 7 .9 4 7 3 .3 8 4 9 .0 9
INFECTED 1 0 5 .4 3 1 8 7 .6 2 5 9 .4 3 4 0 .2 8
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AFSC/SSC
6hr
24hr
48hr
72hr
Uninfected cells Infected cells overlay
FSC/SSC Uninfected cells Infected cells overlay
6hr
24hr
48hr
72hr
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Figure 6.3 IFN-y R expression on A549 and HEp-2 cells following C, pneumoniae Infection. 
Cells were Infected with C. pneumoniae (M0I=1) and samples were collected 6, 24, 48 and 72 
hours after Infection (A) A549 cells (B) A549 cells overlay of Infected and uninfected cells (C) 
HEp-2 cells (D ) HEp-2 cells overlay of Infected and uninfected cells. Key: purple field-IFN-R; 
yellow line -  2"^ step control; blue line - step control. In the overlay: purple field -  
uninfected cells; green line - Infected cells.
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Given that both A549 and HEp-2 cell lines express IFN-y receptor, their 
responsiveness to IFN-y treatment was tested. Expression of IDO following IFN-y 
treatment is a central mechanism of control of chlamydial growth and it has been 
demonstrated previously that lack of IDO expression in response to IFN-y correlates 
with the lack of control of chlamydial growth (Entrican et al., 2002). IDO expression 
was therefore chosen as a marker of IFN-y responsiveness.
6.3.3 Expression of IDO mRNA in epithelial cells in response to 
IFN-y treatment
Expression of IDO mRNA was analysed by RT-PCR in both A549 and HEp-2 cells. 
Neither cell line was found to express IDO mRNA in the resting state, whereas 
treatment of cells with 500 U/ml of IFN-y for 24 hours induces IDO mRNA expression
in both HEp-2 and A549 cells (Figure 6.4).
HEp-2 A549
M con IFN-y con IFN-y
GAPDH ►
983bp
— IDO
322bp
Figure 6.4 Expression of IDO mRNA in response to IFN-y treatment in lung epithelial cells. 
Cells treated with 500 U/ml of IFN-y for 24 hours. Data representative of 5 experiments. Key: 
M=marker; con=untreated cells; IFN-y= IFN-y treatment.
The fact that A549 cells are responsive to IFN-y insofar as they express IDO mRNA, 
yet cannot control chlamydial growth was an unexpected and exciting finding. Taking 
all of the findings into consideration the implication is that IFN-y signalling is inhibited 
in A549 cells, I decided to investigate the expression of SOCSl and S0CS3 in A549 
and HEp-2 cells.
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6.3.4 Analysis of SOCSl and SOCS3 expression in resting cells 
by PGR
SOCSl and S0CS3 have both been shown to interfere with IFN-y signalling and 
therefore their expression was examined in HEp-2 and A549 cells by RT-PCR. The 
primers were designed using the PrimerSelect program within the ON AS tar Version
5.06 sequence analysis package (DNAStar; GATC Biotech AG, Konstanz, Germany). 
Initial attempts to detect SOCSl and S0CS3 were inconclusive with a lot of non­
specific bands. S0CS3 but not SOCSl was detected in A549 cells, while HEp-2 did not 
seem to express either (Figure 6.5.A). In order to obtain a more sensitive reaction 
and a cleaner PCR product, a nested PCR was optimised for S0CS3 analysis. The new 
reaction was a combination of two 25 cycle PCR reactions using a set of 'outer' and 
'inner' primer pairs, respectively. The new reaction proved to be more sensitive and 
now S0CS3 mRNA was also detected in HEp-2 resting cells (Figure 6.5.B).
A549 HEp-2
IFN-y control IFN-y control
M S I S3 G S I S3 G S I S3 G S I S3 G M
S0CS3 
510 bp
GAPDH 
983 bp
SO CSl 
387 bp
B
A549 HEp-2
con IFN-y con IFN-y
S3 G S3 G S3 G S3 G
S0CS3 
510 bp
GAPDH
593bp
Figure 6.5 Optimisation of a nested PCR for detection of SOCS. (A) initial attempts with a 
single step PCR for SOCSl and S0CS3; (B) optimised nested PCR for S0CS3. Key: M-marker, 
Sl-SOCSl, S3-SOCS3, G-GAPDH; IFN-y -  cells treated with 500 U/ml for 24 hours; con -  
untreated cells.
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To confirm the results of the nested PCR and to further analyse SOCSl mRNA 
expression, a new set of primers were obtained for a single step PCR for both SOCSl 
and S0CS3 (kind gift from Prof Jim Johnston, Queens University, Belfast). This was a 
single step PCR with 40 cycles. With this reaction previous results of S0CS3 
expression in resting cells were confirmed (Figure 6.6 A). When cells were infected 
with C. pneumoniae there is a suggestion of a change in expression of S0CS3 (Figure
6.6 A); however given that the target gene is expressed in resting cells, the 
differences are difficult to quantify using a standard RT-PCR.
Very faint bands of SOCSl mRNA are visible in resting HEp-2 cells and cells infected 
with C. pneumoniae (Figure 6.6 B HEP-2 columns 4, 1 and 2 respectively).
In A549 cells there is no SOCSl in resting cells but there seems to be up-regulation of 
mRNA expression in response to C. pneumoniae (Figure 6.6 B A549 column 4, 1 and 2 
respectively).
S0CS3 
543 bp
HEp-2 A549
GAPDH 
593 bp
B
M
SOCSl 
491 bp
HEp-2 
2 3
%
M
A549
—■ GAPDH
593 bp
Figure 6.6 SOCSl and S0CS3 mRNA expression in epithelial cells in the first 24 hours after the 
infection. (A) S0CS3 (B) SOCSl. Columns: 1- C. pneumoniae M0I=1; 2- C. pneumoniae 
MOI=10; 3- IFN-y 500 U/ml and C. pneumoniae M0I=1; 4-uninfected cells.
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These results indicated that S0CS3 is expressed constitutively in both HEp-2 and 
A549 cells irrespective of their ability to control chlamydial growth. Since SOCSl and 
S0CS3 can negatively regulate IFN-y signals it was interesting to investigate whether 
C. pneumoniae Infection can change the level of S0CS3 expression and whether this 
Is Influenced by IFN-y treatment of cells prior to Infection.
6.3.5 C. pneumoniae infection up-reguiates SOCS3 mRNA 
expression in iung epitheiiai ceiis
To analyse the change In S0CS3 mRNA expression quantitatively, Real time RT-PCR 
was used. Cells were Infected with multiplicity of Infection of 1 or 10 over 72 hours. 
There was a time and dose-dependent up-regulatlon of S0CS3 mRNA expression In 
both HEp-2 and A549 cells following C. pneumoniae Infection (Figure 6.7). S0CS3 
mRNA Is up-regulated In the first 6 hours with two peaks, one between 1 and 2 hours 
and another at 6 hours. In A549 cells mRNA expression returns to background levels 
after 6 hours (Figure 6.7 A) while In HEp-2 cells S0CS3 mRNA expression Is up- 
regulated over 72 hours (Figure 6.7 C). In order to Identify the component(s) 
responsible for the effect of C. pneumoniae on S0CS3, as a first step the effects of 
LPS were analysed. Cells were treated with 1 pg/ml of S. minnesota LPS which Is 
similar to chlamydial LPS both In structure and endotoxic activity. S. minnesota LPS 
does not Induce S0CS3 mRNA expression (Figure 6.7 A and D; experiment not 
repeated).
Results described here show that C. pneumoniae does change the level of S0CS3 
expression and It does so Independently of LPS. Promoting S0CS3 expression In lung 
epithelial cells could render them less responsive to IFN-y and this could In turn 
contribute to long term Infection. Since there are speculations that IFN-y can also 
contribute to persistence the next step was to Investigate whether IFN-y alters S0CS3 
expression patterns of Infected cells and whether It can Induce S0CS3 expression on 
Its own.
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Figure 6.7 Expression of S0CS3 mRNA in response to C, pneumoniae infection and S. 
minnesota LPS treatment. (A) A549 cells infection over 72 hours (B) A549 cells, infection over 
6 hours (C) HEp-2 cells, infection over 72 hours (D ) HEp-2 cells infection over 6 hours. Cells 
were infected with C. pneumoniae (M0I=1 (♦) or 10 (m) or treated with Ipg/m l of LPS (A ) and 
samples were analysed up to 72 hours. Analysis was done in duplicates, data expressed as 
mean inducibility of S0CS3 mRNA over untreated cells at each time point. Inducibility -  fold 
increase or S0CS3 expression of treated cells over untreated cells. Data representative of three 
separate experiments (only one experiment done for LPS).
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6.3.6 The effect of IFN-y on SOCS3 mRNA expression
To further explore the responsiveness of epithelial ceiis to IFN-y they were treated 
with 500 U/mi of IFN-y alone or in combination with M0I=1 of C. pneumoniae over 72 
hours, and expression of S0CS3 mRNA was analysed (Figure 6.8). IFN-y unresponsive 
A549 ceiis showed up-reguiation of 1.9 fold of S0CS3 expression when treated with 
IFN-y alone, with a peak at 24 hours post treatment. This change is not considered 
biologically significant. To be considered biologically significant, a change of less than 
0.5 (down-regulation), and greater than 2 fold (up-regulation) must be recorded in 
two separate experiments (Chtanova et al., 2001).
When the cells were pre-treated with IFN-y for 24 hours and then infected with C. 
pneumoniae at M 0I=1, there was a peak of S0CS3 mRNA expression at 2 hours after 
infection and then again at 6 hours which is similar to the pattern seen with C. 
pneumoniae infection alone. There was induction again at 72 hours (2.3 fold).
HEp-2 cells showed steady levels of S0CS3 mRNA over 72 hours in response to IFN-y 
treatment (~2 .5  foid). When treated with both IFN-y and C. pneumoniae there was a 
synergy of the two treatments in inducing S0CS3 mRNA expression, and the pattern 
of expression resembled the pattern of Chiamydia infection only (see Figure 6.7 B).
Analysis of S0CS3 mRNA expression has shown that it is expressed constitutively and 
C. pneumoniae infection up-regulates its expression. IFN-y causes further up- 
regulation of S0CS3 mRNA expression in HEp-2 cells while in A549 cells the effects 
are weaker. Following these findings it was important to analyse the expression of 
S0CS3 protein to find out whether these treatments have an effect on the protein 
expression and whether S0CS3 affects STATl phosphorylation inhibiting IFN-y- 
mediated functions in this way.
123
IFN-y -A549 
- HEp-2
5.00 1
4.00 -
3.00 -
■o 2 . 0 0  -
1.00  -
0.00
0 6 12 18 24 30 36 42 48 54 60 66 72
hour post treatment 
IFN-y +C. pneumoniae ■A549
-HEp-2
5.00
4.00 i
3.00
■a 2.00 1
1.00
0.00
0 6 12 18 24 30 36 42 48 54 60 66 72
hour post infection
Figure 6.8 Expression of S0CS3 mRNA In response to IFN-y and C. pneumoniae. (A) IFN-y 
treatment. Cells were treated with 500 U/ml of IFN-y over 72 hours. (B) IFN-y treatment and 
C. pneumoniae Infection. Cells were pre-treated with 500 U/ml of IFN-y for 24 hours and then 
Infected with C. pneumoniae M0I=1. Samples were collected and analysed up to 72 hours after 
the Infection. Analysis done In duplicate, data expressed as mean Inducibility over untreated 
cells at each time point. Inducibility -  fold Increase or S0CS3 expression of treated cells over 
untreated cells Data representative of three separate experiments.
6.3.7 Analysis of SOCS protein expression in lung epithelial cells
In the view of the findings described above there were several key questions 
regarding SOCS protein expression:
Are SOCS proteins expressed in resting cells?
Is SOCS protein expression changed by C. pneumoniae infection?
Does IFN-y pre-treatment of infected cells influence SOCS protein expression?
Where in the cells do the SOCS proteins localise, and does this change with 
treatment?
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To address these questions three different techniques were used to detect SOCS 
proteins: Western Blotting, DAB (diaminobenzidine) Immunohistochemistry analysed 
by light microscopy, and immunofluorescence analysed by confocal microscopy.
6.3.7.1 Analysis of SOCS protein expression by Western Blotting
At the time of planning these experiments there were a limited number of reagents 
available for detection of SOCS at the protein level. Initial attempts to get any specific 
staining for either SOCSl or S0CS3 failed. A number of different conditions were 
changed without success (different lysis buffer; increased concentration of protein; 
longer blotting time; different blocking reagent; increased concentrations of 
antibodies with longer incubation times; longer exposure of the film to ECL). 
Considering the lack of SOCSl mRNA expression in both cell lines, SOCSl protein 
analysis by western blot was abandoned completely.
In order to solve the problem of S0CS3 protein expression, I initiated a collaboration 
with Professor Jim Johnston at the Department of Immunology and Microbiology, 
Queens University Belfast. The focus of his research is SOCS proteins and their 
functions In immunology (Cacalano et al., 2001, Hortner et al., 2002, Seki et al., 
2003, Haan et al., 2003). I visited Professor Johnston's laboratory for a week in March 
2003 where I analysed S0CS3 expression using an antibody optimised for western 
blotting. A549 and HEp-2 cells were infected with C. pneumoniae at M 0I=1 or pre­
treated with 500 U/ml of IFN-y for 24 hours and then infected. Whole cell lysates were 
prepared with equal amounts of lysis buffer and equal amounts of protein were used 
for analysis. Some of the protein was immunoprecipitated using agarose beads and 
anti-S0CS3 rabbit polyclonal antibody (in-house, QUB, Belfast). The results are 
presented in Figure 6.9.
Analysis of whole cell lysates shows that A549 cells express S0CS3 protein 
constitutively while HEp-2 cells do not. There is an up-regulation of S0CS3 protein in 
both cell lines after infection with C. pneumoniae. In HEp-2 cells the peak is between 
24 and 48 hours after the infection. IFN-y pre-treatment of the cells seems to down-
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regulate S0CS3 expression compared to C. pneumoniae only in the first 48 hours. 
This differs from the Real time RT-PCR results. Unfortunately the HEp-2 sample for 
IFN-y treatment and infection was destroyed in transit and was not analysed (Figure 
6.9 A).
In A549 cells there is up-regulation of S0CS3 protein expression for the whole 72 
hour period with no difference with IFN-y treatment (Figure 6.9 B).
When S0CS3 expression is analysed by immunoprécipitation, there does not seem to 
be a change of expression in either cell line. However, the immunoprécipitation 
protocol did not work well; there was a lot of background when compared to the 
positive control. The protocol needed optimisation, and given that the whole cell 
lysates showed promising results the immunoprécipitation approach was abandoned.
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Figure 6.9 Western blot analysis of S0CS3 protein expression done in Belfast (Mar 2003). (A) 
HEp-2 cells (B) A549 ceils. Blots were repeated twice for whole cell lysates with different 
amounts of lysate. Times refer to hours after infection. WCL-whole cell lysates; IP- 
immunoprecipitate; IFN-y -  cells treated with 500 U/ml IFN-y; C.pn -  cells infected with M0I=1 
of C. pneumoniae; +ve control-recombinant S0CS3.
Further analysis was conducted on S0CS3 protein expression in response to IFN-y and 
S. minnesota LPS treatment, and the previous experiment was repeated to confirm 
the results obtained in Prof. Johnston's laboratory. The whole cell lysates were 
prepared in the same way as before, and the protein concentration was measured. A
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maximum of 120 pg of protein was put on the gel. As seen in Figure 6.10 the results 
were inconsistent. The amount of protein detected in different blots differed even 
though the same amounts of protein were loaded onto the gel. However the (3-actin 
bands are similar in thickness. These results indicate that C. pneumoniae treatment 
does not induce a change in expression which is in conflict with both Real time RT-PCR 
and the western blot results described above. In the case of IFN-y and LPS treatment 
the levels of background production were different from those found with C. 
pneumoniae alone and there was no consistency between the bands so it was not 
possible to draw conclusions.
S0CS3
(3-actin
HEp-2 A549
24 48 72 con^ 24 48 72 con +^ve
B
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Figure 6.10 Western blot analysis of S0CS3 expression in response to different treatments. 
(A) C. pneumoniae infection M0I=1 (B) IFN-y treatment 500 U/ml (C) LPS treatment 1 pg/ml. 
Numbers are hours of treatment.
Any one of a number of reasons could explain the discrepancies in the results 
obtained in different labs: different gel system; different buffer; different transfer 
system - a semi-dry blotter was used in both cases, but they were from different 
companies. All of this may have affected the binding efficiency of the SOCS antibody. 
Taking into account all the results presented here and all the inconsistencies 
encountered it would seem that western blotting was not an ideal technique for
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analysis of differences in S0CS3 protein expression. It did, however, establish that 
both A549 and HEp-2 cells express S0CS3 protein.
Analysis of SOCSl protein expression gave negative results and, given the PCR 
results, it is likely that SOCSl protein is not expressed in either A549 or HEp-2 cells.
Western blotting is limited to revealing the presence of a protein in the cell lysate and 
It is easily affected by the method and quality of the cell lysates. It does not give any 
Information about the localisation of the target protein in the cell. Given that the 
results indicated the presence of the protein in both cell lines, the next logical step 
was to investigate where in the cell S0CS3 is localised and whether the localisation 
changes in response to different treatments. These questions were addressed with in 
situ analysis by immunohistochemistry.
6.3.7.2 Analysis of SOCS protein expression by immunohistochemistry
The localisation of SOCS proteins in the cell was analysed by immunohistochemistry. 
Initially a biotin/avidin/DAB staining was used and analysed by light microscopy 
(section 2.6.1). Cells were treated with (I) C. pneumoniae M 01=l and MOI=0.1 and 
stained at 72 hours after infection; ( II)  500 U/ml of IFN-y at different times in relation 
to the infection with C. pneumoniae M 0I=1; ( I I I)  500 U/ml of IFN-y alone up to 72 
hours. Staining for SOCSl protein was completely negative in both cell types.
C. pneumoniae induces S0CS3 protein expression in both A549 and HEp-2 cells, in a 
dose-dependent manner (Figure 6.11 and 6.12 B and C). 72 hours after the infection, 
when the inclusions are fully developed, S0CS3 protein is concentrated at the site of 
the inclusion. When HEp-2 cells are pre-treated with IFN-y, S0CS3 protein expression 
is down-regulated (Figure 6.11 D). When they are treated with IFN-y at the time of 
the infection there is some suppression and if treated with IFN-y 24 hours after the 
infection the pattern of expression is comparable to untreated infected cells (Figure 
6.11 E and F respectively). The expression of S0CS3 protein in infected A549 cells 
does not change in response to IFN-y treatment and the pattern of expression is 
similar to that of infected cells (Figure 6.12 D to F).
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Figure 6.11. S0CS3 protein expression in infected HEp-2 cells analysed by light microscopy. 
Cells were infected with C. pneumoniae and treated with 500 U/ml of IFN-y at different times in 
relation to infection. S0CS3 is stained brown with DAB. Examples of staining are indicated with 
red arrows. Nuclei were counterstained blue with hematoxylin. Key: Pre IFN - treatment 24 hr 
prior to infection with M0I=1; Co IFN-treatment at the time of the infection with M0I=1; Post 
IFN -treatment 24 hr after the infection with M0I=1. Original magnification 200x.
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Figure 6.12. S0CS3 protein expression in infected A549 cells analysed by light microscopy. 
Cells were infected with C. pneumoniae and treated with 500 U/ml of IFN-y at different times in 
relation to infection. S0CS3 is stained brown with DAB. Examples of staining are indicated with 
red arrows. Nuclei were counterstained blue with hematoxylin. Key: Pre IFN - treatment 24 hr 
prior to with M0I=1; Co IFN-treatment at the time of the infection with M0I=1; Post IFN -  
treatment 24 hr after the infection with M0I=1. Original magnification 200x.
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IFN-y treatment of A549 cells up-regulates S0CS3 two hours after treatment and the 
protein is localised in the cytoplasm of the cells (Figure 6.13 B). This goes back to 
background levels at 4 hours and there does not seem to be a further change of 
expression over the 72 hour period (Figure 6.13 C to G). The darker patches in the 48 
and 72 hour panels could be an artefact of cell density rather than true staining 
(Figure 6.13 F and G). IFN-y can exhibit an anti-proliferative effect in certain cells; 
however as can be seen in these panels there is no growth inhibition in A549 cells 
over the 72 hours of treatment. This may be another indicator of the partial 
responsiveness of A549 cells to IFN-y treatment. IFN-y did not induce S0CS3 
expression in HEp-2 cells, but there is growth arrest as seen in Figure 6.14. HEp-2 
cells were only analysed at 24 hours and later. Considering the results obtained from 
A549 cells this should be included in further studies.
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Figure 6.13 A549 cells stained for S0CS3 protein in response to IFN-y treatment over 72 
hours. Cells were grown on 8 well chamber slides, and staining performed as described (section 
2.6.1). S0CS3 is stained brown with DAB. Nuclei are counterstained blue with haem atoxylin  
Data representative of four experiments. Original magnification 200x.
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Figure 6.14 S0CS3 expression in HEp-2 cells over 72 hours. Cells were treated with 500 U/ml 
of IFN-y and stained at different time points. S0CS3 is stained brown with DAB. Nuclei are 
counterstained blue with haematoxylin. Data representative of at least 3 experiments. Original 
magnification 200x.
Constitutive expression of S0CS3 protein was not detected in either cell line by DAB 
immunohistochemistry. It may be that the levels of S0CS3 protein are beyond the 
sensitivity of this technique. What is very interesting is the induction of S0CS3 protein 
expression in infected cells 72 hours after the infection. The pattern of infection 
resembles chlamydial inclusions; however this could not be confirmed by this method. 
In the light of this it was decided to continue S0CS3 protein analysis by 
immunofluorescence and confocal microscopy that should be more sensitive 
techniques.
6 3 .7 .3  Analysis o f SOCS protein expression by confocal microscopy
To confirm the results obtained by DAB staining and to analyse the localisation of 
S0CS3 protein in relation to chlamydial inclusions S0CS3 expression was further 
analysed by confocal microscopy (method described in section 2.6.2.2). Cells were 
infected for 72 hours and were treated with IFN-y at different times in relation to 
infection as described in the previous section. Cells were also infected for 6 hours to 
investigate the early expression of S0CS3 protein in response to infection. Samples 
were stained for chlamydial LPS to locate the inclusion and for S0CS3. The results are
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presented as confocal Images along with a corresponding diagram. The diagrams 
represent the pixel intensity of each channel of the measured section on the image; 
this graphic form gives a clearer representation for analysis of protein localisation. 
The intensity value Is an arbitrary number with a range 0-256; values under 20 are 
considered as background.
No expression of S0CS3 protein could be demonstrated In resting HEp-2 cells (Figure 
6.15 A). Infection over 6 hours induces some S0CS3 protein expression and the 
protein localises in the cytoplasm and this does not change at 72 hours (Figure 6.15 B 
and C) and this can be better seen in the accompanying graph.
When HEp-2 cells are treated with IFN-y the intensity of LPS staining and the size of 
inclusions changes, depending on the time of treatment in relation to the infection 
(Figure 6.16). Levels of S0CS3 staining change accordingly. The strongest intensity is 
visible in image 6.16 C where IFN-y was added 24 hours after the infection.
A549 cells have some background S0CS3 expression In resting cells (Figure 6.17 A). 
This is enhanced after 6 hours of infection (Figure 6.17 B). S0CS3 protein is again 
localised in the cytoplasm. 72 hours after the Infection S0CS3 is still localised In the 
cytoplasm at similar levels (Figure 6.17 C). The levels of S0CS3 staining are higher in 
A549 cells than in HEp-2 cells for all the conditions.
IFN-y treatment of A549 cells does not affect the staining patterns or levels of S0CS3 
irrespective of when the cells were treated In relation to infection (Figure 6.18). 
Confocal analysis has also confirmed the initial finding that the IFN-y does not control 
chlamydial growth in A549 cells and that the appearance and size of inclusions does 
not change in response to IFN-y (discussed in Section 6.1).
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Figure 6.15 Expression of S0CS3 protein in HEp-2 cells analysed by confocal microscopy both 
as images and corresponding diagrams. (A) uninfected cells (B) C. pneumoniae M0I=1 for 6 
hours (C) C. pneumoniae M0I=1 for 72 hours. Staining: chlamydial LPS (red), S0CS3 (green) 
and DNA (blue). Images were acquired and analysed with Leica confocal software. Data 
representative of 4 experiments. Original magnification 400x.
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Figure 6.16 The effect of IFN-y on S0CS3 expression in infected HEp-2 cells.(A ) Pre-IFN (B) 
Co IFN (C) Post IFN. Cells were treated with 500 U/ml of IFN-y and infected with M0I=1 of C. 
pneumoniae. Key: Pre- 24 hours prior to the infection; Co- at the time of the infection; Post- 24 
hours after the infection. Staining: chlamydial LPS-red; S0CS3-green; DNA-blue. Data 
representative of 4 experiments. Original magnification 400x.
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Figure 6.17 Expression of S0CS3 protein in A549 cells analysed by confocal microscopy both 
as images and corresponding diagrams. (A) uninfected cells (B) C. pneumoniae M0I=1 for 6 
hours (C) C. pneumoniae M0I=1 for 72 hours. Staining: chlamydial LPS (red), S0CS3 (green) 
and DNA (blue). Images were acquired and analysed with Leica confocal software. Data 
representative of 4 experiments. Original magnification 400x.
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Figure 6.18 The effect of IFN-y on S0CS3 expression in infected A549 cells.(A ) Pre-IFN (B) 
Co IFN (C) Post IFN. Cells were treated with 500 U/ml of IFN-y and infected with M0I=1 of C. 
pneumoniae. Pre- 24 hours prior to the infection; Co- at the time of the infection; Post- 24 
hours after the infection. Staining: chlamydial LPS-red; S0CS3-green. Data representative of 4 
experiments. Original magnification 400x.
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In previous sections I discussed the roie of LPS in the induction of S0CS3 expression. 
S. minnesota LPS did not induce S0CS3 mRNA or protein expression in either celi line. 
However E. coli LPS has previously been shown to induce S0CS3 expression. To 
confirm the results obtained earlier ceils were treated with S. minnesota LPS and 
E.coli LPS as a positive control and analysed by confocal microscopy. S. minnesota 
LPS treatment for 6 hours does not induce S0CS3 expression in either ceil line (Figure 
6.19). On the other hand, E. coii LPS treatment up-regulates S0CS3 expression in 
A549 ceils, and the staining intensity is comparable to chlamydial infection in both celi 
lines (Figure 6.20).
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Figure 6.19 Effect of S. minnesota LPS treatm ent on S0CS3 protein expression both as images 
and corresponding diagrams. (A) A549 cells (B) HEp-2 cells. Cells were treated with Ip g /m l of 
LPS for 6 hours and then stained. Staining:S0CS3 (green); DNA (blue). Original magnification 
400x.
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Figure 6.20 Effect of E. coli LPS treatment on S0CS3 protein expression both as images and 
corresponding diagrams. (A) A549 cells (B) HEp-2 cells. Cells were treated with Ipg /m l of LPS 
for 6 hours and then stained. Staining: S0CS3 (green); DNA (blue). Original magnification 
400x.
One last attempt was made to investigate the expression of SOCSl protein in 
response to C. pneumoniae, 72 hours after infection. In A549 cells there was 
background expression of SOCSl and it was up-regulated by Infection (Figure 6.21 A 
and B). HEp-2 cells did not show any expression of SOCSl protein in resting cells, and 
72 hours after Infection there was low Intensity staining (Figure 6.21 C and D).
Negative controls for all experiments discussed In this section were obtained by 
omitting the primary antibodies. There was no background In any samples (Figure 
6 .22).
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Figure 6.21 Expression of SOCSl In A549 and HEp-2 cells. (A) infected A549 cells (B) 
uninfected A549 cells (C) infected HEp-2 cells (D ) uninfected HEp-2 cells. Cells were infected 
with C. pneumoniae M0I=1 for 72 hours. Staining: SOCSl (blue); chlamydial LPS (red). 
Original magnification 400x.
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Figure 6 .2 2  Negative controls for infected and uninfected cells. Negative controls were 
obtained by omitting the primary antibody. Original magnification 400x.
In summary, confocal microscopy proved to be the most suitable technique for the 
investigation of S0CS3 expression. After the initial optimisation the results were 
reproducible and the technique proved reliable. It also provided the largest amount of 
information about the patterns of SOCS expression. A549 cells express S0CS3 protein 
constitutively and HEp-2 cells do not. C. pneumoniae infection induces further protein 
expression in both cell types. When infected cells are treated with IFN-y there is no 
change in A549 cells however there is suppression of S0CS3 expression in HEp-2 
cells.
As an initial attempt to assign a function to constitutive S0CS3 expression in A549 
cells, and considering the role of SOCS as inhibitors of Jak/STAT pathways, A549 cells 
were analysed for phosphorylation of STATl following IFN-y treatment.
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6.3.8 S ta tl phosphorylation in response to IFN-y treatment in 
A549 ceils
SOCS interfere with Jak/Stat signalling pathways and S0CS3 can inhibit activation of 
Statl. IFN-y signalling is largely Jak/Stat dependent, and to see whether constitutive 
S0CS3 expression in A549 cells is the reason behind their partial responsiveness to 
IFN-y, phosphorylation of STATl was analysed.
A crucial step in activation of S tatl is phosphorylation of tyrosine 701 (Y7Ü1). This 
was chosen for analysis in A549 cells following IFN-y treatment. Cells were treated 
with 500 U/ml of IFN-y for 5, 10 and 30 minutes and then analysed by western 
blotting. A549 cells show constitutive STATl Y701 phosphorylation and this is not 
changed by IFN-y treatment (Figure 6.23)
IFN-y O' 5' 15' 30'
STATl 
pSTATi
Figure 6.23 Tyrosine 701 STATl phosphorylation in A549 cells In response to IFN-y treatment. 
Upper panel STATl; lower panel phosphorylated STATl (pSTATl).
6.4 Discussion
Early production of IFN-y following C. pneumoniae infection has been to shown to be a 
crucial factor in host immune control and protection against disease (Rottenberg et 
al., 1999, Rotten berg et al., 2000, Rothfuchs et al., 2004). Lung epithelium is the first 
target for C. pneumoniae infection and is a site of multiplication of the organism. 
Therefore, any inability of these cells to respond to IFN-y is likely to be detrimental to 
the host.
In this chapter two lung epithelial cell lines are described (HEp-2 and A549) with 
differential responsiveness to IFN-y and differential ability to control the growth of C. 
pneumoniae: HEp-2 cells controlled the growth as shown previously, while A549 cells 
did not (Figure 6.2). Both HEp-2 and A549 cells express IFN-y receptor and are
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responsive to IFN-y insofar as they express IDO mRNA following treatment (Table 6.1 
and Figures 6.4 and 6.5). The failure of A549 cells to control C. pneumoniae is 
therefore surprising since tryptophan degradation by IDO has been shown to be the 
major mechanism of chlamydial control by IFN-y in human cells In vitro (Beatty et al., 
1994), and failure of IFN-y to induce IDO results in uncontrolled chlamydial growth 
(Entrican et al., 2002). Since IFN-y-mediated control of chlamydial growth is highly 
dose-dependent, this finding suggested that IDO message was not translating into 
control of C. pneumoniae, either through lack of functional protein or qualitative 
differences in IFN-y signalling in A549 cells. This prompted investigation of SOCS 
expression.
Both A549 and HEp-2 cells express S0CS3 mRNA in the resting state and chlamydial 
infection induces up-regulation of S0CS3 expression at both mRNA and protein level 
(Figures 6.7 and 6.15 to 6.18).
During this investigation I encountered a number of difficulties in finding the best 
method in for detection of S0CS3 protein expression. Western blotting proved 
inconsistent and unreliable. The levels of protein in resting cells varied from blot to 
blot and no consistent trends could be seen (Figure 6.10). Immunohistochemistry 
proved to be better with more consistent results (Figure 6.11 and 6.12). However, the 
pattern of S0CS3 staining in infected cells was very similar to that of chlamydial 
inclusions thereby making the results inconclusive. Nevertheless, when the primary 
antibody was omitted there was no staining at all and the results were comparable to 
control samples (not shown). The question remained whether the staining was 'true' 
and whether S0CS3 protein localises in the vicinity of chlamydial inclusions in the host 
cell. In addressing these issues confocal microscopy proved to be the most sensitive 
and the most suitable technique.
S0CS3 protein is cytoplasmic and its location seems to change as the inclusion 
develops. Early after infection the protein is found diffusely in the cytoplasm, whereas
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it becomes associated with the inclusion as it matures (Figure 6.17 B and C) and in 
the later stages it is in the vicinity of the inclusions (Figure 6.18). This raises the 
question that S0CS3 might be associating with chlamydial components in the 
inclusion membrane. One potential candidate is the Inc family of proteins that are 
putatively secreted into the host cell cytoplasm from the inclusion and thereby can 
interfere with a variety of host cell pathways (Rockey et al., 1997, Wyrick, 2000). 
Secretion of these proteins may be a way by which C. pneumoniae communicates with 
the host cell and how it can manipulate the host-cell responses.
In an effort to identify the chlamydial component(s) responsible for the up-regulation 
of S0CS3 following infection, the cells were treated with Saimoneiia minnesota LPS, 
which is similar to chlamydial LPS in both structure and endotoxic activity. It  was 
found that it did not change S0CS3 expression; however E. coii LPS treatment did 
(Figure 6.19 and 6.20). There are differences in the structure and endotoxic activity 
between chlamydial and E. coli LPS, and this may influence their differential ability to 
induce S0CS3. This finding is in keeping with other reports suggesting that chlamydial 
LPS although antigenic, is not a potent inducer of inflammatory responses, and that it 
is the secretion of cHSP 60 that induces inflammation (Kol et al., 1998, Ko I et al., 
1999, Kol et al., 2000). Other bacterial components such as CpG, and other 
intracellular pathogens, including Listeria monocytogenes and Mycobacterium 
tuberculosis, can induce SOCSl and S0CS3 expression, and this correlates with 
inhibition of IFN-y signalling and the ability of the host cells to control the infection 
(Dalpke et al., 2001, Imai et al., 2003, Stoiber et al., 1999, Stoiber et al., 2001).
In investigating how IFN-y modulates S0CS3 expression, I showed that IFN-y 
treatment enhanced S0CS3 mRNA expression in infected HEp-2 cells but not in 
infected A549 cells (Figure 6.7). In addition, IFN-y alone induces S0CS3 mRNA 
expression in uninfected HEp-2 cells but has a limited effect on uninfected A549 cells. 
It is interesting to note that Song and Shuai have previously shown that over­
expression of SOCSl and S0CS3 in epithelial cells inhibits control of viral infections by
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type I and type I I  interferons (Song and Shuai, 1998), thus putting these findings 
together with the fact that A549 cells express S0CS3 protein constitutively may 
explain their partial responsiveness to IFN-y treatment. The effect of IFN-y on S0CS3 
protein expression was only analysed in relation to C. pneumoniae infection and the 
pattern of S0CS3 expression followed that of chlamydial control. In HEp-2 cells, IFN-y 
treatment prior to infection inhibited S0CS3 expression, while in A549 cells there was 
no change. In retrospect it would have been interesting to analyse also the effect on 
S0CS3 protein expression by IFN-y alone by confocal microscopy, in order to get a 
more complete picture of how S0CS3 expression is controlled.
Induction of S0CS3 expression following C. pneumoniae infection in the lung 
epithelium is potentially beneficial to the pathogen as it prevents the development of 
protective Th l type immunity and favours Th2 type responses, that have been shown 
to be detrimental to the host (Rottenberg et al., 1999, Rottenberg et al., 2000). Cells 
infected by C. pneumoniae are induced to release different inflammatory mediators 
and they also release chlamydial components. These may include LPS, Inc and hsp60, 
all of which may modulate IFN-y signalling. Infected epithelial cells produce IL-6 and 
PGE2 following chlamydial infection, and these mediators both induce S0CS3 
expression (Jahn et al., 2000, Gasperini et al., 2002). S0CS3 expression controls the 
range of responses to IL-6, as demonstrated by selective deletion of socs3 gene. The 
lack of S0CS3 causes a wider transcriptional response to IL-6 that is dominated by 
IFN-y-regulated genes, owing to an excess of STATl phosphorylation (Croker et al., 
2003, Lang et al., 2003). PGE2 down-regulates Th l type T cell responses (reviewed by 
(Harris et al., 2002) and there is some indication that S0CS3 is preferentially 
expressed in Th2 CD4+ T cells, and that it is associated with the inhibition of Th l type 
responses and the release of pro-inflammatory cytokines (Seki et al., 2003, Egwuagu 
et al., 2002). Some reports have demonstrated high expression of S0CS3 in T h l 
CD4+ T cells, nevertheless still with an inhibition of Th l type responses (Anderson et 
al., 2003). Given that Th l type immunity, and IFN-y in particular, is important for 
protection from chlamydial infections, our findings propose a novel way by which C.
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pneumoniae could manipulate the immune response in the early stages of the 
infection, thereby contributing to the establishment of persistence, that can lead to 
serious chronic conditions such as atherosclerosis and coronary heart disease.
As discussed earlier, SOCS interfere with JAK/STAT signalling pathways and IFN-y 
signalling is largely Jakl/Jak2/STAT1 dependent. S0CS3 has an effect on IFN-y 
signalling through inhibition of STATl phosphorylation (Stoiber et al., 1999). Binding 
of IFN-y to the receptor causes STATl phosphorylation on tyrosine 701 (Y701) via Jak 
kinases. To act with maximal efficiency as a transcription factor, STATl must also be 
phosphorylated on serine 727 (S727) and this happens through the p38 kinase 
pathway (Ramana et al., 2002, Goh et al., 1999). Given the constitutive expression of 
S0CS3 in A549 cells it could be assumed that STATl phosphorylation is inhibited. 
However these cells show constitutive STATl Y701 phosphorylation and this is not 
changed by IFN-y treatment.
Considering these opposing results, there are a few possible explanations. S0CS3 
might be preventing secondary phosphorylation of STATl at S727, and there are also 
other inhibitors of cytokine signalling that could be involved. Protein Inhibitors of 
Activated STATs (PIAS) are a novel group of inhibitory molecules that inhibit the 
translocation of already activated (phosphorylated) Stats thereby preventing the 
Jak/STAT dependent signals (Wormald and Hilton, 2004). PIASl inhibits STATl and 
hence IFN-y signalling. For PIAS 1 to inhibit it, STATl needs to be phosphorylated on 
Y701 (Liu et al., 1998, Ungureanu et al., 2003). Also, high constitutive expression can 
cause lack of responsiveness to IFN-y treatment (Coccia et al., 2002).
Taking these findings into consideration it is clear that my investigation of IFN-y 
unresponsiveness could have been expanded to include analysis of PIASl expression 
and, instead of taking phosphorylation of STATl as a marker of activation, I could 
have investigated translocation of STATl into the nucleus by confocal microscopy.
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Nevertheless I believe that the experiments conducted show a potentially important 
role of SOCS proteins in chlamydial infections.
In summary, the results presented in this chapter demonstrate a complex, intimate 
host-pathogen interaction whereby C. pneumoniae may induce biochemical changes in 
the host cells that are favourable to its long term survival. Induction of S0CS3 
expression may be one of the many pathways induced in the early stages of the 
infection and diminish IFN-y-dependent control mechanism, thereby contributing to 
the establishment of persistent infection.
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Ch a p t e r  7
P r e l im in a r y  I n v e s t ig a t io n  in t o  t h e  ro le  o f  ELAFIN
AND SLPI OVEREXPRESSION IN  CONTROLLING CHLAMYDIAL
G r o w t h
7.1 Introduction
The presence of small cationic antimicrobial proteins in rabbit and guinea pig 
granulocytes was first reported in the mid-1960s (Zeya and Spitznagel, 1966a, Zeya 
and Spitznagel, 1966b, Zeya and Spitznagel, 1966c) and they have recently emerged 
as an important factor in the innate immunity of plants and animals alike. Research in 
recent years suggests that antimicrobial peptides are a key component of the innate 
immune responses of the lung. There are a number of different antimicrobial peptides; 
however a substantial portion of studies investigating the role of these peptides has 
focused on defensins (Lehrer et al., 1993, Kagan et al., 1994, McCray, Jr. and Bentley, 
1997, Singh et al., 1998, Lehrer and Ganz, 2002).
7.1.1 Defensins
Defensins are a large family of antimicrobial peptides, contributing to the antimicrobial 
action of granulocytes, and mucosal host defence in the small intestine, in the lung 
and elsewhere. Structurally they can be divided in three groups: a-, |3- and 0- 
defensins. o-defensins are small peptides with approximately 30 residues, cysteine 
rich, mostly expressed by granulocytes and some lymphocytes (Selsted et al., 1985); 
p-defensins are slightly larger (approximately 45 residues), with different cysteine 
pairing, and they are expressed by epithelial cells in skin and lung (McCray, Jr. and 
Bentley, 1997, Harder et al., 1997); 0-defensins were recently found in leukocytes of 
rhesus monkeys, are smaller and have a circular structure (Tang et al., 1999).
Defensins have a broad spectrum of activity against Gram-positive and Gram-negative 
bacteria (Ganz et al., 1985, Lehrer et al., 1989, Shafer et al., 1988, Miyasaki et al., 
1991, Miyasaki et al., 1990, Ogata et al., 1992, Kohashi et al., 1992) as well as
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against fungi (Lehrer et a!., 1986, Lehrer et a!., 1988) and enveloped viruses (Daher 
et al., 1986, Nakashima et al., 1993, Welling et al., 1998, Yasin et al., 2000, Bastian 
and Schafer, 2001, Quinones-Mateu et al., 2003). Defensins show synergistic activity 
with other host defence molecules such as lysozyme and lactoferrin (Singh et al., 
2000). The microbicidal activity of defensins stems from their ability to permeabilize 
anionic lipid bilayers, release cellular contents and destroy the membrane's electrical 
potential.
Expression of o-defensins is increased in the airway secretions of patients with 
inflammatory lung diseases such as cystic fibrosis, COPD, chronic bronchitis and acute 
respiratory distress syndrome. Their role as effectors of the immune response in the 
lung seems to be two fold; they direct antimicrobial effects and cause 
immunomodulation that could contribute to immunopathology (reviewed in (van 
Watering et al., 1999, Lehrer and Ganz, 2002). They have chemotactic properties, 
recruit inflammatory cells, activate T cells and epithelial cells; decrease levels of 
glutathione (a powerful anti-oxidant) in epithelial cells which can lead to oxidative 
damage, and by binding protease inhibitors released by the epithelium o-defensins 
can promote neutrophil-induced damage (Lillard et al., 1999, van Watering et al., 
1997, Yang et al., 1999, Yang et al., 2000). o-defensins also contribute to 
exacerbations of COPD by increasing bacterial adherence to the epithelial cells (Gorter 
et al., 1998).
There is evidence that defensins have bactericidal activity against intracellular bacteria 
such as Mycobacterium tubercuiosis (Sharma et al., 1999, Sharma et al., 2000, Fu, 
2003). Also o-defensins and protegrins were shown to have bactericidal effects on C. 
trachomatis growth in McCoy cells (Yasin et al., 1996b, Yasin et al., 1996a) There 
have been no reports on the effects of antimicrobial peptides on C. pneumoniae; 
however given the importance of defensins in the chronic diseases of the lung they 
may have a role in C. pneumoniae infections.
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7.1.2 Proteinase Inhibitors
Proteinase inhibitors (Pis) are important molecules involved in the acute-phase 
response (APR), an important part of the initiation and development of inflammation. 
Pis are produced either locally in the mucosal sites, or systemicaIly in the liver. 
Secretory leucocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ELAFIN) 
are two Pis produced locally at the site of injury and have very low concentrations in 
the circulation. Other Pis such as Ci-antichymotrypsin and ai-protein inhibitor (o l-P I) 
are produced in abundance by the liver with a high concentration in the circulation 
(Perlmutter et al., 1989).
Expression of SLPI and ELAFIN is up-regulated by inflammatory signals, including 
cytokines such as IL-1 and TNF-o, LPS, neutrophil elastase and defensins (Sallenave 
et al., 1994, Jin et al., 1998), while anti-inflammatory cytokines such as TGF-(3 down- 
regulate their expression (Jaumann et al., 2000). The function of SLPI and ELAFIN 
seems to be anti-inflammatory, as they can inhibit the expression of TNF-o and matrix 
metalloproteinases (Jin et al., 1998, Zhang et al., 1997). Antiproteinases have also 
been shown to have "defensin"-like antimicrobial activities. They have antimicrobial 
properties in vitro against bacteria, fungi and, potentially HIV (Hiemstra et al., 1996, 
Simpson et al., 1999). Simpson et ai have also shown by adenovirus-mediated gene 
transfer over-expression, that ELAFIN is active against Pseudomonas aeruginosa 
infection in the mouse lungs in vivo (Simpson et al., 2001). SLPI and ELAFIN were 
first isolated from the sputum secretions from patients with COPD as the most 
abundant elastase inhibitors (Hochstrasser et al., 1981, Kramps and Klasen, 1985, 
Sallenave and Ryle, 1991). They are also up-regulated in a number of other 
pulmonary diseases, including cystic fibrosis, acute respiratory distress syndrome, 
pneumonia and possibly asthma (reviewed in (Sallenave, 2000). Their role in these 
conditions is still under investigation, but it seems that they may be relevant in the 
onset of inflammatory responses, and they are also interesting as potential 
therapeutic targets.
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Given their importance in lung pathology I decided to investigate the role of ELAFIN 
and SLPI in C. pneumoniae infections by studying how over-expression of these genes 
influenced the rate of chlamydial growth in lung epithelial cells.
7.2 Experimental Approach
Adenovirus-mediated over-expression of ELAFIN and SLPI was optimised by Sallenave 
et al (Sallenave et al., 1998), and the experiments described here were conducted 
using the same system. Briefly, A549 cells were incubated at 37°C in IMDM 
supplemented with 5% FCS (IMDM + 5%) and grown to confluence on 8 well chamber 
slides. Cells were gently washed twice with PBS and then incubated for 1 hour with 
one of the following treatments; Ad-ELAFIN in IMDM+5%; Ad-SLPI in IMDM+5%; 
empty virus Ad-DL70 in IMDM+5%; or IMDM+5% only with no virus added. 
Adenovirus was applied at a multiplicity of infection (MOI) of 100 PFU/cell (particle 
forming units). After 1 hour the cells were washed with PBS twice and fresh 
IMDM+5% was added, before incubation for 48 hours. Cells were then washed with 
PBS and infected with C. pneumoniae at MOI of 20, 2 or 0.2 inclusion forming units 
(IFU), cultured for another 72 hours, fixed and stained for chlamydial inclusions as 
described in section 2.6.2.1 of chapter 2. The results were analysed by confocal 
microscopy (Leica TCSNT confocal system; Leica Microsystems Heidelberg GmbH, 
Germany). Evaluation was done by counting the number of inclusions in a field 
representative of the sample at the original magnification of 200x. The rate of 
protection was calculated as the percentage of the total number of inclusions in 
untransfected cells.
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7.3 Results and Discussion
Before presenting the results, it is important to mention that there were problems with 
the experimental design: the results showed that the transfection with the control viral 
construct (Ad-DL70) induced more cell death compared to ELAFIN and SLPI. It  seems 
that this "non-replicating" construct had picked up the necessary genes for replication 
and was no loner of use as a control. This was confirmed after the experiments 
presented in this chapter were finished. However, a brief summary of the results and 
ideas for further experiments are presented in the following section.
The summary of the results is presented in Table 7.1 as number of inclusions per cells 
in a field. Over-expression of ELAFIN partially restricted chlamydial growth in A549 
cells. At MOI=20 of C. pneumoniae the rate of protection is about 20% and there is a 
similar level of protection when cells are treated with MOI=0.2. At M 0I=2 the 
transfection with ELAFIN seems to enhance the susceptibility of the cells to C. 
pneumoniae infection. Similar results are seen with SLPI transfection where cells are 
more susceptible (by ~100% ) than un-transfected cells, while there is some 
protection at C. pneumoniae MOI=0.2.
Table 7.1 Number of inclusions per/cell in response to different adenoviral treatment. n/ a =  not 
applicable.
A d e n o v ir a lt  reatm ent
MOI=100
C. PNEUMONIAE  MOI
20 2 0.2
UNTRANSFECTED CELLS 0.302 0.032 0.017
Ad-ELAFIN 0.265 0.057 0.012
Ad-SLPI 0.629 0.081 0.011
EMPTY VIRUS AO-DL70 n / a n / a n / a
As can be seen in Figure 7.1, when the transfection of A549 cells with Ad-ELAFIN was 
followed by a high dose of C. pneumoniae (MOI=20), the cells looked unhealthy and 
appeared to be dying, with some cells detaching from the slide. Fewer cells were 
visible in the field compared to un-transfected cells, and there were some signs of 
apoptosis (condensed and fragmented nuclei; Figure 7.2 A; Ad-ELAFIN). Lower doses
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of c .  pneumoniae did not have such a detrimental effect on the cells (Figure 7.1 B and 
C; Ad-ELAFIN).
SLPI transfection did not damage the cells to the same extent but also failed to inhibit 
chlamydial growth (Figure 7.1 A to C Ad-SLPI). SLPI-transfected cells were much 
healthier in culture, and their numbers were much higher.
The detrimental effects of Ad-ELAFIN transfection combined with a high dose of C. 
pneumoniae suggest that it might be the condition of the host cells that is limiting 
chlamydial growth.
U ntransfected  cells Ad-ELAFIN Ad-SLPI
B
M O I=20
M O I=2
M O I=0.2
Figure 7.1 Effect of ELAFIN and SLPI over-expression on chlamydial growth. (A) C 
pneumoniae MOI=20 (B) C. pneumoniae M01=2 (C) C. pneumoniae MOI=0.2. A549 cells were 
transfected with MOI=100 of Ad-ELAFIN or Ad-SLPI and 48 hours later infected with C. 
pneumoniae. After 72 hours the cells were fixed and stained with o-chlamydial LPS to visualise 
chlamydial inclusions (red) and the nuclei were counterstained with To-pro 3 (blue). Original 
magnification 200x. White circles -  apoptotic nuclei.
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As discussed at the beginning of this section, it was established that the control virus 
has entered a replicating cycle. This may explain why transfected cells looked very 
unhealthy within 24 hours of chlamydial infection irrespective of the chlamydial dose, 
and after 72 hours most of the cells had detached and were dead. In comparison, both 
ELAFIN- and SLPI- transfected cells appeared healthier in culture. Since most of the 
cells were dead at the point of collection, it was difficult to fix and stain them. When 
they were stained, it was clear that C. pneumoniae is capable of developing inclusions 
in these cells; however it was impossible to count their number due to the clumping of 
the cells (Figure 7.2).
B
Figure 7.2 Chlamydial growth In cells transfected with the control virus. (A ) C. pneumoniae 
MOI=20 (B) C. pneumoniae M0I=2. A549 cells were transfected with MOI=100 of Ad-DL70 
control construct, and 48 hours later they were infected with C. pneumoniae. After 72 hours the 
cells were fixed and stained with o-chlamydial LPS to visualise chlamydial inclusions (red) and 
the nuclei were counterstained with To-pro 3 (blue). Original magnification 200x.
The fact that the control transfection caused more cell death compared to ELAFIN and 
SLPI transfection suggests that ELAFIN and SLPI do convey at least some protection 
from the detrimental effects of adenoviral transfection, and potentially C. pneumoniae. 
To summarise, transfection of cells with ELAFIN seems to induce a degree of 
protection against C. pneumoniae infection and a number of other experiments were 
planned, but due to the failure of the experimental design they were not done. 
Nevertheless, I outline these experiments:
♦ Titre out the adenovirus to a minimum dose that still gives a good expression of 
the target gene using an Ad-GFP construct and evaluate by fluorescence microscopy.
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♦ Optimise the length of incubation with the virus before chlamydial infection.
♦ Since it is clear that C. pneumoniae MOI=20 is too high a dose, titre down the 
Chlamydia and use a dose that does not damage the cells as much. Also lower doses 
would be more similar to a real infection in the lung.
Once the experimental approach was optimised, the investigation could be expanded 
to include other read out systems. To assess the effects of ELAFIN and SLPI on the 
rate of chlamydial growth, determine the relative number of inclusions per number of 
cells. Also analyse the expression of chosen chlamydial genes at mRNA level by Real 
time RT-PCR. To determine the effect of SLPI and ELAFIN on Chlamydia-induced 
inflammation, investigate secretion of cytokines by the transfected cells compared to 
un-transfected cells.
The experiments outlined here, would, I believe, give an rounded picture of the role of 
ELAFIN and SLPI in chlamydial infections in the lung. Given the importance of 
antiproteinases in chronic lung diseases such as COPD and cystic fibrosis, and given 
the association of C. pneumoniae with these diseases, it is highly likely that ELAFIN 
and SLPI contribute to building protective immunity against C. pneumoniae and also to 
the outcome of the infection.
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C h a p t e r  8  
G e n e r a l  D is c u s s io n  a n d  Co n c l u s io n s
Atherosclerosis and coronary heart disease are fast becoming the number one cause 
of death in the developed countries. Saikku et al., (1988) were the first to report the 
presence of Chlamydia spp. TWAR {Chlamydia pneumoniae) in atherosclerotic plaques 
and suggested a correlation between chronic infection and atherosclerosis. Since then 
numerous investigations and clinical studies have been conducted to confirm the 
association of C. pneumoniae infection and the development of atherosclerosis, 
however this still remains an area of controversy.
Lung epithelium is the primary target of C. pneumoniae infections. To better 
understand how C. pneumoniae may contribute to the development of chronic 
conditions, early immune responses and host-pathogen interactions in the lung need 
to be dissected and understood. The work described in this thesis was designed to 
investigate a number of early responses in human infections with a view to better 
understand how early immune responses might contribute to persistence. It  was 
shown that host cells are activated to release cytokines following infection, and that 
the cytokine profile depends on the cell type (presented in Chapter 4); that C. 
pneumoniae modulates the expression of cell-surface molecules in MdMs and that 
infected epithelial cells activate MdMs (presented in Chapter 5); and that C  
pneumoniae induces inhibitory intracellular pathways (S0CS3) in lung epithelial cells 
that may interfere with the control of chlamydial growth in the host cell (presented in 
Chapter 6 ). A preliminary study into the role of natural antimicrobials in controlling C. 
pneumoniae growth was conducted and it indicated that these molecules may 
contribute to control and clearance of C. pneumoniae (presented in Chapter 7).
Events following C. pneumoniae infection are a combination of pro- and anti­
inflammatory responses and I will try to summarise them here. Infected epithelial cells
and MdMs both produce IL- 8  and IL-6 , while MdMs also release IL -lp  and TNF-o. The
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amount of IL- 8  and IL - 6  released by infected epithelial cells is increased by IL-17 
treatment. Infection of MdMs increases the levels of CD14, CD40 and CD54 surface 
expression. All of these responses promote inflammation by recruitment and activation 
of neutrophils (IL-8 ), activation of Th l type responses (IL-1 (3, TNF-o, IL-6 , up- 
regulation of CD40 and CD54) and suppression of CD4+CD25+ regulatory T cells (IL- 
6 ) and also increase the cells' susceptibility to C. pneumoniae infection (up-regulation 
of CD14). These responses taken together may contribute to chronic inflammation and 
the development of atherosclerosis. However the pro-inflammatory responses are 
balanced by the activation of regulatory/inhibitory events. Infected MdMs produce IL-
10, but no IL-12, while the amount of IL-8 , TNF-o and IL -lp  released by infected 
MdMs shows a downward trend when treated with IL-17. Levels of MHC class I and I I  
molecules on MdMs decrease following infection, while CD45 levels increase. C. 
pneumoniae also induces the expression of S0CS3 in lung epithelial cells. The anti­
inflammatory responses can dampen the inflammation and promote persistent 
infection in a number of ways: inhibiting the control of chlamydial growth through lack 
of IL-12 production thereby reducing the amount of IFN-y; inducing expression of 
S0CS3 and up-regulation of CD45 that may both interfere with IFN-y mediated 
control; and promoting immune evasion through down-regulation of MHC class I and
11, thereby inhibiting antigen presentation and processing, and activation of adaptive 
immune responses.
In addition to host cells responding to infection, they can also activate other cells, 
thereby modulating the cells' ability to participate in immune responses. It  was shown 
that infected epithelial cells activate MdMs by modulating the expression of cell- 
surface molecules. Unlike the infection, CM-treatment of MdMs down-regulates CD14 
and CD45 expression, while up-regulating MHC class I and I I  and also CD91 
expression. This kind of response may prime the MdMs to be less sensitive to C. 
pneumoniae infection and more efficient in controlling chlamydial growth (down- 
regulation of CD14 and CD45), while becoming more efficient in activation of adaptive 
immune responses (up-regulation of MHC class I and I I  and CD91).
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A schematic of the early immune responses analysed in this project is presented in 
Figure 8.1.
C. pneumoniae induced Immune responses
pro-inflammatorv
IL-17
Î IL -6  
Î IL -8
PGE,?
CHSP60?
Inc?
anti-inflammatorv 
a/  EBs
IL -6
IL -8
T SOCS3
PGEz?
Î  CD14 
T CD40 
T CD54
IL -6
IL -8
IL lp
TNF-o
EBs
IL-17
Î CD45 
IL -10  ; MHC I
no IL -12  ; MHC I I
i I L i p  ? 
I IL -8  ?
I  TNFa ?
I  CD45 
Î  CD91 
Î  MHC I  
Î  MHC I I
i
Chronic inflammation
i  CD14
i
Imm une evasion
Figure 8.1 Immune responses analysed in this project. Responses are divided in pro- and anti­
inflammatory. Key: RED l e t t e r s  a n d  a r r o w s  - pro-inflammatory response; BLUE l e t t e r s  a n d  
ARROW S -  anti-inflammatory response; GREEN l e t t e r s  a n d  a r r o w s  -  effects of IL-17 treatment 
of infected cells; CM treatment. EBs - elementary bodies.
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As I discussed before, it is difficult to dissect out the Immune responses in such a way 
as to determine the sequence of events following the infection, because of the number 
of contributing factors. From the data presented and discussed in this thesis and 
previous research, it is becoming clear that the early immune responses may play a 
crucial role in the final outcome of C. pneumoniae infection. There Is a low-level 
Inflammatory response that Is beneficial for the long-term survival of the pathogen. A 
strong inflammatory response would cause eradication of the organism, while a lack of 
inflammation might allow the bacterium to multiply very quickly, leading to the death 
of the host. Long-term, persistent infections with a low-level inflammatory response 
may contribute to the development of chronic diseases such as atherosclerosis and 
COPD that C. pneumoniae is associated with.
At the beginning of this project an in vitro model was established and described 
(presented in Chapter 3) in order to analyse early Immune response to C. pneumoniae 
infection in human cells. Investigating Immune responses in humans Is very difficult 
for a number of reasons. The reagents for analysis are abundant; however the 
experiments are almost exclusively done in vitro, unless they are a part of a clinical 
study, and even then the responses may be measured ex vivo. With C. pneumoniae 
there is the added problem of the high seroprevalence in the population, meaning that 
obtaining samples from naïve individuals Is almost impossible.
In the current model a combination of established human lung epithelial cell lines and 
primary blood-derived MdMs was used. Using cell lines is technically simple and the 
samples are abundant, however they are mostly derived from cancerous tissue and 
are genetically different both from primary tissue and from each other. The two cell 
lines used in this project are of different origins; HEp-2 cells are derived from a larynx 
carcinoma and A549 cells from a lung carcinoma. There are differences In the way 
they respond to C. pneumoniae infection. They show similar kinetics of chlamydial 
growth; however they differ In the amount of LPS released from infected cells when 
infected with the same MOI. They preferentially release different cytokines following 
Infection: A549 release more IL- 8  than IL-6 , while HEp-2 release more IL- 6  than IL-8 .
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The major difference between A549 and HEp-2 cells is their ability to control 
chlamydial growth in response to IFN-y. This phenomenon was a very interesting basis 
for investigating the role of SOCS in chlamydial infections.
Another issue arising from working with human models is the analysis that can be 
conducted. The investigations are largely observational, with limited manipulation of 
responses possible such as treatment with blocking antibodies, transfection of cells 
with a particular gene (eg. adenoviral gene therapy) or gene silencing (RNA 
interference; RNAi). In future studies it would be Ideal to combine the in vitro human 
work with mouse models where the observations may be taken further and there is 
more scope for manipulation of the immune responses.
As a result of the research conducted in this project there are a few interesting 
avenues that may be pursued in future.
♦ Detailed analysis of the role of IL-17 in C. pneumoniae infections in vivo.
IL-17 modulates cytokine production by infected cells in vitro (Chapter 4). In future 
investigations it would be interesting to analyse the presence of IL-17 in the lungs of 
infected mice. For that purpose bronchial lavage fluid (BAL) may be used for both Real 
time RT PCR and protein analysis (Western blots rather than ELISA). To determine the 
role of IL-17 in the lung infections, different avenues could be pursued by 
manipulation of IL-17 expression: over-expression of IL-17 receptor, blocking IL-17 
function with a blocking antibody or using IL-17 knock out mice In order to block the 
effects of IL-17; over-expression of IL-17 through gene transfer for the analysis of the 
opposite effects. A number of different responses could be measured, such as cytokine 
production, the composition of the cell population in the lung (BAL), bacterial load and 
infection clearance. Similar experiments were conducted by Ye et al (2001a and 
2001b) in the investigation of the role of IL-17 in K. pneumoniae infections.
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♦ The role of CD91 in C. pneumoniae infections
Given the importance of HSPs in chlamydial infection, it would be interesting to 
expand the investigation into the role of CD91. In the current study it was shown that 
CM-treatment of MdMs up-regulates CD91 expression, while infection had a mixed 
effect. Considering the size of the sample analysed (n=4 for infection, n=3 for CM- 
treatment), this should first be expanded to confirm current results. Further analysis 
might include blocking CD91 and monitoring any differences in the production of 
cytokines and other markers of MdM activation such as CD80/86 and MHC class I and 
I I  molecules; investigating by confocal microscopy the localisation of the receptor 
following infection and also analysing the contents of CM to confirm that it contains 
cHSPs and/or human HSPs. The investigation could be expanded in vivo in a similar 
way to the experiments proposed for IL-17 to get an idea whether CD91 has a crucial 
role in anti-chlamydial immune responses.
♦ How does the expression of cytokine signalling inhibitors (SOCS, PIAS, CD45) affect 
the outcome of C. pneumoniae infections?
The current investigation has demonstrated that infected epithelial cells express 
S0CS3. There was also an indication that over-expression of S0CS3 (as in A549 cells) 
impairs the cell's ability to control chlamydial growth in response to IFN-y treatment. 
Statl phosphorylation was also analysed in A549 cells, however it was shown that it is 
phosphorylated (p -S tatl) constitutively. To confirm that Statl-dependent signalling is 
impaired It would be interesting to analyse the localisation of p-Statl by confocal 
microscopy instead of by western blotting. This would confirm the level at which IFN-y 
signalling is Inhibited in A549 celis. To expand this, other Inhibitors such as PIASl 
could be analysed by Real time RT-PCR and confocal microscopy. Other in vitro 
experiments could include silencing of socsl and socs3 genes with RNAi or over- 
expression by gene transfer, and in both cases subsequent analysis of C. pneumoniae 
growth rates in epitheliai cells.
In vivo analysis into the role of S0CS3 is difficult since S0CS3 knock out mice do not 
survive beyond the embryonic stage. In a seminal paper into the role of S0CS3 in IL - 6  
signalling Croker et al (2003) used Cre-loxP site-specific recombination to knock the
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socs3 gene from target tissues (liver and macrophages). In future studies this 
technique could be used for targeted deletion of the socs3 gene In the lung, and 
analysis of the Impact on cytokine profile, bacterial load and the outcome of Infection.
Before this project started, there was already a heated scientific discussion on the role 
of C. pneumoniae Infections In the development of atherosclerosis and other chronic 
diseases. The results presented In this thesis support the Idea that C. pneumoniae 
Infection In the lung may contribute, or even cause the development of chronic 
diseases such as atherosclerosis and COPD through Inducing a low-level Inflammatory 
response. However a lot more research Is needed to understand the underlying 
mechanisms of host - C. pneumoniae Interactions, and design novel therapies and safe 
and effective prevention strategies.
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9  A p p e n d ic e s
9.1 Appendix 1-Solutions
9.1.1 PBS (MRI Scientific Services)
900 ml CIH2O
8.0 g NaCI (Sigma Aldrich)
1.15 g Na2HP0 4  (Sigma Aldrich)
0.2 g KH2PO4 (Sigma Aldrich)
0.2 g KCI (Sigma Aldrich)
Adjusted to 1 L In volume at pH 7.4, autoclaved and stored at RT
9 .1 .2Trypsin/Versene (MRI Scientific Services)
2 0 % Trvpsin solution (MRI Scientific Services)
40.0 g NaCI (Sigma Aldrich)
3.8 g KCI (Sigma Aldrich)
0.5 g Na2HP0 4  (Sigma Aldrich)
15.0 g Tris (hydroxymethyl)methylamlne (Sigma Aldrich)
7.5 ml 1% Phenol red solution (Sigma Aldrich)
12.5 g Trypsin (DIfco Laboratories, Surrey, UK)
Made up to 5 L In deionised water pH 7.6
80%Versene solution (MRI Scientific Services)
48.0 g NaCI (Sigma Aldrich)
1.2 g KCI (Sigma Aldrich)
6.9 g Na2HP0 4  (Sigma Aldrich)
1.2 g Versene (EDTA; Ethylene Diamine Tetra acetic acid (DIsodlum salt: Dlhydrate)) 
(Sigma Aldrich)
9.0 ml 1% Phenol red solution (Sigma Aldrich)
Made up to 6  L In deionised water pH 7.2
9.1.3 Chlamydial Transport Medium (MRI Scientific Services)
3 7 3  g Sucrose (Sigma Aldrich)
2.560 g KH2PO4 (Sigma Aldrich)
6.185 g K2HPO4 (Sigma Aldrich)
3.605 L-glutamIc acid (Sigma Aldrich)
Made up to 5 L In delonsed water
20 ml 0.4% Phenol Red solution (Sigma Aldrich) added
500 ml PCS (GIBCO BRL) added
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25 ml (1 /4  vial) Gentamycin (GIBCO BRL) added
0.5 g Streptamycin (GIBCO BRL) added
Filtered and 25 ml 10000 U/ml Nystatin suspension added
9.1.4 Red Cell Lysis Buffer
79 mg NH4 HCO3 (Im M )
6  g NH4CI (114mM)
Made up to 1 L and filter sterilised
9.1.5 Agarose gels for RNA or DNA
9.1.5.1 RNA gels
Add 0.8g agarose (Promega) to 80 ml of Ix  MOPS/EDTA buffer and dissolve It In a 
microwave at low heat.
Mix well, cool under tap to ~60°C and add 4ml of 37% formaldehyde (SIgma-Aldrlch). 
Pour Into tray with comb In place and let It set. Place tray In the tank filled with Ix  
MOPS.
Mix 2pl of RNA sample with 8 pl of loading buffer and leave at 65°C for 10 minutes. 
Cool Instantly on Ice.
Load samples and run at lOOV for 30-45 minutes. Visualise under UV light.
lOx MOPS ([3-(N-morphollno) propanesulphonic acid]) /EDTA buffer 
41.86 g MOPS (0.2M) (Sigma Aldrich)
16.7 ml 3M Sodium acetate (0.05M, pH 4.8)
20.0 ml 0.5M EDTA (O.OIM)
Add to 800ml of dH2 0 , dissolve and adjust pH to 7.0 and make up to IL.
Use 1:10 to make up working solution.
RNA loading buffer
0.75 ml Formamlde
0.15 ml lOx MOPS
0.24 ml Formaldehyde
0.1 ml Glycerol
0.1 ml 10% Bromophenol blue
0.01 ml lOmg/ml Ethldlum bromide
0.1 ml dH2 0
9.1.5.2 DNA gels
Add 0.8g-1.6g (1-2% ) of agarose In 80 ml of IxTBE and dissolve It In a microwave at 
low heat.
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Mix well, cool under tap to ~60°C, pour Into the tray and let It set.
Transfer the tray In the tank filled with Ix  TBE containing 5pg/ml of ethldlum bromide. 
Mix 5pl of DNA with Ipl of 6 x DNA loading buffer (Promega) and load the samples.
Run the gel at 80-100V for 45-90 minutes as needed. Visualise under UV light.
lOX TBE 
108g Tris 
55g Boric Acid 
40ml 0.5M EDTA
Add to 800 ml of dHzO, mix well and make up to 1 L. To make a working solution 
dilute 1:10 and add 5pg/ml of ethldlum bromide.
Ethldlum Bromide solution
Add 0.1 g of ethldlum bromide to 10ml dHzO mix on magnetic stirrer for several 
hours. Wrap In foil and store at RT.
9.1.6 Detachment Buffer
12mM LIdocalne-HCI (SIgma-Aldrlch) 
lOmM EDTA (From 0.5M pH 8  stock)
In PBS (see 11.1.1)
9.1.7 Protein Lysis Buffer
50 mM HEPES pH=7.5 (stock 0.5 M; 1:10) 11.9g
50mM NaCI (stock 5 M; 1:100) 2.92g
50mM NaF 2.1g In 1 L of dHzO
lOmM Na pyrophosphate 4.46g
0.5 M Na3V0 4  (stock lOmM; 1:20)
Add protease Inhibitor cocktail (Complete R, Roche Diagnostics ltd, Lewes, UK) 1 
tablet per 15 ml of lysis buffer
9.1.8 Western Blot Buffers
MOPS buffer (see 9.1.5.1)
Transfer Buffer 
3.03g TrIs 
14.4g Glycine 
800ml dHzO 
200ml Methanol 
StrlDDlno Buffer 
0.75 g Tris
2 g SDS (Sodium dodecyl sulphate; SIgma-Aldrlch)
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Add to 100 ml of dH20. Prior to use add 700|jl of p-mercaptoethanol (SIgma-Aldrlch). 
Cover membranes with buffer and leave at 50°C for 1 hr. Wash 3 times with wash 
buffer and re-staIn membranes according to protocol.
9.1.9 Mowiol mounting medium
Add 2.4g Mowiol 4.88 (Sigma Aldrich) to 6g glycerol and stir briefly with a pipette 
AddlZmI dHzO and stir at RT for several hours (best left overnight)
Add 12ml 0.2M Tris (pH 8.5) and heat to 50°C for l-2hours while stirring 
When the Mowiol has dissolved, clarify by centrifugation at 500x g for 15 mlns 
Add DABCO to 2.5% (0.72g), aliquot and store at -20°C . Bubbles can be removed by 
centrifugation. Aliquots can be stored for up to 2 weeks at 4°C.
9.2 Appendix 2 -  Standard Curves
9.2.1 CBA standard curves
IL-6
Concentration (pg/ml)
Curve-Fitting Model: 4-Param eter Logistic 
y = ((A - D)/(1 + (x/C)/'8)) +  D
f it
iiffl pWli
100 1000
Concentration (pg/ml)
Curve-Fitting Modei: 4 -Paranieter Logistic 
y = ((A - D)/(1 + (x/C rB)) + D 
A = 1.04 8 =  1.69 C = 5.98 D = 9.72 R''2 = 0.9999
IL -lb
Concentration (pg/ml)
Curve-Fitting Model: 4-Param eter Logistic 
y = ((A - D)/(1 + (x/O-'B)) + D
TNF-a
Concentration (pg/ml)
Curve-Fitting Model: 4 -P a ra m ele r Logistic 
y = ((A - D)/(1 + (x/C):'B)) + D 
I B = 1 .6 7  C = 6.40 0 =  10.36 R *2  =
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IL-12p70
Concentration (pg/ml)
Curve-Fitting Model: 4-Param eter Logistic 
y = ((A - D)/(1 -r (x /C )^ ) )  +  D
IL-10
Concentration (pg/ml)
Curve-Fitting Model; 4-Pararrieter Logistic 
y = ((A - D )/(l -r (x/C)rrB)) + D
R''2 = 0.9996
9.2.2 ELISA standard curves
9.2.2.1 IL-6
3D
3.162
Fitl
1.000
0.316
0.100
0.032
0.010
0.003
316.228 1000.000 3162.27810.000 31.623 100.000
Concentration (pg/ml)
Log/log axes scaling
Quadratic regression with data extrapolation 
Y= -4.1007 -H1.67307X -0.1070X^ 
R-Squared = 0.9930
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9.1.2.2 LPS
DD
- • -F i t l
1.259
0.794
0.501
0.316
0.200
0.100 0.316 1.000 3.162 10.000 31.623 100.000 316.228
rnnrontraMnn
Log/log axes scaling
Quadratic regression with data extrapolation 
Y= -4.867 +0.4193X -0.0552X^
R-Squared = 0.9848
9.3 Appendix 3 - CBA raw data
The following tables present raw values of the CBA cytokine analysis in pg/ml. Some 
of the cells are In colour. Key: -  values not available (samples lost or experiments
not done); -  values over the threshold of 5000 pg/ml; B  -  values over the
threshold even when diluted lOx.
9.3.1 HEp-2 cells
HEP-2 CELLS IL -6 pg/ml
2 4  hours
control cells IL-17 M O I= l M O I= l + IL -17 M O I=10 M OI=10 + IL -17
d l 122.6 807.8 175.1 1299.9 280.9 958.1
d2 53.9 249 73.3 433.9 139.3 516.2
d3 77.8 361.4 93.6 927.7 140.1 648
4 8  hours
control cells IL-17 M O I= l M O I= l + IL -17 M O I=10 M OI=10 + IL -17
d l 171.6 742.4 180.4 1405 566.3 2591.6
d2 77.4 431.6 91.7 563.4 442.8 1033.1
d3 82.5 378.3 94.6 543.4 234.4 1033.1
9 6  hours
control cells IL-17 M O I= l M O I= l + IL -17 M O I=10 M O I=10 + IL -17
d l 621.6 1930.7 1257.5 5000 5000 5000
d2 272.6 1126.9 400 2143.9 5000 5000
d3 326.7 1243.7 456.5 2169.2 5000 5000
167
HEP-2 CELLS IL -8 pg/ml
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL -17
d l 4.6 24.5 12.3 51.8 40 .2 16.1
d2 11.7 10.1 6.5 21.6 8.1 23.5
d3 8.7 14.5 6.5 35.9 10.6 17.1
48 hours
control cells IL -17 M 0 I= 1 M O I= l+ IL -1 7 M O I=10 M O I=10+ IL -17
d l 11.2 29.2 13.1 88.2 29.5 220.7
d2 9.8 21.2 8.4 33.1 26.8 70
d3 12.1 21.8 11.6 23.5 15.8 77
96 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL -17
d l 29.2 137.3 78.6 458.5 5000 5000
d2 19.5 61 20.1 164.8 5000 5000
d3 17.4 63 25 166.5 5000 5000
9.3.2A549 cells
A549 ' IL -6 pg/ml
24 hours
control cells IL -17 M O I= l M O I= l + IL -17 M OI=10 M O I=10+ IL -17
d l 5.7 6.2 8.4 11.3 32 .4 23.3
d2 9.4 5.7 5.6 8.5 33.6 40 .6
d3 13.2 49 .2 14.9 56 11.4
48 hours
control cells IL -17 M O I= l M O I= l + IL -17 M O I=10 M O I=10+ IL -17
d l 8 5.6 7.5 10.3 31.6 30 .8
d2 1.6 4.5 6.2 9.8 31.2 28.5
d3 7.2 9.9 10.5 9.5 39.8 47
96 hours
control cells IL -17 M O I= l M O I= l + IL -17 M O I=10 M O I=10+ IL -17
d l 4.2 10 14.2 10.2 72.1 38
d2 7.4 10.3 9.1 8.8 45 .4 44 .3
d3 9.8 14.5 13.1 16.2 63 52.7
A549 IL -8 pg/ml
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL -17
d l 12.8 13.7 14.6 34.7 75.4 81 .6
d2 14.1 18.1 20.1 32.4 88.7 187.9
d3 18.1 105.2 13.9 107.4 7.3
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M OI=10 M O I=10+ IL -17
d l 16.7 42 32.4 47 .8 216.3 326.2
d2 27.5 51 35.9 . 124 349.9 589.5
d3 18 34.3 47.5 34.9 148.9 304.1
96 hours
control cells IL -17 M 0 I= 1 M O I= l+ IL -1 7 M OI=10 M O I=10+ IL -17
d l 721.5 1418.8 1502.3 1084.7 4518.1 3392.8
d2 566.2 1227.3 1279.1 2277.1 3999.7 5000
d3 560.6 1676.5 1062.7 1240.1 2561 2978
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9.3.3 MdMs
IL-6 p g /m l
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 9.3 3.1 5360 4729.4
d2 11.2 9.35 9.1 10 7 9.5
d3 3.4 6.2 11060 6300 11290 9870
d4 8.9 6.6 12260 7490 12710 7740
d5 0 0 1230.1 1190.1 20570 27260
d6 2.6 0 5570 4640 82080 105580
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M OI=10 M O I=10+ IL17
d l 6.7 8.8 3750 4232
d2 5.8 11.4 18040 15500 21630 16150
d3 6.8 8560 7900 11770 11180 9970
d4 8.1 8.7 16810 11890 18230 8340
dS 0 0 958.1 1536.8 32670 38800
d6 32 10.4 5570 63470 87010
96 hours
control cells IL-17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 9.9 2.6 4540 4451
d2 14.2 10.2 14010 14290 19760 22520
d3 2.1 6.8 22290 26980 12330 17680
d4 7.4 13.7 15430 5960 20990 6370
d5 11.4 0 989.5 994.5 56630 70450
d6 0 6.5 5630 6870 89840 170170
IL-8 p g /m l
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7
d l 1086.2 1755 32290 25650
d2 608.8 1089.5 569.2 983
d3 333.8 695.7 137530 87510
d4 314.8 410.2 118990 103050
dS 814.9 1020 43610 29510
d6 2047.7 2702.4 96910 83160
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7
d l 2492.2 4159.7 35340 25650
d2 390.5 1013.8 258870 27710
d3 428.8 88400 85740 176670
d4 520.3 901.2 209160 202620
d5 1020 1361.1 34990 57780
d6 3583.4 3583.4 116570
96 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7
d l 7780 10630 50200 54940
d2 1089.5 1653.5 285200 258870
d3 731.8 1159.1 328360 366280
d4 1779.6 1618.3 282140 171200
dS 2791.1 1921.9 40660 4940
d6 4619.9 4650 38960 146370
439.6
87510
122730
256110
896.6
83160
99930
282140
M O I=10 M O I=10+ IL17
222920
116570
202620
446820
194230
118990
15740
467170
M O I=10 M O I=10+ IL17
301040
175840
362290
1842,6
370320
232620
184260
1942.3
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IL -IP p g /m l
24 hours
control cells IL-17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 39.2 15 277.4 294.2
d2 67.45 46.8 48.1 56.6 45.9 73.5
d3 9.1 7.9 24.9 61.1 356.6 379.4
d4 50.4 33 826.9 58.2 712.9 67 .4
d5 0 0 0 0 351.3 445.8
d6 0 0 0 0 590.9 718.2
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 49.4 27.2 251.7 158.7
d2 59.4 72.1 72.6 57.4 460.3 373.5
d3 274.2 32.3 29.6 0 288.6
d4 33.4 59.9 908.1 56.6 1007.1 44 .4
dS 0 0 0 0 1027.5 973.8
d6 0 0 0 0 1435.6 1660
96 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 62.2 9 258.7 187.1
d2 67.4 47.4 0 0 156.1 118.1
d3 0 9.9 29.6 60 90.4 79.4
d4 31 58.6 633.2 41.5 666.5 73.9
dS 0 0 0 0 1700.6 1475.7
d6 0 0 0 0 2689.9 2268
IL- 10 p g /m l
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M OI=10 M O I=10+ IL17
d l 15.8 5.7 22.8 36.2
d2 13.05 10.5 7.9 7.8 11 15.5
d3 2.3 8.3 24.2 33.3 36.6 54.7
d4 12.8 9.5 336.8 178.6 348.3 204.7
dS 0 0 32.8 23 299.2 415.5
d6 0 0 49.5 37.7 654.5 575.7
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M OI=10 M O I=10+ IL17
d l 7.7 10.1 30 21.1
d2 11.4 14.4 71 64.2 81.7 83
d3 7.5 5.5 29.6 13.4 44.9
d4 11.7 11.7 257.1 185.7 325.6 197.9
d5 0 0 27.7 33.8 454.2 635.4
d6 0 5.1 41.4 37.2 572.8 623
96 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 MOI = 10+IL17
d l 18.6 4.1 20.5 15.1
d2 11.9 12.2 62.2 77.6 69.9 65.6
d3 1.9 5.9 31 35.7 30.3 26.8
d4 12.7 12.2 219.1 83.9 263.4 94 .4
dS 3.5 0 29.3 19.8 359.8 467.8
d6 1.4 0 37.7 42.5 521.5 604.8
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TNF-a p g /m l
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 5.4 2.2 648 784
d2 6.8 5.95 4.7 5.7 4.7 5.4
d3 2.2 2.4 420 491.7 1321.7 1301.4
d4 5.5 4.9 1406.6 335.4 1363.5 313.3
d5 0 0 22.2 22.2 315.4 196.6
d6 0 0 55.8 42.3 300.6 546.8
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 7.8 9.2 189 210
d2 5.5 7.7 48 .9 50.6 587.6 682.5
d3 4.5 3.2 630 150.2 617.6
d4 3.4 4 851.5 85 951.9 141.8
dS 0 0 0 0 55.8 50.8
d6 0 0 0 0 79.5 138
96 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL17
d l 13.1 6.5 55.4 71.8
d2 7.5 6.7 4.3 5.7 154.6 148.8
d3 2.2 4 52.4 94.5 208.5 208.5
d4 7.3 7.2 238.7 15.3 362.6 23 .9
dS 0 0 0 0 33.2 28
d6 0 0 0 0 46.1 91 .2
IL- 12 p g /m l
24 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL 17
d l 12.1 5.5 0 11.3
d2 11.7 10.1 11.1 10.1 15.5 7.4
d3 2.9 7.9 8.3 ■ 13 7.8 9.2
d4 9.1 5.7 11.5 10.3 13.5 11.9
d5 0 1.2 1.3 0 0 0
d6 0 0 8.1 3.4 0 0
48 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL 17
d l 10.9 9.4 11.7 14.6
d2 9.3 12.5 12.5 12 12.7 10.6
d3 5.5 6.2 7.6 6.9 0
d4 7.2 9.3 4 .2 13.4 9.9 13.4
dS 1.6 0 2 0 0 3.2
d6 0 0 0 0 0 3
96 hours
control cells IL -17 M O I= l M O I= l+ IL -1 7 M O I=10 M O I=10+ IL 17
d l 15.8 3.6 9.6 6.2
d2 11.6 6.6 1.7 2.3 3.7 0
d3 3.6 3.1 7.2 11.7 5.8 2.7
d4 7.6 7.8 13.9 7.6 6.4 14.5
d5 1.2 1 0 2.1 0 1.3
d6 0 0 0 0 1.3 2.1
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9.4 Analysis o f cytokine data
Data for monocytes were available from six donors. Blood samples from each donor 
were each treated with six different reagents, and the presence of cytokines measured 
at three time points, 24, 48 and 96 hours respectiveiy. For the first donor oniy four 
reagents were used (M O l=10 and lO+IL-17 were missing) giving a total of 102 
measurements for the complete set.
Data for epithelial cells were available for 3 separate experiments for each ceil line 
(HEp-2 and A549).
9.4.1 Statistical model
Because of the unbalanced nature of the data the REML directive was used in Genstat 
7^  ^ edition to fit a modei to the data. A repeated measures model was used with a 
uniform correlation structure (subjects were taken as the donor/treatment 
combinations or experiment/treatment combinations). This is equivalent to fitting a 
split-plot model with donors designated as blocks, treatments as main plots and time 
as spiit piots. The data for each cytokine were positively skewed and so all analyses 
have been carried out using log transformed data, logio(x+l).
Below is an example (IL-10) of the analysis that was conducted on all experiments
IL -10  (log scale)
Table of raw means In log scale
T im e s / h r 24 48 96
T r e a t m e n t s
M O I= l+ IL -1 7 1.545 1.619 1.590
M O I=10+ IL -17 2.131 2.445 2.140
IL -17 0.646 0.822 0.631
M O I= l 1.581 1.722 1.675
M O I=10 2.098 2.302 2.209
UT 0.672 0.678 0.839
* * * * *  REML Variance Components Analysis * * * * *
Response Variate: logIL-10
Fixed model: Constant+Donors+Tlmes+Treatments+Tlmes.Treatments
Random model: unlts.tlmes
Number of units: 102
*  units.Times used as residual term with covariance structure as below
* Sparse algorithm with AI optimisation
* Units with missing factor/covarlate values Included
* Units with missing data values Included
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* * *  Covariance structures defined for random model * * *  
Covariance structures defined within terms:
Term Factor Model Order
units.Times units Identity 1
Times Uniform 1
* * *  Residual variance modei * * *
Nrows
34
3
Term
units.Times
Factor
units
Times
Model(order) Parameter 
Sigma2
Identity
Uniform thetal
Estimate S.e.
0.224 0.0563
0.7675 0.0691
* * *  Wald tests for fixed effects * * *
Fixed term Wald statistic d.f.
*  Sequentially adding terms to fixed modei
Donors 9.54 5
Times 4.90 2
Treatments 63.88 5
Times.Treatments 5.03 10
*  Dropping individual terms from full fixed model 
Times.Treatments 5.03 10
Donors 7.53 5
W aid /d .f. Chi-sq prob
1.91
2.45
12.78
0.50
0.50
1.51
0.090
0.086
<0.001
0.889
0.889
0.184
*  Message: chi-square distribution for Wald tests is an asymptotic approximation (i.e. for large 
samples) and underestimates the probabilities in other cases.
* * *  Table of predicted means for Constant * * *
1.515 Standard error: 0.0761
* * *  Table of predicted means for Donors * * *
Donors 1 2 3 4 5 6
1.543 1.433 1.274 1.913 1.397 1.529
Standard errors: Average 0.1856
Maximum 0.2247 
Minimum 0.1776
* * *  Table of predicted means for Times * * *
Times/hr 24
1.448
48
1.581
96
1.516
Standard errors: Average
Maximum
Minimum
0.08274
0.08316
0.08253
173
* * *  Table of predicted means for Treatments * * *
Treatments MOI= 1+IL-17 MOI=10+IL-17 IL-17 M0I=1 M01=10 ut
1.585 2.206 0.700 1.659 2.209 0.730
Standard errors: Average 0.1848
Maximum 0.1996
Minimum 0.1776
* * *  Table of predicted means for Times.Treatments * * *
Treatments MCI= 1+IL-17 MOI=10+IL-17 IL-17 M0I=1 MOI=10 ut
Times/hr
24 1.545 2.137 0.646 1.581 2.104 0.672
48 1.619 2.336 0.822 1.722 2.308 0.678
96 1.590 2.146 0.631 1.675 2.214 0.839
Standard errors: Average 0.2010
Maximum
Minimum
0.2239
0.1932
Conclusion:
There strong evidence that treatment of cells Induces significant differences In IL-10 
levels. There Is no significant difference between donors and different times. There Is a 
dose dependent response to Chlamydia pneumoniae Infection, while IL-17 does not 
significantly affect the levels of IL-10 In either
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